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LIST OF ABBREVIATIONS  
Akt Protein Kinase B 
ALL Acute lymphoblastic leukemia 
AML Acute myeloid leukemia 
AMPA α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor 
ANKLE2 Ankyrin Repeat And LEM Domain 
Containing 2 
ANP32a Acidic nuclear phosphoprotein 32a 
APC Adenomatous polyposis coli 
ARF ADP Ribosylation Factors 
ARPP-16/19 cAMP-regulated phosphoprotein 
AUL Acute undifferentiated leukemia 
BAF Barrier-to-autointegration factor 
bc Blast crisis 
BSA Bovine serum albumin 
cAMP cyclic adenosine monophosphate 
C/S Cesarean section 
CC Corpus callosum 
CCDC6 Coiled-Coil Domain Containing 6 
CCM Cerebral cavernous mal- formation 
Cdk cyclin-dependent kinase 
CGH Comparative genomic hybridization 
CHX Cycloheximide 
CIP2A Cancerous inhibitor of PP2A 
CLL chronic lymphocytic leukemia 
CML chronic myelogenous leukemia 
cMyc Cellular Myelocytomatosis oncogene 
CNV Copy number variation 
CTTNBP2NL Cortactin Binding Protein 2 N-Terminal 
Like 
COSMIC Catalogue of Somatic Mutations in Cancer 
CT Computed tomography 
DARPP32 Dopamine & cAMP regulated 
phosphoprotein of 32kDa 
DD Developmental delay 
DDD Deciphering Developmental Disorders 
DECIPHER Database of Chromosomal Imbalance and 
Phenotype in Humans Using Ensembl 
Resources 
DMEM Dulbecco's Modified Eagle's medium 
DNA Deoxyribonucleic acid 
DTT DL-Dithiothreitol 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
ENSA α-Endosulfin 
ERα Estrogen receptor α 
ERK extracellular signal-regulated kinase 
FECH Ferrochelatase 
FGFR1OP Fibroblast growth factor receptor 1-
oncogenic partner 2 
FIGO Federation of Gynecology and Obstetrics 
FTY720 Fingolimod 
GCKIII Germinal center III kinases 
GFP Green fluorescent protein 
GSK3β Glycogen synthase kinase 3 β 
GST Glutathione S-Transferase 
HA HemAgglutinin 
HEAT Huntington/elongation/A-subunit/TOR 
HEC Human endometrial cancer 
HEK293 Human embryonic kidney 293 
HNPCC Hereditary Non-Polyposis Colon Cancer 
HR HEAT repeat 
HRP Horseradish peroxidase 
hTERT Catalytic subunit of telomerase 
IB Immunoblotting 
ID Intellectual disability 
IKKε inhibitor of NF-κB kinase ε 
IP Immunoprecipitation 
INHAT Inhibitor of acetyl transferase 
IQ Intelligence quotient 
kDa Kilodalton 
KI Knockin 
KO Knockout 
LATS Large tumor suppressor kinase 
LCMT1 Leucine carboxyl methyltransferase 1 
LEM LAP2-Emerin-MAN1 
Leu Leucine 
LRR Leucine rich repeat 
LT Large T 
mAKAP cAMP-dependent PKA anchoring protein   
MAP Microtubule-Associated Proteins 
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MAPK Mitogen-activated protein kinases 
MCAP Megalencephaly-capillary malformation-
polymicrogyria 
MEK1 Mitogen-activated protein kinase kinase 
MIP Molecular inversion probes 
MMR Mismatch repair 
Mob4 Phocein 
MPPH Megalencephaly-polymicrogyria- 
polydactyly-hydrocephalus 
MRI Magnetic resonance imaging 
MS Mass spectrometry 
MSI Microsatellite instability 
MST Mammalian Sterile 20-like kinase 
mRNA Messenger riconucleic acid 
mTOR Mammalian target of rapamycin 
N2A Neuro-2a 
NAP Nucleosome Assembly Protein 
NF-κB Nuclear factor-κB 
NGF Nerve Growth Factor 
NGS Next-generation sequencing 
NLS Nuclear localization signal 
NMDA N-methyl-D-aspartate receptors 
OA Okadaic acid 
P53 Protein 53 
PAD PP2A-activating drug 
PBS Phosphate-buffered saline 
PDE Phosphodiesterase 
PDK1 3-phosphoinositide-dependent kinase-1 
PEI Polyethylenimine 
PET Positron emission tomography 
PI3K Phosphoinositide 3-kinase 
PKA Protein kinase A 
PKC Protein kinase C 
PME1 PP2A Methyl Esterase 1 
PMSF Phenylmethylsulfonyl fluoride 
PP1 Protein phosphatase 1 
PP2A Protein phosphatase 2A 
PPZ phenothiazine 
PTPA Phosphatase Two A Phosphatase 
Activator 
PRR14L Proline rich 14-like 
Pwo Pyrococcus woesei 
Rb Retinoblastoma 
REC Research Ethics Committee 
RT-PCR Reverse Transcription-PCR 
SAM S-adenosylmethionine 
Ser Serine 
SET Suvar 3-9/Enhancer of zeste/Trithorax 
SGA Small for gestational age 
SIKE Suppressor of IKKε 
SLMAP Sarcolemmal membrane–associated 
protein 
SNP Single nucleotide polymorphism 
St Small t 
STK25 Serine/Threonine Kinase 25 
STRIPAK Striatin-interacting phosphatase and 
kinase complexes 
STRIP1 Striatin Interacting Protein 1 
SV40 Simian virus 40 
TAZ Tafazzin 
TBS Tris-buffered saline 
TEV Tobacco Etch Virus 
TGFβ Transforming growth factor 
TH Tyrosine hydroxylase 
Thr Threonine  
TIPRL Type-2A interacting protein 
TLCK N-alpha-tosyl-L-lysinyl-
chloromethylketone 
TrkA tropomyosin-related kinase A 
Tyr Tyrosine  
VEP Variant Effect Predictor 
WAIS Wechsler Adult Intelligence Scales 
WISC Wechsler Intelligence Scales for Children 
WT Wildtype 
YAP1  Yes-associated protein 1 
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INTRODUCTION 
1. Protein phosphatases of type 2A  
Reversible protein phosphorylation is extremely important in regulating many intra- and 
inter-cellular processes and is orchestrated by protein kinases and protein phosphatases, 
which attach and remove a phosphate group to and from a substrate protein, respectively 
[1, 2]. This post-translational modification can alter the activity, conformation and subcellular 
localization of target proteins in various signaling pathways, thereby affecting processes like 
cell proliferation, differentiation, apoptosis, DNA replication, growth and cell division [3]. In a 
normal cell, the function of one third of the cellular proteins is controlled by phosphorylation  
[4]. The majority of phosphorylations occurs on Ser/Thr residues with 86.4% on Ser and 
11.8% on Thr residues, followed by 1.8% on Tyrosine (Tyr) residues [5]. Paradoxically, 385 
Ser/Thr kinases exist in the cell, which are counteracted only by 21 Ser/Thr phosphatases, 
leading to the misconception that phosphatases are less specific enzymes [4]. Specificity is 
however achieved through the formation of large protein phosphatase families made up by 
many multi-subunit holoenzymes and assembled from just a limited number of catalytic 
subunits. In addition, transient phosphorylations and interactions with regulatory and 
inhibitory proteins regulate activity and substrate specificity. So, phosphatases are clearly 
subjected to strict regulation and are equally important as kinases in maintaining proper 
protein phosphorylation balance [6]. 
 
1.1. PP2A: a family of specific serine/threonine phosphatases 
Protein Phosphatase type 2A or PP2A represents such a large family of phosphatases and 
constitutes the majority of Ser/Thr phosphatase activity in the cell together with protein 
phosphatase 1 (PP1) [7]. PP2A is essential, ubiquitously expressed and highly conserved 
(from yeast to mammals) [8]. Importantly, its dysfunction has been linked to diverse 
pathologies, like Alzheimer's disease, diabetes, intellectual disability, cancer, etc. [9-12].  
In mammalian cells, PP2A exists as either a dimer (PP2A-AC) or a trimer (PP2A-ACB) [6] 
(Figure 1). The 36 kDa catalytic subunit (PP2Ac, C) can associate with a 65 kDa structural or 
scaffold subunit (PR65/A, A) to form the dimeric complex PP2A-AC [13, 14]. For both A and 
C subunits two isoforms exist in the cell, α and β. Although they possess high sequence 
similarities, these isoforms are functionally non-redundant [15-18]. Furthermore, Aα 
accounts for 0.1% of the total cell protein [4]. The core dimeric structure can exist in this 
form and is estimated to constitute one third of the total PP2A pool [6]. However, the dimer 
also associates with one of multiple regulatory B-type subunits with a molecular weight 
ranging from 48 to 130 kDa, to form a trimer. The B subunit is the major regulator of PP2A 
activity, defining substrate specificity and subcellular localization [19]. The B-type subunits 
are grouped into four different families, called B55/PR55/B, B56/PR61/B', PR72/B'' and 
PR93/PR110/B'''. These families are diverse and do not show any sequence similarities [6]. 
Every family contains at least 4 different isoforms with varying tissue distribution, subcellular 
localization and developmental expression. Together, the B regulatory subunits comprise a 
minimum of 26 different transcripts and splice variants encoded by 15 different genes [4]. As 
a consequence, the combination of the different isoforms of A, B and C can give rise to at 
least 96 different PP2A holoenzymes, all presumably with different functions in diverse 
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cellular processes such as transcription, translation, DNA replication, apoptosis and cell 
division [6]. 
 
Figure 1: PP2A holoenzyme structure [6]. The PP2A holoenzyme consists of two or three different 
subunits. The PP2A core dimer (PP2A-AC) consists of a catalytic C subunit that binds with a structural 
A subunit (PR65/A). This dimer can associate with a regulatory B-type subunit, which determines the 
activity, substrate specificity and localization of the trimeric complex. There are two isoforms of A and 
C subunits, namely α and β. The B-type subunits are grouped into four families: B55/PR55/B, 
B56/PR61/B', PR72 /B'', PR93/PR110/B'''. 
The structural A subunit bridges PP2Ac and the regulatory B-type subunit. It consists of a 
unique structure which contains 15 tandem repeats of 39 amino acids, known as HEAT 
(Huntington/elongation/A-subunit/TOR) motifs [20]. This 15-HEAT-repeat-molecule adopts a 
flexible L-shape structure [21]. The catalytic subunit binds with HEAT repeats 11-15, 
whereas regulatory subunits bind to HEAT repeats 1-8 [22, 23]. The different crystal 
structures of A in the monomeric (A [21]), dimeric (A-C [14, 24] and A-PR70 [25]) and 
trimeric (Bα [26], B’γ [20, 27, 28], PR70 [29]) forms reveal that the A subunit undergoes 
drastic conformational changes upon C and B binding, from a hook shape to a horseshoe-like 
conformation, probably contributing to the stability of the holoenzymes.  
 
The B55/PR55/B family consists of five isoforms (α, β, β2, γ and δ) encoded by four different 
genes (PPP2R2A, PPP2R2B, PPP2R2C and PPP2R2D). Bα and B δ are widely expressed, while 
Bβ, Bβ2 and Bγ are highly enriched in the brain. Structurally, the B subunits contain five 
degenerate WD-40 repeats, i.e. minimally conserved sequences of approximately 40 amino 
acids that typically end with tryptophan-aspartate, involved in protein-protein interactions 
[6]. B55/PR55/B subunit-containing complexes regulate apoptosis [30], mitosis [31], 
transforming growth factor-β (TGF-β) signaling [32], extracellular signal-regulated kinase 
(ERK) signaling [33], angiogenesis [34], DNA damage signaling [35] and tau 
dephosphorylation [36]. 
 
The B56/PR61/B' subunits represent the largest family (isoforms α to ε) and is encoded by 
five different genes (PPP2R5A, PPP2R5B, PPP2R5C, PPP2R5D and PPP2R5E), of which some 
are alternatively spliced or translated. B’α and B’γ isoforms are abundant in heart, while B’β 
and B’δ have a high expression in brain. These family members possess a highly conserved 
central region, which is 80% identical, and very divergent N- and C-terminal domains. It is 
believed that the central core mediates interactions with A and C, while the divergent ends 
regulate the substrate specificity and subcellular targeting of the specific B’ holoenzyme [6]. 
Based on amino acid similarity and evolutionary conservation, the B56/PR61/B' family can be 
divided in two subgroups, B’αβε and B’γδ [37]. These subunits possess a unique feature 
among the different families because they are phosphoproteins (except B’γ1) [38]. 
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Holoenzymes harboring a B’ subunit have other substrates in mitosis/meiosis [31, 39], 
apoptosis [30], development [40] and dopaminergic signaling in the brain [41]. Importantly, 
they are also key regulators of several oncogenic targets like Akt, Wnt and c-myc [6, 42-45], 
and are therefore considered as the main tumor suppressive PP2A complexes.  
 
Human PR72/B” subunits are encoded by three different genes (PPP2R3A, PPP2R3B and 
PPP2R3C), of which the first two give rise to two alternative splice variants. All are 
ubiquitously expressed, except B”α2 and B”2, which are only found in heart and skeletal 
muscle. The PR72/B” subunits bind and are regulated by Ca2+ ions [46]. These PP2A 
holoenzymes have functions in non-canonical Wnt signaling [33], epidermal growth factor 
(EGF) signaling [47], DNA synthesis [6, 48], pocket protein dephosphorylation [49] and 
neuronal signaling [41]. 
 
The fourth B-type subunit family consists of the three highly homologous proteins PR110/B’’’ 
(striatin), PR93/B’’’ (S/G2 Nuclear Antigen, SG2NA) and zinedin, encoded by three genes 
(STRN, STRN3 and STRN4). All members are highly expressed in the central and peripheral 
nervous system, but are also present in many other tissues. They all contain four protein-
interaction domains: a Ca2+-calmodulin-binding domain, a caveolin-binding domain, a coiled-
coil domain and a WD-repeat domain [50]. Striatin family members serve as scaffold proteins 
to assemble multiple diverse and large signaling complexes that are involved in numerous 
functions like e.g. organ size control and development through the Hippo signaling [51], 
apoptosis [52], cell cycle control [53], Golgi assembly [54], estrogen receptor α (ERα) 
signaling [55], cell migration [56], and neural development [57]. All striatin family complexes 
encompass PP2Ac and A subunits. Together with germinal center kinase III (GCKIII) kinases 
and other components, they form STRIPAK or striatin-interacting phosphatase and kinase 
complexes [50, 58]. It is believed  that PP2A negatively regulates the kinases within this 
complex. In addition, distinct STRIPAK-like complexes have been discovered that are not yet 
known to contain both a kinase and PP2A. Interestingly, STRIPAK complexes have been 
linked to diseases like diabetes, autism, cancer, heart disease and cerebral cavernous 
malformation [50]. 
 
So far, studies addressing the functional roles of different PP2A complexes mainly relied on 
overexpression and/or depletion of specific B-type subunits in cellular models in vitro. Only a 
limited number of in vivo studies have been performed in mammals, showing a role for 
B56/PR61/B'δ in the central nervous system [59] and for B56/PR61/B'γ in cardiomyocyte 
maturation and survival [60]. This at least demonstrates that despite significant homology 
within a given B subunit family, individual B-type subunits serve non-redundant functions in 
a complex mammalian system.  
 
1.2. PP2A biogenesis: a complex and partially understood process 
During the formation or biogenesis of PP2A, the C subunit is synthesized as an inactive 
enzyme in order to prevent promiscuous/unrestricted activity of free PP2Ac immediately after 
translation [61]. This is necessary because uncontrolled phosphatase activity would pose a 
risk to the cell as long as it is not restrained by the interaction with other subunits. As a 
result, an activation mechanism exists that is coupled to the assembly of the complete 
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holoenzyme [62]. This biogenesis of active PP2A trimers is a complex step-by-step process 
that is tightly controlled by several essential PP2A regulators and modulators, including 
Phosphatase Two A Phosphatase Activator (PTPA), leucine carboxyl methyltransferase 1 
(LCMT1), protein phosphatase methylesterase 1 (PME1), Type-2A interacting protein 
(TIPRL1) and α4. 
The currently proposed model for PP2A biogenesis is shown in Figure 2. When PP2Ac is 
translated as an inactive form, it is believed that α4 binds to it to prevent its degradation 
[63]. Inactive PP2Ac can then associate with the A subunit, which competes with α4 to form 
an inactive PP2A-AC that is stabilized by complex formation with PME1. PME1 has a dual 
role, stabilizing inactive PP2Ac by binding to it and preventing premature PP2Ac methylation 
via its methylesterase activity [64]. In a next step, PTPA is responsible for the catalytic 
activation of the complex. PTPA induces a conformational change in PP2Ac, potentially via its 
peptidyl-prolyl cis/trans isomerase activity on Proline 190 [65], resulting in the dissociation of 
PME1 [14]. After activation by PTPA, the PP2Ac C-terminal tail is able to be methylated on 
the free carboxyterminus of the C-terminal Leucine (Leu) 309 by LCMT1 [66]. This 
modification, on its turn, promotes association with most/certain B-type subunits to form an 
active holoenzyme [19] (See further). Recently, a role for the A subunit was suggested in 
facilitating Leu309 methylation by LCMT1 through stabilization of a proper protein fold and 
an active conformation of PP2Ac, via limiting the space of PP2Ac-tail movement for facilitated 
entry into the LCMT1 active site, and by conferring weak electrostatic interactions with 
LCMT1 through the N-terminal HEAT repeats [67]. How TIPRL1 is involved in this process is 
speculative: it could play a role in the assembly process, or rather later on, in neutralizing 
PP2Ac upon stress-induced holoenzyme disassembly and, subsequently, making it available 
for reassembly (as part of the adaptive responses to the stress) or promoting its 
degradation. 
 
Figure 2: Biogenesis model proposed for PP2A. Figure adapted from [62].  
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1.3. The role of PP2Ac post-translational modifications in holoenzyme assembly 
All PP2A-like phosphatases, including PP4 and PP6, possess a conserved C-terminal tail in 
their C subunit. Different post-translational modifications (phosphorylation and methylation) 
of this 304-TPDYFL-309 tail can influence the binding affinity with certain B-type subunits, 
and therefore, might either play a positive or a negative role in the assembly of a certain 
holoenzyme. Moreover, fluctuations in the methylation and/or phosphorylation levels of the C 
subunit tail might provide a theoretical basis for dynamic subunit exchange in PP2A 
complexes, resulting in altered PP2A targeting and substrate specificity [19]. Indeed, 
variations in C-tail methylation patterns have been demonstrated in both physiological and 
pathological circumstances [68].  
 
As introduced in the biogenesis model, a vital post-translational modification of the flexible 
304-TPDYFL-309 motif of the C subunit is the methylation of the carboxy-terminal Leu309. 
In vivo, 70 to 90% of PP2Ac is estimated to be methylated [19]. It is catalyzed by the S-
adenosylmethionine (SAM)-dependent enzyme LCMT1 and reversed by the methylesterase 
PME1. These PP2Ac modifying enzymes bear indispensable functions since knockout of either 
LCMT1 [69] or PME1 [70] in mice is lethal. While PME1 is mainly localized in the nucleus, 
LCMT1 is predominantly present in the cytoplasm and also in the Golgi apparatus and early 
endosomes. So, spatial control of methylation/demethylation exists [19]. PME1 fulfills a dual 
role: it reverses the Leu309 methylation on the C-terminal tail of PP2Ac [71] and 
binds/stabilizes the newly synthesized inactive PP2A in the early steps of PP2A biogenesis 
[64, 71, 72]. The PP2A-LCMT1 structure reveals that the C-terminal tail occupies the deep 
active site pocket in the Lid domain of LCMT1. In addition, contacts with the active site of 
PP2A are necessary to facilitate binding of the C-tail to LCMT1. Like that, conformational 
changes of the LCMT1 active site are induced to form the C-tail binding pocket and the 
binding affinity between LCMT1 and PP2Ac is increased. So, a tight link between PP2A 
methylation and the active conformation of PP2A exist, highlighted by the facts that (1) 
mutations in the PP2A active site abolish its methylation, (2) two highly potent phosphatase 
(active site) inhibitors okadaic acid (OA) and microcystin LR prevent PP2A methylation and 
(3) the C subunit conformation in the PP2A-LCMT1 complex is very similar to that in the 
PP2A-ACB trimer [73]. According to mutational studies, PP2Ac subunit methylation is 
essential for binding of the B55/PR55/B subunits but is not absolutely required for interaction 
with the PR65/A, B56/PR61/B', PR72/B” and PR93/PR110/B''' subunits (Figure 3). Moreover, 
B’δ, PR72, PR70 and the striatins [74, 75] can still associate with a deletion mutant of the 
entire C-tail, suggesting that these B-type subunits do not need stabilizing contacts with the 
catalytic subunit within the holoenzyme. For B'αβε subunits, Leu309 methylation is not 
essential but facilitates the incorporation in the holoenzyme. In these cases, a contact with 
PP2Ac is required [74]. For B'γ, the PP2Ac C-terminal determinants facilitating its 
incorporation in the holoenzyme have not been reported. Recently, the crystal structure of 
an A-PR72 PP2A dimer was published, confirming that at least PR72 is able to associate with 
the A subunit without the need for C subunit binding [25]. 
 
The C-terminal tail motif also undergoes phosphorylation of Tyr307 and Thr304. Either Tyr 
or Thr phosphorylation leads to inhibition of PP2A activity [62]. Tyr307 can be 
phosphorylated by different Tyr kinases, such as pp60v-src, pp56lck, and the epidermal 
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growth factor and insulin receptors. This Tyr307 phosphorylation is increased by OA-
mediated PP2A active site inhibition, implying that there is a reactivation mechanism for 
PP2A via auto-dephosphorylation [76]. This also implies that PP2A could function as a 
phospho-tyrosine phosphatase. The formation of B55/PR55/B and B56/PR61⁄B’-containing 
PP2A complexes is inhibited by Tyr307 phosphorylation, possibly because addition of a bulky 
phosphate on Tyr307 prevents access of the tail into the C-tail binding pocket of LCMT1, 
therefore preventing methylation [77]. On the other hand, only the formation of 
B55/PR55⁄B-containing PP2A complexes is inhibited by Thr304 phosphorylation, which 
occurs during mitosis [78] and does not affect Leu309 methylation (Figure 3).  
 
 
Figure 3: Different PP2A holoenzyme families require specific codes of post-translational 
modifications on the PP2Ac C-terminal 304-TPDYFL-309 tail for stable integration within trimeric 
holoenzymes. Flags represent a phosphorylation event and methylation is indicated by circles. Red: 
not modified, green: modified, yellow: no preference. Figure adapted from [19]. 
 
2. PP2A alterations in disease 
Alterations in PP2A function and/or activity have been reported in many human diseases, 
including Alzheimer's disease, diabetes, intellectual disability, cancer, etc. [9-12]. For the 
puspose of this thesis, I will here discuss in more detail the pathological role of PP2A 
alterations in human cancer and intellectual disability.  
 
2.1. Cancer  
Cancer is a generic term for a group of diseases, characterized by uncontrolled growth, 
invasion and potentially metastasis of cells. The transformation from normal into malignant 
cells, called tumorigenesis, is a multistep process in which genetic or epigenetic alterations 
activate oncogenes and/or inactivate tumor suppressors. When cells become malignant, they 
acquire essential common characteristics or hallmark capabilities, reviewed by Hanahan and 
Weinberg [79], which include: sustained chronic proliferation, growth repression evasion, 
apoptosis evasion, replicative immortality, angiogenesis induction, invasion and metastasis, 
avoidance of immune destruction, deregulation of cellular energetics, genomic instability and 
increased mutation rates. These hallmarks are common, but the order in which they are 
acquired can differ between cancer types and subtypes. Moreover, the role of a specific 
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genetic aberration may vary substantially between tumors, in the sense that it can partially 
or fully contribute to the acquisition of a certain hallmark, or that this event may aid in the 
simultaneous acquisition of several distinct hallmarks. Nevertheless, independently of how 
and when these hallmarks are acquired, at the biological endpoint of cancer, the same 
hallmarks will be shared by all types of human tumors.  
2.1.1. PP2A, a well-established tumor suppressor 
Since the large family of PP2A holoenzymes is involved in nearly every cellular process, it 
comes of no surprise that malfunctioning of PP2A can contribute to the acquisition of the 
hallmarks of cancer. PP2A is indeed considered as an important tumor suppressor in the cell. 
Several observations firmly establish this: 
(1) The pharmacological PP2A inhibitor Okadaic Acid (OA) is a potent tumor promoter, 
underscoring a negative role for PP2A in tumorigenesis. OA is a polyether fatty acid 
produced by marine dinoflagellates and causes diarrhetic shellfish poisoning [80]. In 1998, it 
was found to bind to PP2Ac, via a hydrophobic cage not found in other Ser/Thr 
phosphatases, and to potently inhibit its phosphatase activity [3]. Moreover, when injected 
into mice, OA causes cancerous laesions on the skin and tumors in the liver and stomach 
[80].  
(2) The expression of viral tumor antigens by small DNA tumor viruses plays an important 
role in cell transformation, since they can bind to cellular proteins involved in signaling 
pathways controlling cell growth, thereby affecting their normal functioning [43]. Moreover, 
these viral tumor antigens can inactivate tumor suppressors, including p53, retinoblastoma 
(Rb) and PP2A. For instance, small t antigen of simian virus 40 (SV40 st) or polyoma virus 
are able to inactivate PP2A by binding to the A subunit and substituting for the B subunit in 
the holoenzyme [81]. 
(3) In a cellular model of transformation, the so-called HEK-TER system reported by Hahn 
et al. 1999, inhibition of PP2A by SV40 st is essential to cause the full transformation of 
human cells immortalized by hTERT, SV40 large T (LT) and oncogenic Ras [82]. 
Transformation was evaluated in vitro by anchorage-independent growth and in vivo by 
tumor formation in immune-deficient mice.  
With an increasing amount of cell divisions, the telomeres become increasingly shortened, 
leading to genomic instability and cell death. Expression of the catalytic subunit of 
telomerase hTERT ensures a stable length of the telomeres, thereby preserving chromosome 
integrity and cell viability. SV40 LT inhibits the tumor suppressors p53 and Rb, and 
expression of oncogenic Ras stimulates cell growth (MAPK pathway), survival (Akt pathway) 
and migration (Ral pathway). At least two of these Ras effectors need to be activated in 
order for human cells to become tumorigenic. Also, sole expression of Ras in normal cells 
causes oncogenic stress-induced senescence, therefore p53 and Rb need to be inactivated to 
circumvent this and cause cellular transformation [83]. Of note, members of the Ras 
signaling pathways are the most mutated oncogenes in human tumors [82]. Together, co-
expression of hTERT, Ras and SV40 LT results in the immortalization of human cells. To 
achieve complete transformation, PP2A needs to be inhibited by SV40 st [84]. Indeed, PP2A-
binding defective mutants of SV40 st are not able to cause transformation within the HEK-
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TER system [37], plus reduction of Cα levels (accompanied by the degradation of multiple 
PP2A subunits) nearly completely mimics the tumorigenic phenotype caused by SV40 st 
expression, confirming that PP2A is the major cellular target of SV40 st [84, 85]. By 
manipulating the levels of A in the HEK-TER system, it was revealed that a 50% reduction of 
Aα could completely transform cells, while complete deletion causes apoptotic cell death 
[86]. Interestingly, the main holoenzyme affected by 50% loss of Aα is AB’γC, as opposed to 
other PP2A complexes which were less affected by Aα suppression [86]. This observation 
indicates that dynamic subunit exchange could occur in vivo due to competition of the B-type 
subunits for binding to Aα.  
 
The HEK-TER system was also exploited to identify specific PP2A subunits involved in cell 
transformation by scoring to what extent loss-of-function of a certain subunit could mimic 
the tumorigenic phenotype caused by SV40 st. Three regulatory B subunits, B’α, B’γ and 
PR72/PR130, and the biogenesis regulator PTPA were identified as being important for 
protection against cellular transformation [87]. Several key oncogenic proteins were 
disturbed in these tumorigenic cells: B’α and PR72/PR130 suppression caused increased 
expression of c-myc, while suppression of B’γ resulted in Akt activation and increased β-
catenin-dependent transcription (canonical Wnt pathway). All three pathways were affected 
by PTPA suppression, consistent with its role in PP2A biogenesis and holoenzyme formation. 
Indeed, a decreased level of C-tail methylation was detected together with reduced 
interaction between A and C [87]. Importantly, while PTPA suppression was able to very 
closely mimic cell transformation caused by SV40 st expression, suppression of the individual 
B-type subunits could only partially transform cells. In addition, overexpression of B’γ could 
only partially rescue the SV40 st tumorigenic phenotype, suggesting that SV40 st likely 
affects multiple tumor suppressive PP2A complexes [86]. Several additional studies confirm 
the importance of PP2A’s tumor suppressive function on the Wnt, Akt and c-myc pathway. 
For instance, constitutive PI3K signaling [88], a combination of constitutive active Akt and 
Rac1 [89], and oncogenic c-myc (T58A mutant, unable to be dephosphorylated on Ser62 by 
PP2A) [90] replaced SV40 st in anchorage-independent growth assays. However, it is likely 
that additional oncogenic pathways controlled by PP2A are involved. For instance, loss of the 
cyclin-dependent kinase (CDK) inhibitor p27/Kip1 also substitutes for SV40 st [91]. Finally, 
either LCMT1 knockdown or PME1 overexpression cause cell transformation (evaluated via 
anchorage-independent growth) only in combination with B’γ suppression, resulting in 
upregulation of Akt and p70S6 kinase pathways [92]. Also, Cancerous Inhibitor of PP2A 
(CIP2A), a cellular inhibitor of PP2A activity towards oncogenic c-myc, is able to completely 
mimic the tumorigenic phenotype of SV40 st [93].  
 
(4) Perhaps, the most convincing evidence sustaining a tumor suppressive role of PP2A is the 
in vivo data from two PP2A knockout (KO) mice, obtained in our laboratory. Both Ppp2r5d 
(encoding PR61⁄B’δ) and Ppp2r4 (encoding PTPA) KO mice show indeed spontaneous cancer 
phenotypes (unpublished work).  
2.1.2. Genetic alterations of PP2A in tumor cells 
Not surprisingly, a growing amount of PP2A-inactivating mechanisms in cancer is being 
discovered, further sustaining its important tumor suppressive properties. These include 
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mutations in PP2A subunit encoding genes, aberrant expression of PP2A subunits and 
regulatory proteins involved in PP2A biogenesis (PTPA, PME1 and TIPRL1), and 
overexpression of cellular PP2A inhibitors.  
Mutations in and aberrant expression of PP2A subunit encoding genes 
In different types of cancer, the A and B-type subunits have been found to be mutated or 
abnormally expressed.  
(1) Reduced expression of Aα was found in 43% of gliomas [94]. In addition, several 
mutations of the Aα subunit, identified at low frequency (E64D in lung cancer, E64G in 
breast carcinoma and R418W in melanoma), cause defects in holoenzyme formation through 
haploinsufficiency [95-97]. In accordance, a knock-in mouse expressing the E64D mutation 
showed a 50 to 60% increase in the incidence of lung cancer induced by benzopyrene [17]. 
In the last few years, however, it became apparent that the frequency of Aα mutants is 
much higher in certain subtypes of endometrial cancer, ranging roughly from 20% to 40% 
[98-105]. This suggests an important role for Aα (and PP2A) in the pathogenesis of uterine 
cancer. Many of these mutations (P179L/R, R182W, R183G/Q/W, R249H, S256F/Y, 
W257C/G, R258C/H/Y) are recurrent and cluster together in HEAT repeats 5 and 7.  
(2) Aβ mutations have been discovered in colorectal, lung, breast and gastric cancers and 
some of these can result in increased activity of RalA, due to complete loss of RalA 
dephosphorylation, and tumor formation [18]. The Aβ gene locus is prone to loss-of-
heterozygosity and subsequent loss of this locus is reported in cervix, ovary, stomach, 
bladder and breast carcinomas and in melanoma [106].  
(3) Mutations in B-type subunits occur at low frequency in a wide variety of cancers. For 
example, in melanoma (B’γ), c-kit-positive acute myeloid leukemia (Bα and multiple B’), lung 
cancer (Bα and B’γ) and breast cancer (Bα). These mutations result in defects in paxillin 
dephosphorylation, double strand DNA repair, p53 functioning and Akt dephosphorylation 
[35, 107-112]. To further elaborate on this, a search in the cBioportal for Cancer Genomics 
database (http://cbioportal.org) for aberrations in the different PP2A subunits revealed some 
additional interesting observations. Firstly, Cβ and Bα are obviously deleted in a large 
number of cancers, for instance in up to 13.1% of metastatic prostate adenocarcinoma and 
up to 14.7% of prostate adenocarcinomas, respectively. Another obvious observation is the 
amplification of B’α and B’δ in up to 12.4% in liver and breast cancer and up to 10% in 
esophageal carcinoma, respectively. Bβ is mostly amplified (most frequently in kidney renal 
clear cell carcinoma (16.9%)) and mutated (highest frequency in colorectal adenocarcinoma 
(5.6%)). PR72/PR130 has the highest frequency of amplification (13.5%) and mutation 
(9.4%) in lung squamous cell carcinoma. Cα was found overexpressed in kidney renal clear 
cell carcinoma (16.1%). B’β,γ,ε and PR110/B’’’ (striatin), PR93/B’’’ (SG2NA) and zinedin show 
mixed aberrations, not exceeding frequencies above 8%. 
Alterations in regulators of PP2A biogenesis  
α4 is found highly expressed in hepatocellular carcinoma (HCC), lung cancer, and breast 
cancer [113]. PME1 is also overexpressed in several cancers like glioblastoma, endometrial 
cancer, breast cancer, melanoma, head and neck cancer, etc. with a frequency of 5-10% 
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(cBioportal). Thus, increased PP2A demethylation may be tumorigenic. Heterozygous loss of 
PPP2R4, the gene encoding PTPA, was discovered at strikingly high frequencies in uterine, 
lung, liver, renal breast and pancreatic cancer and in melanoma (cBioportal). This loss may 
be associated with the presence of less active PP2A in the cell, responsible for the tumor 
formation. Besides heterozygous loss of PPP2R4, other alterations, like mutations, were 
found at a lower frequency in various cancers (cBioportal). 
Overexpression of cellular PP2A inhibitors 
By far the most frequent PP2A aberration in cancer is the overexpression of cellular inhibitors 
of PP2A, the most studied being SET (Suvar 3-9/Enhancer of zeste/Trithorax) and CIP2A. 
This occurs in a variety of cancer types, often with high frequency and associated with 
cancer aggressiveness and poor outcome. In my review article, ‘Cellular inhibitors of Protein 
Phosphatase PP2A in cancer’ (Chapter 3, [114]), the mechanisms of action, regulation and 
function of these PP2A inhibitors are highlighted, and it is discussed how this knowledge 
might be exploited for therapeutic use.  
 
Together, the above findings highlight the multiple mechanisms by which PP2A can be 
inactivated in cancer, underscoring the fact that PP2A is an important tumor suppressor. 
Specifically for hematological malignancies, these mechanisms causing aberrant PP2A 
functioning are reviewed in ‘The basic biology of PP2A in hematologic cells and malignancies’ 
(Chapter 4 [115]). Although reluctantly, the combined data have increased the interest in 
exploiting ‘PP2A reactivation’ as a therapeutic strategy in human cancers, as discussed later 
on [116]. Nevertheless, the clinical utility of using the “PP2A status” as a stratification marker 
in human tumors cells still largely remains underestimated and underexploited. This is 
particularly relevant in cancer types where PP2A aberrations occur with high frequency, such 
as certain subtypes of endometrial cancer.  
2.1.3. Epidemiology of endometrial cancer 
Endometrial cancer is the most common gynecological malignant disease; others are ovarian, 
cervical, vulval and vaginal cancer. Worldwide, endometrial cancer is the sixth most common 
malignant disorder with approximately 290,000 new cases annually and it is the fourth most 
common cancer in Belgian women after breast, colorectal and lung cancer ([117], Stichting 
Tegen Kanker). In 2010, 1450 (5%) new cases and 214 deaths were reported in Belgium. 
Newly diagnosed patients have a 5-year relative survival rate of 80%, ranging from 94.5% 
for early disease to 19.5% for advanced disease [118]. Over 90% of cases occur in women 
older than 50 years of age, with 63 as a median age [119]. The most common symptoms 
patients suffer from, include abnormal uterine bleeding and vaginal discharge, presenting in 
90% of the cases. Patients with advanced disease may also experience abdominal or pelvic 
pain, early satiety, abdominal distension, or change in bowel or bladder function, symptoms 
often associated with advanced ovarian cancer [120]. Of all the gynecologic cancers, only 
cervical cancer can be detected by a standard screening test, called the Papanicolaou or Pap 
test, and this early in the disease when treatment is most effective. For endometrial cancer, 
the diagnosis is based on the histology of endometrial tissue obtained during a biopsy with 
the Pipelle aspiration catheter. To determine the stage of the disease, clinical examination, 
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transvaginal ultrasound, computed tomography (CT) scan, magnetic resonance imaging 
(MRI), and integrated positron emission tomography and computed tomography (PET/CT) 
scan can be performed to evaluate the presence of metastases. Preoperative staging aids in 
determining the proper treatment options for patients and is based on the international 
Federation of Gynecology and Obstetrics (FIGO) system. 72% of patients are diagnosed with 
stage I disease, meaning that the tumor is confined to the body of the uterus. When the 
tumor has invaded the cervical stroma, but does not extend beyond the uterus, patients 
suffer from stage II endometrial cancer, as is the case in 12% of patients. Stage III defines 
local and/or regional spread (with for example vaginal involvement and lymph node 
metastasis), present in 13% of patients. 3% suffers from stage IV disease, meaning that the 
tumor invaded the bladder and/or bowel mucosa, with or without the presence of distant 
metastases, mostly in the lung [117, 121]. Tumors may additionally be grouped according to 
their level of differentiation in G1 (well differentiated), G2 (moderately differentiated) and G3 
(poorly or undifferentiated) [117]. 
 
Traditionally, endometrial carcinoma is classified into two main groups, as defined by 
Bokhman [122]: type I and type II (Table 1).  
Type I endometrial carcinoma (87-90% of cases [123]) is composed of low grade 
endometrioid carcinoma, which are estrogen dependent and develop from endometrial 
hyperplasia [100]. Most women are diagnosed after menopause and the stage at diagnosis is 
commonly FIGO stage I and II. Established risk factors are early onset of menstruation, 
nulliparity, late menopause and unopposed estrogen exposure due to estrogen replacement 
therapy to control menopausal symptoms, estrogen-producing tumors, tamoxifen treatment, 
polycystic ovarian syndrome, etc. [120]. In addition, insulin resistance, associated with 
obesity (causing high estrogen production in adipose tissue) and diabetes, can co-occur. 
Excessive insulin levels will stimulate insulin growth factor pathway, leading to tumorigenesis 
[124]. Insulin also inhibits the production of globulin, a sex hormone binding protein, 
resulting in increased levels of the sex hormones androgen and estrogen. It also promotes 
synthesis of androgens in the ovaries. An epidemic of obesity in high-income countries is 
likely the reason for a difference in incidence of endometrial cancer in high-income vs. low-
income countries (5.5% vs. 4.2%). However, the specific mortality is higher in the latter, due 
to a higher prevalence of the aggressive, high-grade cancer type. Other risk factors are age 
and a family history of Hereditary Non-Polyposis Colon Cancer (HNPCC), also known as 
Lynch Syndrome, which is an inherited cancer syndrome causing mainly colon cancer, but 
also other cancer types, most commonly endometrial cancer. Inactivating mutations in DNA 
mismatch repair (MMR) genes cause this disease. Patients with HNPCC have a 20 to 70% 
risk for developing endometrial cancer depending on the specific MMR mutation [125]. 
Interestingly, a reduced risk is associated with the use of combination oral contraceptive pills 
or progesterone secreting intra-uterine devices. Smoking also reduces the risk for 
endometrial cancer, especially in postmenopausal women [120]. Type I endometrial cancer 
is typically diagnosed at early stage before extra-uterine metastasis and, therefore, has an 
overall favorable prognosis. Surgery is curative in many cases. This type is characterized by 
high frequency genomic alterations affecting PIK3CA, PIK3R1, PTEN, KRAS, FGFR2, ARID1A 
(BAF250a), and CTNNB1 (β-catenin), as well as microsatellite instability (MSI) due to 
epigenetic silencing of MMR genes [126]. So, mainly the PI3K/Akt/mTOR (cell growth and 
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survival) and Wnt/β-catenin signaling (gene transcription and development) pathways drive 
tumorigenesis in these tumors.  
Type II endometrial carcinoma includes mainly the uterine serous adenocarcinoma (2.9-
10.5% of cases [123]) and the clear-cell adenocarcinoma (2.2-3.2% of cases [123]). Serous 
adenocarcinoma is estrogen independent and arises in atrophic endometrium and 
endometrial polyps from preinvasive lesions called serous endometrial intraepithelial 
carcinoma [100]. Although this type constitutes only a small percentage of all endometrial 
cancers, it accounts for a disproportionately high number of deaths due to its high 
aggressiveness and high tendency to metastasize. These tumors are typified as FIGO stage 
III and IV. Moreover, type II endometrial carcinomas are highly resistant to conventional 
chemotherapy and recurrence is almost inevitable. These tumors tend to be aneuploid and 
are characterized by frequent genomic alterations affecting TP53 (p53), PPP2R1A (PP2A Aα), 
HER-2/ERBB2, PIK3CA, and PTEN; plus dysregulation of E-cadherin, p16 and BAF250a. So, 
again the PI3K/Akt/mTOR and Wnt/β-catenin signaling seem to be important, together with 
inactivation of tumor suppressors p53 and PP2A.  
 
Table 1: Traditional classification of endometrial cancer. Table constructed with data obtained from 
[123, 126, 127]. PPP2R1A is highlighted in bold. 
 Type I  Type II 
Features   
Background endometrium 
Estrogen dependent 
Myometrial invasion 
Metastatic spread 
Prognosis 
Prototypical histological type 
Stage at diagnosis 
Hyperplasia 
Yes 
Superficial 
Low 
Favorable 
Endometrioid 
Early (FIGO stage I and II) 
Atrophy 
No 
Deep 
High 
Unfavorable 
Serous 
Advanced (FIGO stage III and IV) 
Common genetic aberrations  
PTEN mutation 
PIK3CA mutation 
PIK3CA amplification 
PIK3R1 mutation 
KRAS mutation 
AKT mutation 
ARID1A mutation 
CTNNB1 mutation 
TP53 mutation 
PPP2R1A mutation 
FGFR2 mutation 
HER2 amplification 
HER2 overexpression 
Nuclear accumulation of β-catenin 
E-cadherin loss 
Loss of function of p16 
MSI 
52-78% 
36-52% 
2-14% 
21-43% 
15-43% 
3% 
25-48% 
23-24% 
9-12% 
5-7% 
12-16% 
1% 
3-10% 
18-47% 
5-50% 
8% 
20-45% 
1-11% 
24-42% 
46% 
0-12% 
2-8% 
0% 
6-11% 
0-3% 
60-91% 
15-43% 
1% 
27-44% 
32% 
0% 
62-87% 
45% 
0-5% 
 
Important to emphasize is that an overlap exists between type I and type II endometrial 
tumors and that heterogeneity is present within each of these types. To clarify, low-grade 
endometrioid and high-grade serous adenocarcinoma integrate well in the Bokhman model, 
but 10 to 19% of endometrioid adenocarcinomas are high-grade and have features that are 
intermediate between type I and II or are more resembling those of type II endometrial 
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cancer [127]. Likewise, not all serous adenocarcinomas show prototypical type II 
characteristics. Moreover, none of the mutations in any of the disease genes identified so far 
can be exclusively assigned to a specific type. For instance, mutations in TP53 are present in 
90% of the serous type and 10% of low-grade and 30% of high-grade endometrioid 
adenocarcinomas [127]. Consequently, the Cancer Genome Atlas Research Network recently 
proposed a genomic classification, which can aid in reclassification of the different subtypes 
of endometrioid and serous carcinomas and the identification of potential targets for 
targeted treatment of different subgroups of the disease (Table 2). From these data, it is 
clear that mutations in PPP2R1A are associated with poor outcome and aggressive behavior 
of both the endometrioid and serous types of endometrial adencarcinoma.  
 
Table 2: Features of the four genomic classes of endometrioid and serous carcinomas, as defined by 
The Cancer Genome Atlas Network. Table adapted from [127]. PPP2R1A is highlighted in bold. 
 POLE 
(ultramutated) 
MSI  
(hypermutated) 
Copy-number low 
(endometrioid) 
Copy-number high 
(serous-like) 
Copy-number 
aberrations 
low Low  Low  High  
MSI Mixed (high, low, 
stable) 
High stable Stable 
Mutation rate Very high High Low Low 
Genetic aberrations  POLE (100%) 
PTEN (94%) 
PIK3CA (71%) 
PIK3R1 (65%) 
FBXW7 (82%) 
ARID1A (76%) 
KRAS (53%) 
ARID5B (47%) 
PTEN (88%) 
RPL22 (37%) 
KRAS (35%) 
PIK3CA (54%) 
PIK3R1 (40%) 
ARID1A (37%) 
PTEN (77%) 
CTNNB1 (52%) 
PIK3CA (53%) 
PIK3R1 (33%) 
ARID1A (42%) 
TP53 (92%) 
PPP2R1A (22%) 
PIK3CA (47%) 
Histological type Endometrioid Endometrioid Endometrioid Serous, 
endometrioid, and 
mixed 
serous and 
endometrioid 
Progression-free 
survival 
Good Intermediate Intermediate Poor 
 
 
The golden standard treatment of endometrial carcinoma is surgery, including total 
hysterectomy (surgical removal of uterus and cervix) and bilateral salpingo-oophorectomy 
(surgical removal of fallopian tubes and ovaries). The type and FIGO stage determines the 
precise surgical procedure and the need for additional lymph node dissection and 
omentectomy. Moreover, the need for adjuvant therapies is evaluated based on information 
obtained from surgery [117, 119, 121, 128]. These adjuvant therapies include radiotherapy, 
chemotherapy, hormone and targeted therapy. Regarding radiotherapy and 
chemotherapy, depending on the FIGO stage and grade of the tumors, pelvic radiotherapy, 
vaginal brachytherapy and/or chemotherapy are performed, possibly in combination [119]. 
The combination of the chemotherapeutics carboplatin and paclitaxel is the standard 
adjuvant therapy for stage III endometrial cancer and is also standard first-line therapy for 
metastatic or recurrent disease [129]. Hormonal therapy is recommended for 
endometrioid histologies. The main hormone treatment for endometrial cancer employs 
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progesterone-like drugs called progestins which slow down the growth of cancer cells. 
Progestins represented the first-line treatment for endometrial cancer in the 1970s and are 
still used in appropriate settings, particularly for low-grade tumors that recur long after 
primary therapy. Tamoxifen, which is an anti-estrogen drug often used in breast cancer 
treatment, may also be used in the treatment of advanced or recurrent disease. 
Furthermore, gonadotropin-releasing hormone agonists are a way to lower estrogen levels in 
women who still have functioning ovaries. Aromatase inhibitors can block estrogen 
production in adipose tissue. These drugs are used in the treatment of breast cancer, but 
may also be utilized to treat endometrial cancer. The use of antiangiogenic agents, like 
bevacizumab, is currently under investigation. Recent understandings of the signaling 
pathways underlying tumorigenesis in endometrial cancer led to the evaluation of targeted 
therapies against these affected signaling molecules. For instance, the PI3K/Akt/mTOR 
pathway can be targeted at different levels via multiple drugs, for example with Akt, 
mTORC1, isoform-specific PI3K, Pan-PI3K, dual PI3K/mTOR and mTORC1/2 inhibitors [130]. 
Currently, however, the benefit of blocking the PI3K/Akt/mTOR pathway is disappointing and 
limited by cross-talk with the Ras/Raf/MEK pathway (Figure 4). Therefore, dual blockage 
might be more efficient in the future [131]. 
 
 
 
Figure 4: Pathway crosstalk exists between the Ras/Raf/MEK and PI3K/Akt/mTOR pathways. These 
pathways regulate each other via cross-activation (green) and cross-inhibition (red), often the basis 
for resistance. Figure adapted from [131]. 
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2.1.4. PP2A aberrations in endometrial cancer 
From the previous chapter it is clear that until the molecular pathogenesis of endometrial 
(serous) carcinoma is better understood, therapeutic interventions to improve the clinical 
outcomes of these patients remain empirical. The high frequency of mutations in PPP2R1A, 
hinting towards an important role of aberrant PP2A functioning in the pathogenesis, may be 
one of the opportunities that could be further exploited in this respect.  
 
Historically, a publication from 2010, reporting PPP2R1A mutations in 7% of ovarian 
clear-cell carcinoma [132], prompted the evaluation of the PPP2R1A mutational status in 
other gynecological cancers via whole genome sequencing and targeted (exon 5 and 6) 
approaches [100-103, 105, 133-135]. These studies revealed that somatic mutations in 
PPP2R1A occur at high frequency (18.4-43.2%) in the serous type of endometrial cancer, 
while the percentage is low (2.5-6.9%) in the endometrioid subtype. Since PPP2R1A 
mutations are specifically correlated with high grade endometrial carcinoma, both serous and 
endometrioid of origin (genomic classification of The Cancer Genome Atlas Research 
Network), these findings link the presence of these mutations to aggressiveness of the 
tumors and poor patient outcome [127]. The heterozygous mutations identified include 
P179L/R, R182W and R183G/Q/W, located in HEAT-repeat 5, and R249H, S256F/Y, 
W257C/G and R258H, located in HEAT-repeat 7; they all have been recurrently found in 
ovarian and in endometrial cancer (Table 3). Because structural and functional studies of 
PP2A indicate that the mutated HEAT-repeats 5 and 7 directly contact the B subunits, it was 
hypothesized that the mutations might affect PP2A holoenzyme assembly [22, 23, 96, 97, 
136]. The mutations described in endometrioid endometrial carcinoma and in ovarian 
carcinoma seem to more frequently involve residues R182 and R183, while in the serous 
endometrial tumors residues S256 and W257 and P179 seem to be much more affected. 
However, the significance of this uneven distribution is unclear [126]. Another interesting 
finding is the fact that PPP2R1A mutations occur in endometrial serous carcinomas but not 
(or barely) in ovarian serous carcinomas. This suggests that, although both tumor types 
share several clinical and pathological features, their pathogenesis is likely different. 
Therefore, the PPP2R1A status could also be used to distinguish these two serous cancer 
types [100, 101]. Lastly, no correlation was found between the occurrence of mutations in 
PPP2R1A and other genes frequently mutated in serous endometrial cancer, like TP53, KRAS 
and PIK3CA [103, 133]. 
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Table 3: Overview of the PPP2R1A mutations found in endometrial and ovarian carcinoma. 
Endometrial 
 
Ovarian 
Endometrioid Serous Endometrioid Serous Clear-cell 
[132]     7.1% (3/42) 
 
R183G (1) 
R183W (1) 
R182W (1) 
[101] 5% (3/60) 
 
R183Q (2) 
R249H (1) 
40.8% (20/49) 
 
P179R (6) 
P179L (3) 
R182W (1) 
R183W (2) 
S256F (6) 
S256Y (1) 
W257G (1) 
12.2% (5/41) 
 
P179R (1) 
R183W (2) 
S256Y (1) 
W257G (1) 
0% (0/62) 4.1% (2/49) 
 
R183W (1) 
W257C (1)§ 
R258C (1)§ 
[103] 6.7% (2/30) 
 
R183W (1) 
R182W (1) 
5/26 (19.2%) 
 
S256Y (1) 
P179R (1) 
S256F (2) 
W257G (1) 
10% (4/40) 
 
R183W (2) 
R183Q (1) 
R182W (1) 
0% (0/91) 9.1% (4/44) 
 
R183W (3) 
R183Q (1) 
[102] 6.9% (19/276) 
Low-grade 
 
R183Q (4) 
R183W (4) 
H87Y (2) 
R249H (1) 
R48Q (1) 
S256F (1) 
P179L (1) 
S219L (1) 
Q237R (1) 
S219L (1) 
VE99del (1) 
182insV (1) 
 
10% (3/30) 
High-grade 
 
R182W (1) 
R221W (1) 
R183W (1) 
43.2% (16/37) 
 
 
P179R (8) 
S256F (4) 
T102K (1) 
R183W (1) 
P179L (1) 
V182M (1) 
   
[133] 2.5% (3/118) 
 
W257C (1) 
E216K (1) 
R258Y (1) 
32% (8/25) 
 
R258H (1) 
P179R (3) 
R258Y (1) 
P179L (2) 
W257C (1) 
   
[100]  18.4% (14/76) 
 
P179R (7) 
R183W (3) 
S256F (1) 
S256Y (1) 
W257G (1) 
W257C (1) 
   
[105]  20% (6/30) 
 
P179R (4) 
S256F (2) 
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Table 3: Overview of the PPP2R1A mutations found in endometrial and ovarian carcinoma. 
(Continued from previous page) 
Endometrial 
 
Ovarian 
Endometrioid Serous Endometrioid Serous Clear-cell 
[134]   6.6% (1/15) 
High-grade 
 
P179R (1) 
4.5% (1/22) 
 
 
R183W (1) 
4.5% (1/22) 
 
 
R183Q (1) 
[135]   2.7% (1/37) 
 
W257C (1) 
0% (0/76)  0% (0/43)  
[137]  25% (13/52) 
 
P179R (5) 
S256F (3) 
W257S (1) 
W257C (3) 
L286P (1) 
   
[138]  4.5% (14/307) 
 
S256F (1) 
R183W (2) 
R258C (1) 
R258H (1) 
R221W (1) 
L173M (1) 
A41T (1) 
A164V (1) 
R105Q (1) 
R28C (2) 
A114V (1) 
R144C (1) 
V298L (1) 
A136T (1) 
Q237R (1) 
27.9% (12/43) 
 
S256F (2) 
P179R (7) 
S256Y (1) 
L_27splice (1) 
V220M (1) 
   
 
Worthwhile to mention is that PPP2R1A is also found mutated in endometrial 
carcinosarcoma. Two studies report frequencies of 26.8% (15/56) [139] and 21.4% (9/42) 
[102]. The recurrent mutations included P179R, S256F, R183W and S219L. Carcinosarcoma 
is a rare cancer of the endometrium, with a prevalence of less than 2%. It is a highly 
aggressive cancer, likely to present in an advanced stage [123]. Furthermore, PPP2R1A 
mutations were detected in 20% (4/20) of patients diagnosed with undifferentiated 
carcinoma. This relatively uncommon neoplasm is classified as a type of endometrioid 
carcinoma, although undifferentiated carcinoma displays a more aggressive behavior [99].  
Besides PPP2R1A mutations, two mutations in PPP2R5C, the gene encoding B’γ, were 
identified in endometrioid endometrial carcinoma, namely T182M and L168V [102]. 
PME1 overexpression was recently also detected in the endometrioid adenocarcinoma cell 
lines, RL95-2, Ishikawa, and ECC-1; and in 83% (24/29) of type I endometrial carcinomas 
[140]. This overexpression results in decreased PP2A activity, increased cell proliferation and 
metastases by causing ERK and Akt hyperphosphorylation. Increased PME1 levels also led to 
increased anchorage-independent growth and tumor formation in vivo. In addition, an 
enhanced interaction with PP4c, a tumor promoter, was found. However, whether PME1 
overexpression activates PP4 to promote cell proliferation or inhibits PP4 to counterbalance 
PP2A inhibition is unclear [140].  
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2.2. Intellectual disability 
Intellectual disability (ID), also called mental retardation, is defined as a collection of diverse 
and genetically heterogeneous disorders primarily characterized by central nervous system 
defects of varying severity. It can present as isolated cognitive defects or in association with 
additional neuromuscular, metabolic, dysmorphic or psychiatric features. The disability 
originates before the age of 18. Typically, patients have limitation in two areas: intellectual 
functioning and adaptive behaviors. Intellectual functioning is the ability to learn new and 
complex information, to learn new skills, to solve problems and make decisions, and is 
measured by standardized intelligence quotient (IQ) tests like the Wechsler Adult 
Intelligence Scales (WAIS) and the Wechsler Intelligence Scales for Children (WISC). The 
average IQ is 100 and ID has been defined as an IQ less than 70, with different severities: 
mild (70-51), moderate (49-36), severe (35-21) and profound (less than 20). Adaptive 
behaviors are the conceptional, social, and practical skills necessary to cope in day-to-day 
life, such as self-direction, interpersonal communication and relationship, personal care, etc. 
[141, 142]. ID is the leading socio-economic problem of health care in Western countries, 
exceeding the cost for dementia and even cancer [142]. Management of the disorder often 
requires a multidisciplinary approach, involving neurology, orthopedics, ophthalmology, 
audiometrics, cardiology, physiotherapy, psychology and dermatology. The prognosis of the 
patients depends on the severity of the symptoms. Early deaths have been reported rarely 
and are mainly due to feeding difficulties, complex cardiac heart disease and arrhythmia 
[142].  
 
2.2.1. Epidemiology of intellectual disability 
ID is thought to affect about 1 to 3% of the population worldwide, with in between 0.3 and 
0.5% of the population suffering from a severe form. This prevalence tends to be higher in 
developing compared to developed countries due to a variety of non-genetic factors like poor 
health care and malnutrition. In addition, inbreeding is associated with reduced cognitive 
performance. Other risk factors are low birth weight and prenatal and perinatal 
complications. Fetal alcohol exposure is the most common preventable cause of ID in the 
western world. Furthermore, moderate to severe ID is approximately 1.4 times more 
frequent in males than in females, for which the reason is still unknown. It is believed that 
mild ID is multifactorial, while severe forms are largely caused by catastrophic genetic 
defects, including chromosomal aberrations and mutations. 
 
Cytogenetically visible chromosomal aberrations account for almost 15% of all ID cases, 
including Down syndrome (trisomy 21) which is the most important single cause of ID with a 
prevalence of 1/750 to 1/800. Nevertheless, microdeletions and microduplications, too small 
to be detectable by conventional karyotyping, seem to be equally important and were 
previously overlooked causes of ID. X-linked gene defects are thought to be responsible for 
10 to 12% of the ID found in males [142, 143]. However, this percentage is not sufficient to 
explain higher prevalence of cognitive impairment in males compared to females, meaning 
there must be additional factors. De novo mutations represent an increasingly important 
cause of ID [144]. A de novo mutation affects the offspring but is not detectable in the 
parents. These mutations are typically present in the reproductive cell, sperm or egg, of one 
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of the parents and once transmitted to the child they are present in all cells and tissues. 
Postzygotic mosaicism means that the mutation arises during the mitotic cell divisions that 
generate the embryo, causing only a subset of cells/tissues to harbor the mutation. 
Regardless of the specific type of mutation, they are inherited relatively rarely because 
individuals suffering from these disorders are less likely to bear offspring, placing these 
mutations under strong negative selection. Consequently, the presence of the disorder in 
fact reveals the ongoing appearance of new de novo mutations.  
 
Approximately 80% of de novo mutations are paternal in origin, due to ‘selfish 
spermatogonial selection’ [145]. Because sperm undergoes many more cell divisions across 
the reproductive age compared to the female gamete, somatic mutations build up in the 
sperm which is proven to be associated with an increased transmission of de novo mutations 
onto the offspring of older men. This build-up causes dysregulation of the RAS pathway 
leading to within-testis proliferation of mutant sperm cells, a process akin to oncogenesis. 
Whole exome sequencing of parents and offspring showed that the total number of 
mutations strongly correlates with paternal age in which an increase of approximately two 
point mutations per year was shown, corresponding to a doubling of mutations every 16.5 
years. Indeed, a link was already established between advanced paternal age and other 
neurological disorders, like autism, bipolar disorder, epilepsy, Alzheimer’s disease, etc. [145]. 
 
2.2.2. Diagnosis – whole genome and exome sequencing 
Unfortunally, the cause of ID is still unknown in up to 60% of cases [146]. It is becoming 
more and more clear that ID, but also schizophrenia and autism, represent a heterogeneous  
collection of rare monogenic disorders, of which the large majority is still unknown [147]. 
Identifying the causative genes is crucial to provide molecular diagnosis for patients, to 
enable testing for gene carriers and prenatal testing, and to understand the underlying 
pathology of the disease leading to therapies. Recent advances in next generation 
sequencing technologies, enabling reliable whole genome sequencing and whole exome 
sequencing, have drastically changed the process of disease gene identification. Instead of 
focusing on the whole genome, whole exome sequencing is mainly performed. Exomes 
represent only 2% of the genome, but roughly 85% of known genetic causes of disease 
affect these protein coding regions [147]. Moreover, whole genome sequencing generates 
massive outputs, is time-consuming and is too costly to be used as a routine gene discovery 
technique. The cost of whole exome sequencing is 2 to 3 times lower compared to whole 
genome sequencing [148]. Different exome capturing techniques have been developed to 
enrich exomes before sequencing, like solid-phase and liquid-phase hybridization, 
polymerase-mediated capture and regional capture [149]. However, this is never complete. 
As tens of thousands of variants can be identified in each exome, it is important to select the 
pathogenic variants. For de novo mutations, this is achieved through child-parent exome 
sequencing to identify mutations not present in the parents but present in the child (=de 
novo). The result of such a ‘trio-sequencing’ approach is a limited number of potential 
pathogenic variants, since the average exome contains only 0 to 3 de novo mutations [147]. 
Of consideration is the fact that advances in NGS approaches comes with the inevitable 
identification of mutations unrelated to the condition in question, called secondary or 
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collateral mutations [150], which obviously requires development and application of 
consistent ethical guidelines when application of this technique is considered.  
 
In conclusion, whole exome (and genome) sequencing has provided clinicians and 
researchers with an increasing amount of genes involved in ID, but mechanistic insights and 
treatments have lagged behind. Therefore, efforts need to be made to overcome this gap.  
2.2.3. PP2A aberrations in intellectual disability 
Recently, several large-scale screening studies reported de novo (sometimes recurrent) 
mutations in multiple PP2A genes, suggestive of an important role of PP2A dysfunction in ID 
(Table 4).  
Table 4: De novo mutations in PP2A genes discovered in ID patients. 
PP2A Gene De novo mutation  
PPP2R1A P179L (1) 
R182W (2) 
[151] 
[151] 
PPP2R5B S161L (1) [152] 
PPP2R5C T157del (1) [152] 
PPP2R5D P53S (1) 
E198K (3) 
E200K (2) 
P201S (1) 
W207R (1) 
[153] 
[151, 152] 
[152] 
[151] 
[154] 
 
(1) The Deciphering Developmental Disorders (DDD) study is a large collaboration between 
24 Regional Genetics Services throughout the UK and Republic of Ireland, including scientists 
at the Wellcome Trust Sanger Institute, which aims to identify in large scale new genetic 
causes for developmental disorders via child-parent whole exome sequencing. The project 
includes almost 14,000 patients with a developmental disorder. Published data from the first 
1133 children revealed de novo mutations in PPP2R1A, encoding the Aα scaffold subunit, 
and in PPP2R5D, encoding B’δ [151]. PPP2R1A mutations included P179L and R182W, the 
latter found in two patients. The PPP2R5D mutations identified were P201R and E198K, 
recurrent in two cases and in one case in another study [151, 152]. Additional unpublished 
DDD data of 4295 children in total show additional PPP2R1A and PPP2R5D mutant cases. 
Intriguingly, for PPP2R1A, the mutations are identical to some of the ones 
identified in endometrial cancer.  
(2) Other studies also reported sites mutated in PPP2R5D (P53S, E200K, P201R and W207R) 
by child-parent whole exome sequencing [152, 154] and by targeted sequencing of a panel 
of 21,000 genes [153]. While the P53S mutation localizes in the B’δ-specific N-terminal 
domain, a region likely involved in substrate binding, all other reported B’δ mutations cluster 
in a conserved loop directly facing the A and C subunits. Remarkably, the E198 residue 
makes direct contact with the C subunit and this is the most recurrent mutation among the 
B’δ cases.  
(3) A S161L mutation in PPP2R5B, encoding B’β, and a T157del mutation in PPP2R5C, 
encoding B’γ, were identified by trio-based exome sequencing studies in 111 overgrowth 
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patients and their unaffected parents [152]. Interestingly, these residues map to the same 
ID-associated conserved loop present in all B56/PR61/B' family members (Figure 5).  
 
 
Figure 5: Representation of the B56/PR61/B' family showing the region responsible for holoenzyme 
formation and the predicted substrate binding domains. ID-associated mutations in the different 
subunit genes are indicated in red (arrowheads). 
 
3. PP2A – directed therapy strategies  
Because PP2A dysfunction and dysregulation have been implicated in numerous disease 
states, it has become a attractive, but difficult, therapeutic target. Depending on the setup, 
both PP2A inhibition as PP2A (re)activation seem to have a therapeutic potential. Several 
recent preclinical studies have shown that pharmacological reactivation of PP2A tumor 
suppressor activity by PP2A-activating drugs (PADs) indeed effectively antagonizes cancer 
development and progression [30, 116, 155]. Counter-intuitively, pharmacological inhibition 
of PP2A can equally-well cause cancer cell death, when combined with a DNA-damaging 
agent. This PP2A inhibitor-induced cell death is a result of mitotic catastrophe caused by 
premature entry into mitosis, deficient exit from mitosis or non-functional cell cycle 
checkpoints [30], highlighting the importance of PP2A holoenzymes in the regulation of cell 
division and DNA repair. The review papers in Chapters 3 and 4 briefly touch upon the PP2A-
activating strategies used in the treatment of leukemia and the therapeutic opportunities of  
targeting the interactions between PP2A and cellular (oncogenic) inhibitors. Below, a more 
detailed and complete overview is provided on both PP2A-activating and -inhibiting 
therapeutic approaches.  
 
3.1. PP2A reactivation 
The first PAD to be tested was forskolin, a diterpene derived from Coleus forskohlii roots. 
This drug has the ability to induce adenylate cyclase and to activate PP2A independently of 
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adenylate cyclase stimulation. Later, the derivative 1,9-dideoxy forskolin was designed, 
only harboring the PP2A activator function. In vitro, forskolin is able to suppress BCR-ABL – 
driven oncogenesis, causing apoptosis induction, reduced proliferation and impaired colony 
formation in chronic myeloid leukemia (CML), BCR/ABL-positive acute lymphoblastic leukemia 
(BCR/ABL+-ALL) and acute myeloid leukemia (AML) [30, 155]. Moreover, treatment causes 
decreased leukemogenesis in immune-deficient mice injected with BCR/ABL+ cells. 
Importantly, (1,9 dideoxy)forskolin does not affect CD34+ normal cells, thus preventing 
toxicity on normal hematopoiesis [155].  
 
Likewise, inhibitors of type 4 cyclic nucleotide phosphodiesterase (PDE4), like rolipram, 
elevate intracellular cyclic adenosine monophosphate (cAMP) levels in B-cell chronic 
lymphocytic leukemia (B-CLL), inducing apoptosis via the mitochondrial pathway by a 
mechanism involving PP2A activation and dephosphorylation of Bad [30].  
 
Ceramide, a sphingolipid metabolite, inhibits proliferation and stimulates apoptosis in part 
due to activation of Ser/Thr phosphatases, in particular PP2A. It exerts anti-oncogenic 
effects in several prostate cancer cell lines, including androgen-independent ones 
characterized by decreased PP2A Cα expression. Interestingly, multiple promising 
chemotherapeutic agents are suspected or known to stimulate intracellular ceramide 
formation and subsequently induce apoptosis in a PP2A-dependent manner [30]. Ceramide 
has a direct effect on different PP2A holoenzymes in vitro, however it mainly affects the 
mitochondria-associated holoenzyme containing B’α in cell lines ex vivo. Recently, direct 
binding of ceramide to SET was demonstrated resulting in dissociation of SET-PP2A and 
PP2A activation [30].  
 
A compound structurally related to ceramide is FTY720 (Fingolimod, Gylenia™), one of the 
best studied PADs so far. FTY720 has been approved as immunosuppressant for the 
treatment of multiple sclerosis and for prophylaxis of solid organ transplantation rejection 
[156, 157]. This function is dependent on its phosphorylation. The PP2A activator function, 
however, is not. Therefore, non-phosphorylatable derivates were designed, like [S]-FTY720-
OMe and OSU-2S FTY720. FTY720 shows a high oral bioavailability and lack of side effects 
[155]. Several studies evaluated FTY720 treatment for multiple leukemias (like B-CLL and 
multiple myeloma) and for bladder, breast, prostate and HCC, because of its ability to induce 
mitochondria-dependent apoptosis by interfering with Bcl2 and to suppress growth and 
survival signals by inhibiting ERK and PI3K/Akt pathways [116]. At least in leukemia, these 
effects can be attributed to PP2A activation. Mechanistically, doubt exists on the exact 
manner by which FTY720 activates PP2A. When administered to cells, FTY720 causes a 
transient activation of PP2A and results in dephosphorylation of Akt, Bad and p70S6 kinase, 
which all can be blocked by OA. Furthermore, FTY720 has been shown to activate a purified 
PP2A holoenzyme containing B55/PR55/B [158]. In leukemia, FTY720 (like ceramide) was 
shown to disrupt the SET–PP2A interaction causing PP2A reactivation [159]. FTY720’s ability 
to antagonize leukemogenesis was demonstrated in BCR/ABL+-ALL and B-CML, in which 
PP2A activity is inhibited through BCR/ABL-induced SET expression. Treatment resulted in 
inactivation/degradation BCR/ABL and inhibited survival signals mediated by Akt, ERK and 
Jak2 [116]. This anti-leukemic effect was observed in both imatinib (a BCR/ABL kinase 
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inhibitor)-sensitive and -resistant cells, without adverse effects on normal hematopoiesis. 
PP2A is also inactivated by the Jak2(V617F) oncogene in myeloproliferative neoplasms and 
this is mediated by SET. Consequently, FTY720 can down-regulate/inactivate Jak2 oncogene 
by binding to SET and in Jak2(V617F) leukemic mice this results in increased survival, 
decreased leukemic allelic burden and reduced splenomegaly, without apparent side effects 
[160].  FTY720 was also shown to have antileukemic effects in cell lines, ex vivo patient cells 
and animal models of BCR/ABL-negative lymphoid malignancies, like CLL, T-cell large 
granular lymphocyte leukemia, natural killer cell leukemia, mantle-cell lymphoma, and 
BCR/ABL--ALL. However, whether the FTY720 anti-cancer effect is mediated by PP2A 
activation in these cases remains unclear [116]. Furthermore, for mutant c-Kit+- AML in vitro 
or in vivo administration of FTY720 caused dephosphorylation of c-Kit and of its downstream 
effectors (Akt, ERK1/2 and STAT5), resulting in reduced proliferation, decreased clonogenic 
potential and apoptosis induction. The oncogenic c-KIT mutants in AML affect PP2A activity 
by reducing expression of various subunits, including A, PR55/Bα and PR61/B’αγδ [110]. 
Combined, these data show that PP2A inactivation (by BCR/ABL or Jak2(V617F) oncogene – 
induced SET expression or by c-Kit mutants) might be a key mechanism by which resistance 
to kinase inhibitor-based treatment is caused and leukemias are maintained, or even a key 
step in the cancer induction. Therefore, the possibility rises that patients could be brought 
into remission by kinase inhibitors and cured by FTY720 or derivatives, or that treatment 
with a combination of kinase inhibitors and FTY720 upon diagnosis might overcome 
therapeutic resistance or entirely avoid it.  
 
To further target the SET-PP2A interaction, SET binding peptides COG112 and OP499 
(formerly COG449) were designed, which are apolipoprotein E-mimetic peptides. In addition 
to disrupting the association of SET with PP2A, COG112 disrupts SET’s interaction with the 
metastasis suppressor NM23-H1 and Rac1 in a glioma and breast cancer cell line, inhibiting 
cancer cell migration and invasion [161]. In CLL and non-Hodgkin lymphoma cells, OP449 
downregulates the expression of the anti-apoptotic Bcl2 family member Mcl1 causing 
cytotoxicity in vitro and in vivo in tumor xenografts. Recently, OP449 treatment was shown 
to result in apoptosis of CML progenitors through a mechanism depending on PP2A 
reactivation. Combined with kinase inhibitors or chemotherapy, OP449 efficiently and 
selectively inhibited cell growth of leukemic cells, but not of normal cells.  
 
Also CIP2A might be an attractive therapeutic target. Although mechanistically poorly 
understood, transcriptional downregulation of CIP2A by rhabdocoetsin B, a compound 
extracted from a traditional Chinese medicinal herb, induces apoptosis and Akt inactivation in 
a variety of lung cancer cells [30, 114]. Very similar, the proteasome inhibitor bortezomib 
down-regulates CIP2A in a dose- and time-dependent manner in bortezomib-sensitive liver 
cancer cell lines, resulting in Akt inactivation and apoptosis [30, 114]. The combination of 
bortezomib and sorafenib, a multi-kinase inhibitor, results in synergistic apoptotic effects in a 
CIP2A and PP2A-dependent manner. Furthermore, downregulation of CIP2A and subsequent 
PP2A mediated inhibition of Akt signaling can cause cancer cells to overcome resistance to 
CS-1008 (an anti-human TRAIL Death Receptor 5 antibody) or TRAIL-induced apoptosis [30, 
114]. 
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Recently, phenothiazine (PPZ), an FDA-approved neuroleptic type anti-psychotic drug, was 
demonstrated to activate PP2A in T-ALL cell lines accompanied by rapid dephosphorylation of 
multiple PP2A substrates (Akt, ERK, p70S6 kinase, c-Myc, and Bad), suppressed growth and 
apoptosis [162]. Since shRNA knockdown of the PP2Ac and A subunits attenuated the 
phenothiazine activity, PP2A mediates this antileukemic activity. In addition, PPZ treatment 
of a murine xenograft model of T-ALL diminished cell growth and led to dephosphorylation of 
Akt, p70S6 kinase, and Bad in vivo. Mechanistically, phenothiazine binds to the Aα scaffold 
subunit [162], but it remains unclear how it exactly stimulates PP2A activity. It has been 
suggested that PPZ interaction with Aα might have allosteric effects on PP2Ac activity or that 
PPZ might displace an A subunit regulator [163].   
 
Several naturally occurring anti-oxidants have also been demonstrated to stimulate PP2A 
activity and induce apoptosis. Dithiolethione compounds inhibit proliferation in aggressive 
breast and lung cancer cell lines through PP2A-mediated downregulation of Akt, mTOR and 
c-Myc [30]. Dihydroxyphenylethanol promotes apoptosis in colon carcinoma cells by 
activation of PP2A, either direct or indirect via scavenging of reactive oxygen species known 
to inhibit PP2A [30]. Interestingly, an added pro-apoptotic effect in BCR/ABL+ K562 cells was 
seen when combining the anti-oxidant amifostine and imatinib, compared to imatinib alone. 
This effect is in part due to transcriptional upregulation of PPP2R5E (encoding the pro-
apoptotic B’ε subunit), suggesting that elevated expression of PP2A subunits may also be 
involved in anti-oxidant-mediated PP2A activation [30]. 
 
Finally, some other PADs are being evaluated as anti-cancer agents [116]: promethylating 
agents such as Chloroethyl Nitrosourea cause PP2A methylation and activation, leading to 
growth inhibition of melanoma cells; apoptosis of cancer cells is seen after α-Tocopheryl 
succinate treatment through a PP2A-dependent mechanism; PP2A activation by vorinostat 
and sorafenib induce gastrointestinal tumor-cell death; carnosic acid induces apoptosis of 
human prostate-carcinoma cells via PP2A-dependent effects on Akt/IKK/NFκB signaling; by 
upregulating the expression of PP2A regulatory subunits, methylprednisolone induces 
complete differentiation of leukaemic cells.  
 
 3.2. PP2A inhibition 
One of the best studied pharmacological PP2A inhibitors is fostriecin, a natural compound 
with high selectivity for PP2A and PP4. Fostriecin directly binds to PP2Ac. It causes 
premature entry into mitosis resulting in potent and selective tumor cytotoxicity. However, 
due to relatively high instability, its clinical use is hampered [30].  
 
Cytostatin, whose PP2A inhibiting mechanism is very similar to that of fostriecin, has anti-
metastatic effects by blocking the adhesion of tumor cells to the extracellular matrix and by 
stimulating the expansion and activation of natural killer cells. However, also like fostriecin, 
cytostatin is instable [30].  
 
Another PP2A inhibitor, rubratoxin A, possesses improved stability and shows anti-
metastatic effects in mice. Unfortunately, hepatotoxicity is an issue [30].  
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Cantharidin is a toxin and anti-cancer agent. It is a non-specific PP2A inhibitor, since it also 
affects PP1. Cantharidin treatment results in apoptosis in different cancers, like in pancreatic 
cancer cell models via induction of caspase-8 and -9 and tumor necrosis factor α. In 
malignant testicular germ cell tumors, a combination of OA and cantharidin leads to 
apoptosis via MEK and ERK-mediated activation of caspase-3. Also in leukemia, PP2A 
inhibition results in apoptosis by activating caspases [164]. However, cantharidin has very 
toxic side effects preventing its clinical use. A less toxic demethylated analogue, 
norcantharidin, has a higher selectivity for PP2A while retaining the anti-cancer properties 
of cantharidin, as demonstrated in melanoma, breast, oral and gallbladder cancers and HCC 
[164]. 
 
Lactoferrin affects apoptosis-inhibiting PP2A complexes, like PP2Ac–α4. α4 is significantly 
upregulated in carcinogen-transformed human cells, HCC, breast cancer and small lung 
adenocarcinoma. Association of lactoferrin with α4 has pro-apoptotic and anti-oncogenic 
effects through reduction of α4-associated PP2A activity [30].  
Lenalidomide is an FDA-approved drug for the treatment of a specific subset of 
myelodysplastic syndrome patients with an isolated deletion of chromosome 5q. It inhibits 
the PP2A Cα subunit resulting in cell cycle arrest and apoptosis, and has been shown to 
confer a significant increase in median overall survival in clinical trials. However, resistance 
can occur through overexpression of the PP2A Cα subunit [164]. 
Finally, the important role of PP2A in DNA damage and repair signaling might be exploited 
therapeutically by combining PP2A inhibitors and DNA-damaging chemotherapeutic 
agents. Indeed, LB1.2 (LB-102), a norcantharidin-like small molecule PP2A inhibitor, blocks 
the DNA-damage defense mechanisms induced by temozolomide (a DNA-methylating drug) 
or doxorubicin (a DNA-intercalating agent), leading to apoptotic cell death in cellular and 
mouse models of glioblastoma multiforme and neuroblastoma [30, 164]. It was predicted 
that such combination strategy might also be particularly beneficial to eradicate cancer cells 
of slow-growing and well-differentiated tumors or even quiescent ‘cancer stem cells’, both 
insensitive to cytostatic drugs [30]. Furthermore, LB-100 is currently in phase 1 clinical 
trials examining the safety and efficacy of the small molecule PP2A inhibitor in the treatment 
of advanced solid cancers.  
 
Despite the therapeutic promise of the above PP2A-targeting approaches, several challenges 
remain. It should be stressed that not all PP2A holoenzymes are tumor suppressive; some 
activate a certain signaling pathway, while others inhibit it. Thus, inhibiting or activating all 
forms of PP2A might not only be unnecessary for achieving the desired therapeutic effect, it 
may also pose serious risks for unwanted toxic side effects. Thus, targeting a specific 
holoenzyme or a specific PP2A-substrate interaction may be amongst the better future 
strategies to fully exploit the therapeutic potential of PP2A in human cancer or other 
diseases. In order to do so, more knowledge needs to be gained on the particular 
holoenzyme involved in a given pathway and the specific substrates of that holoenzyme.  In 
addition, targeting a specific PP2A-inhibitor interaction, although challenging, remains a very 
attractive and cancer cell selective therapeutic approach [30].  
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OBJECTIVES 
 
PP2A represents one of the major protein phosphatase families in the cell, whose function is 
known to be disturbed by a variety of mechanisms in different pathologies, including 
Alzheimer’s disease, diabetes, heart failure and cancer. Very recently, genetic screening and 
exome sequencing also implied PP2A dysfunction in ID. The general aim of my thesis is to 
biochemically and functionally characterize specific PP2A mutations, identified in patients 
with ID and endometrial cancer, of which the mechanism-of-action was still unknown. This 
seemed a particularly intruiging research question, as some of the involved mutations are 
surprisingly identical in both pathologies. With the obtained results, we eventually aimed to 
be able to suggest novel, potentially promising, therapeutic strategies. 
 
Specific aims: 
 
1. To firmly establish PP2A dysfunction as a novel cause for ID  
Previously, the DDD study put forward PPP2R5D and PPP2R1A as novel candidate disease-
causing genes [151]. Moreover, during the course of my thesis work, we became aware of 
more patients with different PPP2R5D and PPP2R1A mutations. In order to provide firm 
biochemical proof for causality and to identify the underlying mechanism by which PP2A 
dysfunction might affect signaling in the brain, we aimed to characterize the effects of B’δ 
and Aα mutations on PP2A holoenzyme formation and function. Strikingly, the ID-associated 
Aα mutations are identical to some found in serous endometrial cancer, highlighting the 
possibility of a common disease mechanism and rising the concern that ID patients harboring 
these mutations are at risk for developing cancer.  
 
2. To biochemically and functionally characterize Aα mutations identified with 
high frequency in serous endometrial cancer  
Mutations in PPP2R1A seem an important strategy of cancer cells to inactivate PP2A, and this 
occurs with high frequency in the more aggressive subtypes of endometrial cancer, i.e. 
serous endometrial cancer and carcinosarcoma. The reported Aα mutations are 
heterozygous, missense and show a high degree of recurrence. They cluster into HEAT-
repeat 5 (P179L, P179R, R182W, R183G, R183Q, R183W) and HEAT-repeat 7 (R249H, 
S256F, S256Y, W257C, W257G, R258H), both believed to be involved in B-type subunit 
binding. However, the impact of these mutations on PP2A assembly and function was not 
investigated so far. We aimed to get a complete overview of their effects (1) on holoenzyme 
formation via cellular binding assays and (2) on the larger Aα interactome via an MS-based 
proteomics approach. In addition, we aimed to introduce these mutations in endometrial 
cancer cells and study their effect on cancer cell growth and oncogenic signaling. Eventually, 
our work should allow to provide a molecular basis for rational therapeutic intervention in 
this hard-to-treat cancer type, and thus, establish the PPP2R1A state (mutant or WT) as 
therapeutic biomarker.  
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Abstract 
 
Protein Phosphatases of type 2A (PP2A) represent a major class of structurally complex 
Ser/Thr phosphatases, which have recently gained a lot of interest in cancer biology because 
of their establishment as genuine tumor suppressors. PP2A phosphatases comprise a large 
family of >80 holoenzymes with complex structure, pleiotropic functions and diverse ways to 
regulate their biological activities. PP2A catalytic activity can be directly inhibited by an 
emerging set of specific cellular PP2A inhibitory proteins, including Acidic Nuclear Phos-
phoprotein 32a (ANP32a), Suvar 3-9/Enhancer of zeste/Trithorax (SET), Cancerous Inhibi-
tor of PP2A (CIP2A), members of the cAMP-Regulated PhosphoProtein/-Endosulfin 
(ARPP-16/19/ENSA) family, and Type 2A Interacting Protein (TIP). In addition, the PP2A 
Methyl Esterase 1 (PME-1), a regulator of reversible carboxy-terminal methylation of the 
PP2A catalytic C subunit, stabilizes an inactive PP2A C conformation and may be considered 
as an atypical inhibitor. Although sometimes poorly understood at the molecular level, these 
inhibitors either directly bind to the PP2A catalytic subunit or target very specific PP2A 
holoenzymes. In a wide variety of cancers, cellular PP2A inhibitors are aberrantly expressed, 
sometimes with very high frequency, and this constitutes a major mechanism by which the 
tumor suppressive function of PP2A can be impaired within a tumor. This offers interesting 
perspectives for therapeutic interference and some promising pre-clinical studies will be dis-
cussed. 
 
Keywords: ANP32a, ARPP-16/-19, CIP2A, ENSA, phosphatase, PME-1, PP2A, SET, TIP, tumor suppressor  
Accepted October 10 2011 
 
Introduction 
 
Constitutive activation of oncogenic kinases is one of the 
hallmarks of cancer cells, driving uncontrolled cell prolif-
eration, invasion and potentially metastasis [1]. Therefore, 
it should come of little surprise that tumor suppressive 
functions have been attributed to many protein phosphata-
ses, the natural kinase antagonists [2,3]. In particular, the 
Ser/Thr phosphatases of type 2A (PP2A) are currently 
recognized as major tumor suppressors, counteracting 
specific signaling pathways driving survival, proliferation 
and cell migration [reviewed in 4,5,6,7,8,9,10,11]. In ad-
dition, PP2A phosphatases are important physiological 
regulators of proper checkpoint functioning during the 
cell cycle, which contributes significantly to their tumor 
suppressive abilities [reviewed in 12,13,14,15]. However, 
not all PP2A complexes counteract cancer promoting 
pathways, but conversely, rather help sustaining them 
[reviewed in 10,16]. These seemingly contradictory ob-
servations can mainly be explained by the enormous di-
versity of PP2A holoenzymes within the cell (Fig 1). In- 
 
 
         
 
deed, in humans PP2A enzymes comprise an extended 
family of >80 holoenzymes with complex structure, plei-
otropic functions and diverse ways to regulate their cata- 
lytic and biological activities [reviewed in 17]. The core 
structure consists of a catalytic subunit (PP2A-C) and a      
65 kDa structural subunit (PR65 or A subunit), each en-    
coded by two different genes (giving  and  isoforms). This 
dimeric PP2A AC core can exist as such, but is in              
the majority of cases associated with a third variable regu-  
latory B-type subunit. These B-type subunits (at least 20     
in humans) act as targeting and substrate specifying enti-  
ties, thus determining the physiological functions and 
regulation of the trimeric complexes (Fig 1). In addition, 
there is evidence for the existence of some ‘atypical’      
PP2A complexes devoid of any A or B-type subunits, but 
comprising the 4 protein (also called IGBP1 or Tap42 in 
yeast) instead [18,19,20] (Fig 1). The A subunit and 4 
interact in a mutually exclusive way with PP2A-C       
[21,22]. Binding of 4 allosterically modifies the PP2A-C 
active site [23], thus giving rise to the particular substrate 
specificity of the 4–C complex [24]. In summary, the 
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Figure 1. PP2A holoenzyme structure  
The majority of PP2A complexes within a cell are heterotrimers, consisting of a catalytic C, a structural A and 
one regulatory B-type subunit. In humans, the C and A subunits are each encoded by two different genes (indi-
cated in italics), giving rise to an  and  isoform. For the B-type subunits 15 human genes (indicated in italics) 
have been described, giving rise to >20 isoforms belonging to four different families, PR55/B (or B55), PR61/B’ 
(or B56), PR72/B” and PR93/PR110/B”’. A smaller fraction of PP2A exists as the core AC dimer, or as an 4–C 
complex. This enormous structural diversity creates specificity and forms the basis for PP2A’s pleiotropic 
physiological functions. 
 
combinatorial assembly of all these multimeric PP2A 
holoenzymes provides the essential determinants for subs-
trate specificity, subcellular targeting and fine-tuning of 
phosphatase activity [25,26,27], explaining the pleiotropic 
and sometimes opposing functions of PP2A within cells. 
 
The tumor suppressive PP2A complexes mainly appear to 
be constituted of PR61/B’ (or B56) subunit family mem-
bers [5,8,9,10,11], but surprisingly hardly any mutations 
have been found in these or in fact any of the B-type or C 
subunit encoding genes in human tumor patient samples. 
Instead, inactivating mutations and deletions in both 
PPP2R1A and PPP2R1B occur with low frequency in 
several human cancers, identifying A and A as genuine 
tumor suppressors [6]. For A these cancer-associated 
subunit mutants show impaired interaction with the C 
subunit and/or with particular B-type subunits, most nota-
bly those of the PR61/B’ class [28,29], whereas A mu-
tants also show impaired interaction with particular PP2A 
substrates, most notably the small GTPase RalA [30]. 
This results in RalA hyperphosphorylation and activation 
[30], or in impaired dephosphorylation of various 
PR61/B’-containing PP2A substrates, including the sur-
vival kinase Akt, proto-oncogen c-Myc, tumor suppressor 
p53 and some apoptotic regulators of the Bcl-2 family [8-
11]. 
 
Another emerging mechanism by which the tumor sup-
pressive activity of PP2A can be disturbed in human tu-
mors is through aberrant expression of specific cellular 
PP2A inhibitors [9,11,31]. As we will discuss in this re-
view, this occurs in a wide variety of cancers, often with 
 
high frequency and correlating with cancer stage and 
therapeutic outcome. We will highlight the mechanism-
of-action, function and regulation of these important 
PP2A regulators, and eventually we will discuss how this 
knowledge might be exploited for therapeutic purposes. 
 
PP2A Inhibitor-1 and Inhibitor-2 (ANP32a and SET) 
Historically, PP2A   Inhibitor-1   (I1
PP2A
,   also   called  
ANP32a or PHAP-I or pp32 or LANP or mapmodulin) 
and Inhibitor-2 (I2
PP2A
, also called SET or PHAP-II or  
TAF-I) were the first cellular PP2A inhibitors to be dis-
covered [32,33,34]. Both proteins potently inhibit PP2A 
with IC50’s in the low nM range in a non-competitive 
manner, likely through direct binding to the PP2A C sub-
unit [33,34]. At the same time, in the presence of near-
physiological concentrations of Mn
2+
, both PP2A inhibi-
tors can stimulate PP1 activity towards some substrates, 
suggestive for a potential role in coordinating cellular 
PP2A and PP1 activities [35]. 
 
ANP32a and ANP32e  
ANP32a belongs to a large family of at least 9 members 
(denoted ANP32a-h) sharing a highly acidic C-terminal 
domain and a Leucine Rich Repeat (LRR)-containing N-
terminal domain [36,37] (Fig 2A). So far, only the a and e 
isoforms show PP2A inhibitory ability in an in vitro 
phosphatase assay [34,38,39] and their third LRR might 
be required for this [38]. Since this domain is well-
conserved in some other ANP32 isoforms (Fig 2A), it can 
not be excluded that yet other ANP32 members might 
show PP2A inhibitory activity as well. Notably, the LRR 
domains might be involved in homo- or heterodimerisat- 
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ion of ANP32a/e [39,40] leaving open the possibility this 
would be a prerequisite for their PP2A inhibitory effect. 
Both ANP32a and ANP32e are phosphoproteins 
[39,40,41]. Jacalin, a dietary lectin with anti-proliferative 
effect, induces tyrosine phosphorylation of ANP32a on a 
not yet identified site and this releases the association 
with PP2A, allowing increased PP2A activity and inacti-
vation of the ERK signaling pathway [42]. In addition, 
ANP32a Ser-158 and Ser-204 were identified as constitu-
tive in vivo casein kinase 2 phosphorylation sites [43], so 
      199 
 
far with unknown function. Phosphorylation of ANP32e 
was shown to be required for the ANP32e–PP2A interac-
tion [39], but the molecular basis for this remains poorly 
understood. ANP32a and ANP32e are found both in the 
cytoplasm and the nucleus, reflecting their nucleocyto-
plasmic shuttling behavior that is regulated by the pres-
ence of a classical Nuclear Localization Signal (NLS) and 
two Nuclear Export Signals (NES) [36,38,39,40,41,44] 
(Fig 2A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Structural and functional domain organization of PP2A inhibitory proteins  
A. ANP32 family members. The four indicated isoforms, a, c, d and e, are encoded by different genes. The Leu-
cine-Rich Repeats (LRR), Nuclear Export Signals (NES) and Acidic domain are indicated. PP2A inhibition has 
only been shown for ANP32a and e through a putative PP2A binding domain located in LRR3. ANP32c and d 
miss the C-terminal Nuclear Localization Signal (NLS). B. SET isoforms. Both splice variants, SET and SET, 
bind and inhibit PP2A, without a need for dimerisation. The Nucleosome Assembly Protein (NAP) and Acidic 
domains are indicated. C. CIP2A domain structure. A deletion mutant that lacks amino acids 461-533 shows re-
duced PP2A binding. D. ARPP-16/19/ENSA family members. ARPP-16 and -19 are splice variants of a single 
gene, while ENSA is encoded by a different gene. Three highly-conserved phosphorylation sites are indicated, 
resp. for CDK, Greatwall/MASTL kinase and PKA. E. TIP isoforms. Only the longest splice variant, TIPRL1, can 
bind and inhibit PP2A. 
 
ANP32a has multiple cellular functions, and it is currently 
unclear to what extent inhibition of PP2A contributes to 
all these diverse roles. As such, ANP32a was essentially 
identified as a tumor suppressor, inhibiting oncogene-
induced cell transformation [45] through a region encom-
passing amino acids 150-174 [46]. As this region does not 
coincide with the putative PP2A binding domain, this 
could suggest the negative role of ANP32a in cell trans-
formation might be independent of PP2A inhibition (Fig 
2A). In addition, this region is absent in ANP32d and 
somewhat divergent with the corresponding sequences in 
 
ANP32c and ANP32e (Fig 2A), providing a putative ex-
planation for the oncogenic roles of these three ANP32 
isoforms [46,47,48]. In line with a tumor suppressive role, 
ANP32a downregulation results in phenotypic changes 
associated with cell transformation, while ectopic expres-
sion of ANP32a abolishes Ras-mediated transformation in 
vitro and tumorigenesis in vivo [49]. These effects may 
occur in part through negative regulation of the Raf-1/ 
MEK/ERK pathway [50]. In accordance, in pancreas and 
prostate cancer ANP32a expression is severely reduced 
[51,52]. ANP32a is also strongly pro-apoptotic by accel- 
46 
 
200 
 
 
erating caspase-9 and subsequent caspase-3 activation 
after apoptosome formation [53,54]. In some cancer cells, 
ANP32a-mediated apoptosis can specifically be inhibited 
through physical interaction with the hyperphosphory-
lated form of the retinoblastoma tumor suppressor protein 
[55]. Decreased ANP32a expression in non-small-cell 
lung cancer is associated with apoptotic resistance [56]. 
As part of the SET complex (an ER-associated complex 
of five proteins including SET), ANP32a also promotes 
caspase-independent granzyme A-mediated cell death. 
Intriguingly, SET inhibits this process by inhibiting the 
DNase nicking activity of the tumor metastasis suppressor 
NM23-H1, another one of the five proteins constituting 
the SET complex [57]. This suggests that in contrast to 
ANP32a, SET rather has oncogenic properties. ANP32a is 
also involved in the regulation of mRNA trafficking as 
part of the HuR complex, which stabilizes and transports 
short-lived mRNAs of particular proto-oncogenes and 
stress response proteins from the nucleus to the cytoplasm 
[58]. Under lethal stress conditions, ANP32a-mediated 
cytoplasmic translocation of HuR is promoted and this 
contributes to the apoptotic response [59]. ANP32a and 
SET both also function in transcription regulation and 
chromatin remodeling as parts of the INHAT (INHibitor 
of Acetyl Transferase) complex that binds to histones and 
regulates histone modifications [60]. Both SET and 
ANP32a directly bind to basic N-terminal histone tails, 
particularly when the latter are not phosphorylated or hy-
peracetylated, and this is thought to inhibit gene transcrip-
tion by a histone masking mechanism that prevents ace-
tyltransferase access [61,62,63]. In addition, SET and 
ANP32a actively recruit transcription inhibiting histone 
deacetylases [63]. ANP32a may also repress transcription 
of specific genes through binding the transcriptional rep-
ressor E4F and modulating its activity [64]. Ataxin 1, a 
protein mutated in SpinoCerebellar Ataxia type 1 and a 
known interaction partner of ANP32a [65], relieves this 
repression by competing with E4F for ANP32a [64]. By 
affecting expression of the neurofilament light chain gene 
ANP32a may play a role in the epigenetic modulation of 
neuronal differentiation [66]. Finally, a structural role for 
ANP32a in cytoskeletal dynamics and microtubule- and 
dynein-dependent organelle transport has also been in-
ferred, particularly in neurons, through its interaction with 
Microtubule-Associated Proteins (MAPs) [36,40,67]. For 
effective interaction with MAPs, ANP32a phosphoryla-
tion might be required [40]. 
 
Despite all these diverse cellular functions, ANP32a-null 
mice are without any apparent phenotype [68], possibly 
reflecting functional redundancy provided by other mem-
bers of the ANP32 family. Likewise, ANP32e-null mice 
show no apparent abnormalities except for a very subtle 
neurological clasping and mild motoric phenotype 
[69,70], in line with its presumed role in synaptogenesis 
[38,39]. In contrast, ANP32b knockout mice show perina- 
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tal lethality due to variable defects in various organ sys-
tems, demonstrating some hierarchy of importance in 
mammalian ANP32 genes [71]. 
 
SET  
Although SET does not structurally belong to the ANP32 
family, it also harbors a highly acidic C-terminal domain 
[44,72]. Two SET splice variants exist, each with a dif-
ferent N-terminal region of 39 ( isoform) or 26 ( iso-
form) amino acids encoded by alternative first exons [73] 
(Fig 2B). While the Nucleosomal Assembly Protein 
(NAP) domain is essential for SET’s chromatin remodel-
ing and histone chaperone activity [73,74], the PP2A in-
hibitory activity resides within a 95-amino-acid-region 
immediately C-terminally of the alternative N-terminal 
regions (Fig 2B), explaining why both SET isoforms can 
inhibit PP2A [75]. Overexpression of SET induces in-
creased expression, phosphorylation, DNA-binding and 
transcriptional activity of c-jun, and this is reversed by 
ectopic expression of PP2A C, consistent with SET acting 
as a PP2A inhibitor in cells [76]. 
 
SET and SET have originally been identified as the 
host factors that promote adenoviral DNA replication, 
nucleosome assembly and transcription through chroma-
tin remodeling [73,77], an activity that requires their C-
terminal acidic domain and their heterodimerisation 
through a coiled-coil domain [78] (Fig 2B). SET dimeri-
sation is however unnecessary for inhibition of PP2A 
[75]. Like ANP32a, SET is a phosphoprotein, and Ser-9 
and Ser-24 in SET have been identified as potential pro-
tein kinase C sites [79]. Using phospho and non-phospho 
mimicking mutants, phosphorylation of Ser-9 is predicted 
to prevent SET dimerisation, while it is mandatory for 
PP2A inhibition [80]. SET is found in the cytoplasm but 
also in the nucleus, potentially as a C-terminally truncated 
form or as part of a SET homo- or ANP32a–SET het-
erodimer within larger complexes such as the INHAT and 
SET complex [44,57,60,62,63,79,81,82]. It is quite in-
triguing to note that ANP32a and SET can function both 
opposite to each other [57] as well as in conjuction with 
each other [60] within different of these multiprotein 
complexes. Next to its role as a transcriptional repressor 
within the INHAT complex, some reports have identified 
SET as a transcriptional corepressor of specific transcrip-
tion factors, including some members of the nuclear re-
ceptor superfamily [83,84,85] and even as a genuine 
DNA-binding transcription factor [86,87]. 
 
SET expression is modulated as a function of cell prolif-
eration, with high expression in rapidly dividing cells or 
transformed cells, and low expression in quiescent or con-
tact-inhibited cells [82,88,89]. SET can interact with the 
cyclin-dependent kinase (CDK) inhibitor p21/Cip1, cyclin 
B and glyceraldehyde-3-phosphate dehydrogenase and 
these interactions contribute to its regulatory role in the
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cell cycle at the G2/M transition [90,91]. SET also plays 
a positive role in cell migration and is recruited to the cell 
membrane of migrating cells in a Rac1-dependent way, 
requiring Ser-9 phosphorylation of SET [80]. This might 
lead to local amplification of Rac1-stimulated kinase sig-
naling by preventing PP2A activity towards these Rac1 
downstream kinases. In accordance with these inferred 
pro-oncogenic and pro-migratory roles, SET overexpres-
sion has been observed in human patient samples of 
Wilms’ tumour [88], hepatoma [92], choriocarcinoma 
[93] and several types of leukemia including Bcr/Abl 
(Philadelphia chromosome)-positive blast crisis chronic 
myelogenous leukemia (bc-CML) [94], Bcr/Abl-positive 
acute lymphocytic leukemia (ALL) [95], acute myeloid 
leukemia (AML) [96] and B-cell chronic lymphocytic 
leukemia (B-CLL) [97]. Restoration of PP2A activity by 
PP2A-C overexpression or shRNA-mediated knockdown 
of SET in these leukemia cells has a therapeutic effect 
[94,97] and results in decreased levels of hyperphos-
phorylated Rb and Myc, suppression of STAT5, ERK1/2, 
Akt, Bad and Jak2 phosphorylation, and induction of 
SHP-1-mediated Bcr/Abl dephosphorylation (inactiva-
tion) and degradation [94]. 
 
In acute undifferentiated leukemia (AUL), AML and T-
cell ALL (T-ALL), the SET gene is involved in recurrent 
chromosomal rearrangements and translocations, in par-
ticular with the nucleoporin Nup214 gene (also called 
CAN) [98,99,100,101]. In all these cases this gives rise to 
an identical chimeric SET-Nup214 fusion protein with 
altered, exclusively nuclear subcellular localization that is 
causally involved in the overall impairment of NES-
mediated nuclear protein export [102,103], implying that 
not an altered SET but rather an altered Nup214 function 
contributes to the leukemogenic process. In the T-ALL 
LOUCY cell line the SET-Nup21 fusion, but not SET 
itself, activates HOXA gene expression, increases cellular 
proliferation and inhibits differentiation [101]. The latter 
was confirmed in transgenic mice expressing SET-
Nup214 in the hematopoietic lineage as these mice show 
impaired differentiation of erythroid, megakaryocytic and 
B-cell lineages [104]. Likewise, in another transgenic 
SET-Nup214 model an expansion of early hematopoietic 
progenitors and a partial depletion of lymphocytes were 
observed [105]. None of these transgenic models were 
however leukemia-prone, suggesting the fusion protein is 
incapable of inducing transformation on its own and addi-
tional genetic aberrations might be necessary for disease 
development [104,105]. 
 
Cancerous Inhibitor of PP2A (CIP2A) 
 
CIP2A is a cellular PP2A inhibitor with oncogenic activ-
ity that was originally identified as a novel coprecipitating 
partner of the PP2A A subunit [106]. Structurally, it con-
tains an Armadillo Repeat, Leucine Zipper and Coiled-
Coil domain of unknown function, while the PP2A bind- 
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ing domain comprises at least amino acids 461-533 (Fig 
2C). Functionally, CIP2A directly interacts with the c-
Myc oncogene, inhibits cellular PP2A activity toward c-
Myc Ser-62 and thereby prevents c-Myc proteolytic deg-
radation [106]. This implies CIP2A might specifically 
target the PR61/B’-containing PP2A holoenzyme that is 
known to dephosphorylate c-Myc at this site [8], but ex-
actly how this occurs remains largely unknown. In addi-
tion to regulation of c-Myc phospho-status, CIP2A was 
identified as a major player in dependence receptor sig-
naling by inhibiting UNC5H2-dependent apoptosis [107] 
and in phosphatidylinositol 3-kinase-mediated survival 
signaling by inhibiting Akt kinase-associated PP2A activ-
ity [108]. These two functions clearly also contribute to 
its oncogenic characteristics. Notably, CIP2A is barely 
detectable in normal cells, and becomes specifically 
upregulated in a very significant percentage (40-87%) of 
tumor patient samples of various origins, including head 
and neck cancer [106], colon cancer [106], gastric cancer 
[109,110,111], tongue cancer [112], liver cancer [110], 
lung cancer [113,114,115], esophageal cancer [110,116], 
AML [96,117], CML [118], prostate cancer [119], breast 
cancer [120], serous ovarian cancer [121] and cervical 
cancer [122]. In addition, its expression correlates with 
poor prognosis and cancer aggressiveness [109,112,113, 
118,120,121]. While functional SNPs at the CIP2A pro-
moter or promoter methylation are unlikely to account for 
regulating CIP2A expression in cancer cells [123], CIP2A 
transcription was found to be regulated by c-Myc in a 
positive feedback loop, as depletion of either of these two 
oncoproteins inhibits the expression of the other [109]. In 
cancer cells with increased EGFR-MEK1/2-ERK 
pathway activity, ETS1 is involved in mediating 
increased CIP2A transcription [123]. 
 
PP2A inhibitors of the ARPP-16/-19/ENSA family 
 
cAMP-Regulated PhosphoProteins ARPP-16 and ARPP-
19 are splice variants and members of an evolutionary 
conserved protein family with multiple isoforms, initially 
discovered in brain as substrates of PKA in vitro and in 
vivo [124]. ENSA (-endosulfine) is closely related to 
ARPP-19, but is generated from a distinct gene and 
mainly differs within its 20-amino-acid N-terminal do-
main (Fig 2D). ENSA was originally named after its iden-
tification as a putative endogenous ligand of the sulfony-
lurea receptor K
+
 channels in pancreatic  cells [125]. 
ARPP-19 and ENSA have recently come into the picture 
as the long sought-after mitotic PP2A inhibitors in 
Xenopus oocytes that promote the G2/M transition and 
the mitotic state [126,127]. 
 
Both proteins require phosphorylation of a conserved ser-
ine residue (Ser-67 in ENSA and Ser-62 in ARPP-19) by 
the Greatwall kinase in order to bind PP2A and subse-
quently inhibit PP2A activity towards a physiological 
CDK1 substrate. In accordance, ENSA (also called En- 
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dos) mutant oocytes in Drosophila have a prolonged pro-
phase and fail to progress to metaphase [128], while a 
Greatwall loss-of-function allele likewise leads to cell 
cycle delay at the G2/M transition [129]. A similar role 
for ARPP-19/ENSA and the mammalian Greatwall 
orthologue MAST-like kinase have been implicated in the 
regulation of mitosis in HeLa cells [127,130], suggesting 
evolutionary conservation of this regulatory circuit. In 
line with a critical function for the protein(s), ARPP-
16/19 knockout mice exhibit embryonic lethality [131]. 
The particular PP2A holoenzyme that needs to be inhib-
ited to allow mitotic entry, and subsequently needs to be 
reactivated to dephosphorylate CDK1-cyclin B substrates 
and allow mitotic exit, harbors a regulatory PR55/B sub-
unit (PR55/B in Xenopus, Twins/B55 in Drosophila and 
PR55/B or  in mammalian cell lines) [132,133,134, 
135,136]. Notably, Greatwall phosphorylated ARPP-
19/ENSA strongly bind PP2A-PR55/B from interphase 
extracts, but no other B-type subunits or other Ser/Thr 
phosphatases. In addition, they do not inhibit the mono-
meric C subunit or the dimeric AC form of PP2A, sug-
gesting they might be highly specific inhibitors of PP2A-
PR55/B [126,127]. If and how their well-conserved 
CDK and PKA sites (Fig 2D), that can be robustly phos-
phorylated by these kinases in vitro [126], might contrib-
ute to PP2A regulation remains to be determined. 
 
Type 2A Interacting Protein (TIP) 
 
The Tip41 protein was originally discovered in yeast as a 
Tap42/4 interaction partner [137]. In yeast two-hybrid 
assays, like Tap42, Tip41 (bait) was shown to interact 
with all PP2A-like yeast phosphatases including the 
orthologues of PP2A, PP4 and PP6 [138]. In mammalian 
cells however, TIP (also called hTip41 or TIPRL isoform 
1) does not directly bind 4 but rather primarily interacts 
with the PP2A, PP4 or PP6 C subunits [138,139,140]. In 
vitro and in vivo binding assays have supported this view, 
demonstrating that TIP does not compete with 4 for 
PP2A-C binding, and that even a trimolecular TIP–C– 4 
complex can be formed [139]. TIP is a ubiquitously ex-
pressed PP2A inhibitory protein [139,140], and like 4, 
its effect on PP2A activity was proposed to be allosteric 
in nature as okadaic acid, a PP2A C catalytic site binding 
inhibitor, failed to dissociate the TIP–PP2A-C inte raction 
[139,140]. The PP2A inhibitory activity resides in the C-
terminal part that is lacking in the shorter TIP splice vari-
ant TIPRL2 (also called TIP_i2) which does not inhibit 
PP2A in vitro [140] (Fig 2E). Notably, TIP may play an 
important role in DNA damage and repair signaling as it 
regulates PP2A enzymes that oppose ATM/ATR-
dependent phosphorylation events [140] and is part of a 
well-defined yeast PP4 holoenzyme, which is involved in 
regulating cisplatin sensitivity [138]. These observations 
definitely warrant further addressing the TIP status in 
cancer cells, which is currently still unknown. 
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The PP2A methylesterase PME-1: an atypical PP2A 
‘inhibitor’ 
 
The highly conserved C-terminal tail of the PP2A C sub-
unit is post-translationally modified by a methyl esterifi-
cation of the free carboxy-terminus of the C-terminal Leu 
-309 residue. This reaction is catalyzed by an S-adenosyl-
methionine (SAM)-dependent methyltransferase LCMT1 
[141] and the PP2A methylesterase PME-1 [142], both 
essential enzymes for maintaining mammalian cell and 
organism viability [143,144,145]. PP2A methylation 
greatly facilitates PP2A holoenzyme assembly with spe-
cific regulatory B-type subunits, particularly those of the 
PR55/B family, the binding of which absolutely requires 
this modification [reviewed in 146]. These observations 
are underscored by several structural studies [reviewed in 
26]. LCMT1 activity and expression can be regulated by 
changes in homocysteine metabolism, which itself is af-
fected by dietary intake of folate and vitamins B6 and 
B12 [147]. Elevated plasma levels of homocysteine can 
lead to decreased PP2A methylation and impaired 
holoenzyme assembly with PR55/B subunits, contributing 
to conditions such as Alzheimer’s Disease [147] and po-
tentially cancer [148]. However, whether PP2A-C methy-
lation might be affected in human tumors remains to be 
established. 
 
In addition to its methylesterase activity, PME-1 has been 
attributed yet another PP2A regulatory function as it can 
bind and stabilize a native inactive PP2A form [149], es-
timated to represent up to 20-25% of the total cellular 
PP2A pool [150]. This inactive PME-1-bound PP2A can 
be (re)activated by an ATP/Mg
2+
-dependent PP2A acti-
vating enzyme PTPA (Phosphatase Two A Phosphatase 
Activator) [149], originally discovered as an activator of 
PP2A tyrosyl phosphatase activity in vitro [151] but sub-
sequently characterized as a prolyl peptidyl cis/trans 
isomerase with Pro-190 of the PP2A C subunit as its 
unique target [152,153]. This regulatory PTPA–PP2A– 
PME-1 circuit constitutes part of the PP2A biogenesis 
process, as PP2A-C was found to be translated as an inac-
tive form that subsequently needs to be assembled into 
active PP2A trimers in a highly regulated manner 
[154,155]. In order to prevent any promiscuous activity of 
free C subunit in the course of this process, PME-1 appar-
ently stabilizes an inactive PP2A dimer until it is acti-
vated by PTPA, methylated by LCMT1 [156] and eventu-
ally assembled into a functional holoenzyme with re-
stricted catalytic activity due to the presence of the regu-
latory B-type subunit. Thus, unlike genuine PP2A inhibi-
tors, PME-1 is unable to inactivate active PP2A holoen-
zymes [143], but rather seems to act as a stabilizer of an 
inactive PP2A form, in a manner that may be even unre-
lated to its methylesterase activity [157]. Notably, in 
some cancer cells this PME-bound, inactive PP2A frac-
tion might be significantly increased as in glioblastoma 
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PME-1 overexpression correlated with tumor staging and 
increased activity of the MEK/ERK pathway [158]. 
 
Concluding remarks: therapeutic targeting of cellular 
PP2A inhibitors in cancer 
 
In summary, many of the PP2A inhibitors described 
above are clearly aberrantly expressed in various cancers 
and this may contribute significantly to tumorigenesis and 
tumor progression (Fig 3). While most inhibitors, such as 
SET or CIP2A act as oncoproteins, in line with the well-
established tumor suppressor functions of PP2A, some 
inhibitors, such as ANP32a, are tumor suppressive them-
selves, potentially reflecting they might act on different 
PP2A holoenzymes. At least for the oncogenic PP2A in-
hibitors, it seems a valuable therapeutic strategy to at-
tempt interfering with their increased expression in cancer 
cells, or else relieving somehow their PP2A inhibitory 
mode-of-action. Such approaches can indeed be expected 
to restore PP2A’s anti-proliferative and pro-apoptotic 
functions, and ultimately block tumor growth and induce 
apoptotic death. In fact, several recent pre-clinical studies 
have demonstrated the feasibility of such strategies [re-
viewed in 11,31]. 
 
Although mechanistically poorly understood, transcrip-
tional downregulation of CIP2A by rhabdocoetsin B, a 
compound extracted from a traditional Chinese medicinal 
herb, induces apoptosis and Akt inactivation in a variety 
of lung cancer cells [159]. Likewise, bortezomib, a pro-
teasome inhibitor, down-regulates CIP2A in a dose- and 
time-dependent manner in bortezomib-sensitive liver can-
cer cell lines, resulting in Akt inactivation and apoptosis 
[160]. The combination of bortezomib and sorafenib, a 
multi-kinase inhibitor, results in synergistic apoptotic ef-
fects in a CIP2A/PP2A-dependent manner [161]. In addi-
tion, CIP2A downregulation and subsequent PP2A-
mediated inhibition of Akt signalling can sensitize cancer 
cells to TRAIL-induced cell death [162,163]. Along the 
same lines, reduction of SET levels has been demon-
strated following imatinib (a Bcr/Abl kinase inhibitor) and 
Janus kinase 2 inhibitor (HBC or AG490) treatment in 
CML cell lines and mouse cells expressing imatinib-
resistant forms of Bcr/Abl, presumably also through a 
transcription-dependent mechanism [94,164]. 
 
Direct therapeutic interference with the PP2A–SET inter-
action was highlighted in two reports in which SET was 
identified as a novel cellular binding target of COG112 
[165,166], an apolipoprotein E-mimetic peptide, that tar-
gets the oncogenic functions of SET in a glioma and 
breast cancer cell line by disrupting its association with 
three different cellular SET targets: PP2A, the metastasis 
suppressor NM23-H1 and Rac1 [166]. The resulting in-
crease in PP2A activity corresponded to decreased Akt 
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signalling and c-Myc stability [166], while in immune 
cells decreased NF-κB signalling, phospho-p38 and phos-
pho-Akt were observed [165]. In both systems this re-
sulted in potent anti-proliferative and pro-apoptotic ef-
fects. Likewise, treatment of primary B-CLL cells with 
COG449, a dimerised derivative of COG112, increased 
PP2A activity and induced cytotoxicity in vitro and in 
vivo, while normal B cells were 2-log units less sensitive, 
indicative for cancer cell specificity [97]. 
 
Another compound that might directly interfere with 
SET-mediated inhibition of PP2A, is FTY720 (Fingoli-
mod), a sphingosine-like molecule, recently approved for 
multiple sclerosis treatment. FTY720 induces mitochon-
dria-dependent apoptosis and has potent anti-proliferative 
effects, particularly in several leukemias [31,94,95,167, 
168,169]. The underlying mechanism involves a direct 
increase of PP2A activity, which was originally low due 
to increased bcr/abl-induced expression of SET. FTY720-
mediated PP2A activation might involve intracellular 
production of ceramide and subsequent ceramide-induced 
dissociation of the PP2A–SET interaction [170]. In mu-
tant c-KIT-positive AML however, FTY720 also in-
creased inhibited PP2A activity, which was in this case 
low by c-kit-induced reduced expression of various tumor 
suppressive PP2A subunits, including A and PR61/B’ 
or γ [171], indicative for other cellular FTY720 targets 
besides SET. In any case, from these studies it was sug-
gested that reactivation of PP2A might prove particularly 
therapeutically beneficial in those cases where oncogenic 
tyrosine kinase mutations, such as bcr/abl and mutant c-
kit, underlie resistance to current kinase inhibitor thera-
pies [171]. 
 
In conclusion, the aforementioned studies clearly have 
demonstrated the therapeutic promise of interfering with 
oncogenic PP2A inhibitors, such as CIP2A and SET, in 
several human cancers. However, in order to further de-
velop these SET or CIP2A antagonizing molecules into 
drug-like compounds, it will be of utmost importance to 
improve our current insights into the molecular and bio-
chemical mechanisms by which these inhibitors target 
PP2A or specific PP2A holoenzymes and inhibit PP2A 
activity. For this purpose, structural studies are urgently 
needed. All this essentially also applies for the more re-
cently discovered members of the ARPP-16/-19/ENSA 
family and TIP. In these cases, additional studies are re-
quired to investigate their status in human tumor samples 
and cancer cells. For PME-1 highly specific esterase cata-
lytic inhibitors have been reported [172,173], but it re-
mains to be determined how beneficial they might be to 
stop proliferation or induce apoptosis, for instance in cel-
lular models of glioblastoma. It is in any case expected 
that studying these cellular PP2A inhibitors will only gain 
importance in current cancer biology and drug discovery 
research. 
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Figure 3. Cellular PP2A inhibitors and their status in cancer cells  
Currently well-established PP2A inhibitory proteins are depicted alongside the PP2A subunit which they pre-
sumably target: while TIPRL1, SET and ANP32a/e have clearly been shown to directly bind to PP2A-C, the 
PP2A binding partner of CIP2A is not yet entirely clear, although CIP2A was found in immunoprecipitates of the 
A subunit. The mitotic inhibitors ENSA and ARPP-19 target a specific B-type subunit, PR55/B, and this requires 
their prior phosphorylation by Greatwall/MASTL kinase. The inactive PP2A–PME-1 complex is depicted sepa-
rately to indicate that although PME-1 has a high affinity for an inactive PP2A-C conformation, it can likely not 
actively inhibit PP2A. For some of the inhibitors their status in cancer cells is summarized; as far as we know, 
any abnormalities have not yet been described for TIPRL or the ARPP-19/ENSA members. 
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Reversible protein phosphorylation plays a crucial role in regulating cell signaling. In normal 
cells, phosphoregulation is tightly controlled by a network of protein kinases counterbal-  
anced by several protein phosphatases. Deregulation of this delicate balance is widely 
recognized as a central mechanism by which cells escape external and internal self-     
limiting signals, eventually resulting in malignant transformation. A large fraction of hema-
tologic malignancies is characterized by constitutive or unrestrained activation of oncogenic 
kinases. This is in part achieved by activating mutations, chromosomal rearrangements, or 
constitutive activation of upstream kinase regulators, in part by inactivation of their anti-
oncogenic phosphatase counterparts. Protein phosphatase 2A (PP2A) represents a large 
family of cellular serine/threonine phosphatases with suspected tumor suppressive func-
tions. In this review, we highlight our current knowledge about the complex structure and 
biology of these phosphatases in hematologic cells, thereby providing the rationale behind 
their diverse signaling functions. Eventually, this basic knowledge is a key to truly under-
stand the tumor suppressive role of PP2A in leukemogenesis and to allow further rational 
development of therapeutic strategies targeting PP2A. 
 
Keywords: PP2A, subunit, inhibitor, tumor suppressor reactivation therapy, PP2A-activating drugs 
 
INTRODUCTION 
  
With 518 kinases encoded by the human genome and up to 70% of 
all eukaryotic proteins undergoing phosphorylation on a Ser, Thr, or 
Tyr residue, nearly every cellular process is controlled by this key 
modification (1). The covalent attachment of the bulky, negatively 
charged phosphoryl moiety to a protein markedly affects protein 
function through conformational changes that alter catalytic activity 
(for enzymes), affinity for ligands, subcellular localization, or stability 
(2). Several decades of biochemical and genetic studies have 
revealed crucial roles for protein kinases in the processes leading to 
tumor cell proliferation, survival, and migration in hematologic and 
other malignancies. In particular, genetic alterations that lead to 
constitutive activation of kinases, uncoupled from extracellular 
regulatory inputs, are well-characterized drivers of cancer 
development, a knowledge, which has emerged in the development 
of small-molecule kinase inhibitors for anti-cancer therapy (3). Kinase 
inhibitors have been extremely successful in the treatment of cancers 
driven by a single oncogenic kinase, such as chronic myeloid 
leukemia (CML) (4), but several challenges remain, including the 
development of drug resistance, lack of inhibitor selectivity or 
efficacy, and difficulty in drug target validation, particularly in cancers 
that do not exhibit such oncogenic kinase addiction (5). 
 
Obviously, because protein phosphatases antagonize the action 
of protein kinases, they should be considered as equally important 
players in maintaining the correct phosphorylation balance of a given 
protein. Nonetheless, persistent misconceptions regarding the 
 
supposed  lack of specificity and regulation of protein phosphatases 
as opposed to protein kinases, have contributed to a general 
underestimation of their critical role in the regulation of signal 
transduction (6,7). Hence, much less is known about their role in 
cancer development and progression. Research over the past 
decade has begun to highlight the importance of the tumor 
suppressive activities of protein phosphatases, which, upon functional 
inactivation, contribute to persistent kinase or oncogene activation, 
and perhaps even more importantly, to drug resistance development 
(8,9). Therefore, protein phosphatases may represent valuable novel 
drug targets for alternative cancer therapies, either in their own right 
or as part of combination therapies with kinase inhibitors (10–13). 
 
 
Protein phosphatase 2A (PP2A) represents the prototype of a 
highly regulated phosphatase family with suspected critical tumor 
suppressive properties in several human tissues (14–16). Recent 
reports have demonstrated that modulation of PP2A activity can be 
beneficial for the treatment of cancer, particularly of hematologic 
malignancies (17,18). Increasing evidence from cellular and clinical 
studies has indeed underscored the tumor suppressive role of PP2A 
in leukemogenesis, although the complex biology of these enzymes 
in hematologic cells remains incompletely understood. Here, we will 
provide insights into the basics of PP2A structure and regulation in 
hematologic cells and tissues, and highlight how proper PP2A 
function or activity is affected in hematologic malignancies. This 
knowledge is not only imperative to understand the protective role of 
PP2A in leukemogenesis but also equally important to allow for
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FIGURE 1 | Structure of PP2A holoenzymes. The majority of PP2A enzymes 
have a heterotrimeric structure and consist of one catalytic C subunit, one 
scaffolding A subunit, and one regulatory B-type subunit. Owing to the 
existence of various isoforms of each of these subunits – in human tissues, 
two C (encoded by PPP2CA and PPP2CB), two A (encoded by PPP2R1A 
 
 
 
 
 
 
 
 
 
 
 
 
and PPP2R1B), and 23 B-type isoforms (encoded by 15 different genes) – 
92 different PP2A trimeric complexes can be assembled, each 
characterized by its own catalytic properties, substrate specificities, tissue 
or cell-specific expression, and subcellular localization. In addition, about 
one-third of PP2A occurs as a dimer of one A and one C subunit (four 
holoenzymes). 
 
rational design of PP2A-directed drugs, and thus, to fully exploit 
PP2A as anti-cancer target in these devastating diseases. 
 
PP2A FAMILY 
  
PP2A ENZYMES: STRUCTURAL AND FUNCTIONAL 
CENTIPEDES 
 
“PP2A” refers to a large, highly conserved family of ubiquitously 
expressed Ser/Thr phosphatases that, together with PP1, constitutes 
the bulk of Ser/Thr phosphatase activity in a given cell or tissue (19). 
The prototypic PP2A holoenzyme is a heterotrimeric complex of a 
catalytic C subunit, a scaffolding A subunit, and a regulatory B-type 
subunit (Figure 1). In human cells, B-type subunits are encoded by 
15 different genes, which give rise to 23 different isoforms through 
use of alternative gene promoters, alternative splicing events, or 
alternative translation (20). Based on sequence homology, they are 
divided into four distinct families, called B (or B55, or PR55, or by 
gene name: PPP2R2), B’ (or B56, or PR61, or by gene name: 
PPP2R5), B’’(or PR72, or by gene name: PPP2R3), and B’’’ (or the 
striatins, STRN) (Figure 1). The B-type subunits are true “regulatory” 
subunits, in the sense that they dictate substrate specificity of the 
associated PP2A C subunit and can directly modulate PP2A catalytic 
activity. They are often expressed in a cell- or tissue-specific way, 
and can be found at distinct subcellular locations (cytoplasm, 
nucleus, plasma membrane, mitochondria, Golgi apparatus, 
endoplasmic reticulum, and cytoskeleton), thus, restricting PP2A 
activity to cell- or tissue-specific substrates present at specific 
subcellular sites (20,21). Also, the C and A subunits are encoded by 
two different genes each, giving rise to two nearly identical Cα and 
Cβ isoforms (encoded by PPP2CA and PPP2CB), and two highly 
related Aα and Aβ isoforms (encoded by PPP2R1A and PPP2R1B). 
Despite an extremely high degree of sequence identity, there is 
evidence that these isoforms, remarkably, do not serve redundant 
functions (22–25). Besides their assembly into trimeric PP2A 
complexes, A and C subunits can form active A–C heterodimers 
(Figure 1), which are estimated to represent about one-third of 
cellular PP2A in a given cell ( 26). 
The combinatorial assembly of one C and one A, or one C, one A, 
and one B-type subunit can theoretically give rise to 4 different 
heterodimers and 92 different heterotrimers (Figure 1), all exhibiting 
potentially different physiological functions. Thus, the broad diversity 
in PP2A composition creates specificity and constitutes 
 
the basis for the highly diverse and multiple cellular and physiological 
functions of these phosphatases. PP2A has indeed been implicated 
in a wide range of signaling pathways, many of which are involved in 
the control of cell proliferation and death (16,27), cell division (28,29), 
differentiation (28), adhesion and migration (30), and metabolism 
(31,32). Besides function, PP2A composition also largely defines 
regulation by upstream factors, including specific second messengers 
(cAMP, Ca
2+
-ions, lipids) (20), cellular PP2A inhibitors (33) (see 
further), and phosphorylation by specific kinases (20). Most of these 
regulatory inputs are again largely determined by the nature of the 
specific B-type subunit present in the complex. 
  
This being said, it should come of little surprise that “PP2A” (i.e., 
the large family of distinct PP2A complexes) may exert collaborating 
as well as opposing functions within a given signaling pathway by 
acting at different levels in the cascade. This is, for instance, the case 
in growth factor-induced ERK signaling, TGFβ signaling, or in 
canonical and non-canonical Wnt signaling (16,27,34). In addition, 
different PP2A complexes may dephosphorylate the same substrate, 
even on the same site, depending on the regulatory stimulus 
involved, the cell type or the broader physiological context (35–37). In 
contrast, functional redundancies, particularly between PP2A 
complexes harboring a B-type subunit from the same subfamily, have 
also been reported (38), further illustrating the complexity of PP2A 
holoenzyme function and substrate selection. It is clear though that in 
order to fully understand the role and regulation of “PP2A” in any 
(patho)physiological context, it is of utmost importance to identify 
which particular holoenzymes are involved in a non-redundant way. 
Nonetheless, and despite their general importance in PP2A biology, 
the specific PP2A regulatory subunits controlling dephosphorylation 
of a given substrate in a given mammalian cell or tissue remain 
poorly defined, particularly in the physiological context of a whole 
organ-ism (39–41). Additional “PP2A” knockout mice are eagerly 
being awaited to overcome this lack of in vivo knowledge, and 
eventually, to advance the rational development of PP2A as a 
druggable target in the relevant cancer types. 
 
 
EXPRESSION OF PP2A SUBUNITS IN SPLEEN, THYMUS, 
AND BONE MARROW  
To truly understand the biology of “PP2A” in hematologic cells and 
tissues, one should ideally know which PP2A complexes occur in 
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FIGURE 2 | Microarray expression profiles of PP2A subunit encoding 
genes in mouse tissues. Spleen, thymus, bone marrow, brain cortex, and 
heart were hand-dissected from 10- to 12-week-old C57Bl6 mice. Total 
RNA was extracted, labeled, and hybridized to the Affymetrix mouse MOE 
430 2.0 array (44). Scanning, quality control, data processing, and 
statistical analysis of the data were as described (44). Shown is the mean 
mRNA expression signal SD of three (spleen, thymus, brain, and heart) or 
four (bone marrow) biological replicate experiments. (A) Expression of the 
PP2A core subunit encoding genes. (B) Expression of the genes encoding 
PP2A regulatory B-type subunits. Expression of Ppp2r3d could not be 
analyzed because it was not present on the array used. 
 
 
these tissues. Because of general lack of sufficient isoform-specific 
antibodies and because only fragmented relevant information can be 
found in the currently available PP2A literature, we have analyzed, for 
the purpose of this review, mRNA expression of all PP2A subunit 
genes via microarray in mouse spleen (n=3), thymus (n=3), and bone 
marrow (n=4) (Figure 2). Brain cortex (n=3) and heart (n=3) were 
included as “controls” (Figure 2) as in these tissues, expression of 
most PP2A subunits has been investigated and reported before. If we 
presume that hybridization of the PP2A mRNAs to their respective 
gene probes on the chip occurs with comparable efficiency, we find 
overall significantly higher expression of the α isoforms of both C and 
A subunits as opposed to their respective β isoforms (Figure 2A), 
fully in accordance with published data (19,24). When considering 
expression of B-type subunits, most of them are expressed in all 
three hematologic tissues, except Ppp2r2b and Ppp2r2c (encoding 
Bβ and Bγ), which were reported to be exclusively expressed in brain 
(42), Ppp2r3a (encoding B’’α), which was reported to be 
predominantly expressed in heart (43), and Ppp2r5b (encoding 
 
 
B’β) whose hematologic expression is extremely low (Figure 2B). 
Highest expression is seen for Ppp2r5a and Ppp2r5c (encoding B’α 
and B’γ), followed by Ppp2r5e (encoding B’ε), Strn3 (encoding 
B’’’/SG2NA), Ppp2r3c (encoding B’’γ/G5PR), Ppp2r2a, and Ppp2r2d 
(encoding Bα and Bδ). Lowest expression is seen for Ppp2r5d 
(encoding B’δ), Strn, and Strn4 (encoding B’’’/striatin and B’’’/zinedin) 
(Figure 2B). Expression of Ppp2r3d could not be analyzed because it 
was not represented on the microarray chip. For most PP2A subunits 
present in these tissues, expression is comparable between spleen, 
thymus, and bone marrow, except for Ppp2r2a (Bα), which is 
approximately two times more abundant in spleen and thymus as 
opposed to bone marrow, and for Ppp2r5a (B’α), Ppp2r5d (B’δ), and 
Strn4 (B’’’/zinedin), which are least abundant in spleen as opposed to 
thymus and bone marrow (Figure 2B). Thus, these data illustrate in a 
qualitative and semi-quantitative way the repertoire of PP2A B-type 
subunits expressed in the three main hematologic tissues in mice. 
 
INACTIVE PP2A COMPLEXES AND PP2A HOLOENZYME ASSEMBLY  
Besides the prototypical PP2A holoenzymes described above, 
several “atypical” PP2A complexes have been identified that can 
occur within cells as catalytically inactive PP2A complexes. For 
example, the interaction between the C subunit and the a4 protein 
(encoded by IGBP1) stabilizes the C subunit as a latent, inactive form 
(45,46), although there is also some evidence that this complex might 
be active toward very specific cellular substrates [reviewed in Ref. 
(47)]. Another example is the catalytically inactive complex between 
the C subunit, the A subunit, and PME-1 (PP2A Methyl Esterase 1, 
encoded by PPME1) (Figure 3A) that has been estimated to 
represent up to 25% of the cellular PP2A C pool (48,49). It is thought 
that these atypical, inactive PP2A complexes constitute intermediate, 
but stable complexes during the process of PP2A holoenzyme 
biogenesis (47) or holoenzyme disassembly (45). Interestingly, 
increased expression of α4 or PME-1 has been found in several 
human cancers [hepatocellular carcinoma (50), lung carcinoma (50,  
51), breast cancer (50), glioma (52), and endometrial cancer (53)], 
indicative for a relative increase in inactive PP2A complexes as 
opposed to active holoenzymes in these transformed cells.  
The precise mechanism of assembly of active PP2A holoenzyme 
is still incompletely understood (47). A major insight came from the 
finding that the PP2A C subunit is synthesized/translated as an 
inactive enzyme (54) that is subsequently activated in a way that is 
strictly coupled to its incorporation into the complete holoenzyme 
(55). Like that, promiscuous and unregulated phosphatase activity of 
the free C subunit can be avoided (54,55). There is evidence that 
proteins such as α4 and PME-1 can stabilize such inactive PP2A C 
subunits within cells, either in the absence (for α4) (46) or the 
presence (for PME-1) of the A subunit (47). To generate active PP2A 
holoenzymes from these inactive complexes, at least two additional 
PP2A regulating enzymes are needed. First, PTPA (or “PP2A 
Activator,” encoded by PPP2R4) may activate the PME-1-bound 
PP2A complex in the presence of ATP/Mg
2+
 as necessary cofactors 
(Figure 3A) (49). In accordance, in vivo data in yeast have shown 
that PTPA-dependent generation of active C subunit requires a 
functional interaction with the A subunit and is regulated by PME-1 
(55). Crystallographic data suggested that PTPA may act as an
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FIGURE 3 | Regulators of PP2A holoenzyme biogenesis and assembly.  
(A) Simplified schematic of the roles of PME-1, PTPA, and LCMT1 in the 
biogenesis of active PP2A trimers. The PP2A methylesterase PME-1 serves to 
stabilize the inactive PP2A C subunit in a complex with the A subunit, at the 
same time preventing PP2A C methylation. With ATP/Mg
2+ 
 as necessary 
cofactors, PTPA promotes folding of PP2A C in an active conformation, and 
thereby, indirectly, PP2A C carboxymethylation by LCMT1. The latter 
modification is absolutely required for binding of B subunits, facilitates interaction 
of all B’ subunits but the δ isoform, is of no apparent importance for binding of 
B’δ and the B’' subunits, and is disliked by the striatin subunits. α4 (not depicted 
here) is another regulator that stabilizes PP2A C in a latent form. It is currently 
unclear if and how this inactive α4–C complex might become activated by similar 
mechanisms (47).  
 
   (B) Expression of PP2A biogenesis regulators in hematologic tissues, brain, and 
heart. The mean mRNA expression signal ± SD for Ppme1 (PME-1), Lcmt1 
(LCMT1), Igbp1 (α 4), and Ppp2r4 (PTPA) is shown of three (spleen, thymus, 
brain, and heart) or four (bone marrow) biological replicate experiments.  
 
 
 
ATP/Mg
2+
-dependent prolyl-peptidyl cis/trans isomerase of a single 
prolyl-peptidyl bond in PP2A C (56), as well as an ATP/Mg
2+
-
dependent chaperone promoting the incorporation of catalytic metal 
ions into the PP2A C active site (57). Regardless of its precise 
mechanism-of-action, several in vivo studies have underscored the 
importance of PTPA as a physiological activator of PP2A [reviewed in 
Ref. (47)]. The second enzyme important in PP2A biogenesis is 
LCMT1 (leucine carboxyl methyl transferase 1, encoded by LCMT1), 
an S-adenosylmethionine-dependent methyltransferase catalyzing 
the carboxymethylation of the PP2A C subunit (58). This unusual 
post-translational modification of PP2A C is reversible through the 
presence of PME-1, the PP2A methylesterase (59), which may thus 
serve a dual function. Interestingly, PP2A C carboxymethylation 
requires an active PP2A C conformation (60), is facilitated by the 
presence of the A subunit (61), and enhances the affinity of the core 
 
 
 
 
dimer for PP2A regulatory subunits (Figure 3A). Specifically, PP2A C 
methylation is an absolute prerequisite to bind subunits of the B 
family, it facilitates interaction of all members but the δ isoform of the 
B’ family,is of no apparent importance for binding of B’ and the B’’ 
subunits, and is disliked by the B’’’ subunits [reviewed in Ref. (62)]. 
Intriguingly, all regulators involved in PP2A holoenzyme biogenesis 
(α4, PME-1, PTPA, and LCMT1) are indispensable for mammalian 
survival (63– 65, unpublished work), indicative for their physiological 
importance. In accordance, they are all expressed in spleen, thymus, 
and bone marrow, the three hematologic tissues analyzed here by 
microarray (Figure 3B). Our data also show a relatively higher 
expression of PME-1 and LCMT1 in brain, as opposed to other 
tissues analyzed (Figure 3B). 
 
CELLULAR PP2A INHIBITORY PROTEINS 
  
Although the first cellular PP2A inhibitors were discovered almost two 
decades ago (66), their role in direct regulation of PP2A activity has 
only during the recent years come into considerable focus, not the 
least because some of them commonly suppress PP2A activity in 
hematologic and other cancers, and thus, may constitute novel 
therapeutic targets (33). These inhibitors either directly bind to the 
PP2A catalytic subunit or target very specific PP2A holoenzymes, 
thereby preventing dephosphorylation of a large variety of PP2A 
substrates (Figure 4A). 
 
ANP32a AND SET  
PP2A inhibitor 1 (also called ANP32a, or by gene name: ANP32a) 
and inhibitor 2 (also called TAF-Iβ, or PHAP1, or by gene name: SET) 
were originally de novo purified from bovine kidney as two potent, 
heat-stable PP2A-specific inhibitors (66) and subsequently cloned 
from cDNA libraries (67,68). ANP32a belongs to a large family of at 
least nine members (ANP32a–h), of which only ANP32a and ANP32e 
show PP2A inhibitory ability in an in vitro phosphatase assay (69,70). 
Free PP2A C subunit, the core A–C dimer and a trimeric PP2A 
complex with B subunit were inhibited in this assay, suggestive for 
direct binding of ANP32a to the C subunit, and thus, for no specific 
holoenzyme selectivity. Essentially, the same observations were 
made for SET in in vitro PP2A phosphatase assays (68). SET exists 
as two splice variants (SETα and β) that are both capable of inhibiting 
PP2A (71). ANP32a/e and SET are all phosphoproteins and can be 
found in the nucleus as well as the cytoplasm. Tyrosine 
phosphorylation of ANP32a releases its binding to PP2A and relieves 
PP2A inhibition toward MEK (72). In SETα, Ser9, Ser24, Ser93, and 
Ser171 have been identified as phosphorylation sites of functional 
importance (73–75). Phosphorylation of Ser9 functionally disrupts a 
nuclear localization signal and promotes SET retention in the 
cytoplasm (76,77), while Ser171 phosphorylation decreases its PP2A 
inhibitory potential (74) and Ser9/Ser93 phosphorylation increases its 
ability to inhibit PP2A (75). Proteolytic cleavage of SET, either by 
Granzyme A at K176 (78) or by asparaginyl endopeptidase at N175 
(79) is another mechanism that promotes its translocation into the 
cytoplasm (80), while the SET-binding protein SETBP1 stabilizes full-
length SET inside the nucleus (81). Several PP2A substrates are 
known to be affected by SET, either directly or indirectly, including 
ERK1/2 (82), Akt (82–84), PTEN (83), Mcl-1 (85,86), c-Myc 
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FIGURE 4 | Cellular PP2A inhibitors. (A) Schematic representation of 
known cellular PP2A inhibitors, highlighting their potential regulation by 
(yellow) or dependence on (blue) phosphorylation, their holoenzyme 
specificity (if known), and the PP2A substrates they affect. Best 
characterized so far, in terms of phosphorylation dependence and 
holoenzyme specificity, are the mitotic inhibitors ENSA, ARPP-19, and 
Bod1. Both I1 (ANP32a, e) and I2 (SET) are established phosphoproteins, 
but depending on the specific site of modification, these phosphorylations 
may increase as well as decrease their PP2A inhibitory abilities. 
Phosphoregulation of CIP2A or TIPRL has not yet been described. I1, I2, 
and TIPRL are thought to interact with PP2A complexes through the C 
subunit, while holoenzyme specificity of CIP2A-mediated inhibition remains 
undefined. PBD: polo-box domain. (B) Expression of cellular PP2A 
inhibitors in hematologic tissues, brain, and heart. The mean mRNA 
expression signal ± SD for the eight indicated cellular PP2A inhibitory 
proteins is shown of three (spleen, thymus, brain, and heart) or four (bone 
marrow) biological replicate experiments. 
 
 
(82,84,87), c-jun (88),and pRb (82), just to name a few (Figure 4A). 
 
CIP2A  
CIP2A (or cancerous inhibitor of PP2A, or by gene name KIAA1524) 
is an oncoprotein, originally identified as a novel co-precipitating 
partner of the PP2A A subunit (89). CIP2A is barely detectable in 
normal cells, but becomes specifically upregulated in a large variety 
of human cancers, hence its name [reviewed in Ref. (90)]. CIP2A 
knockout mice show no overt phenotypes, except for a defect in 
spermatogenesis (91). In cancer cells, CIP2A upregulation is 
mediated by several oncogenic transcription factors, including Ets 
(92), Myc (93), and E2F (94), and often correlates with cancer 
 
 
 
aggressiveness and poor prognosis (90). At the signaling level, 
increased CIP2A expression has been associated with increased c-
Myc stability and Ser62 phosphorylation (89), increased Akt signaling 
(95), inhibition of dependence receptor-dependent apoptosis (96), 
and more recently, with changes in regulation of cell cycle kinases 
such as Plk1 (97) and NEK2 (98), and activation of the TOR pathway 
(99,100) (Figure 4A). The biochemistry of CIP2A remains, however, 
largely undefined; in particular, it remains to be determined which 
PP2A complexes it may specifically inhibit and how this is achieved. 
 
TIPRL1  
TIPRL1 (also called TIP, or two A inhibitory protein, gene name 
TIPRL) is a ubiquitously expressed PP2A inhibitory protein that has 
been shown to inhibit free PP2A C and the PP2A A–C dimer by an 
allosteric mechanism (101,102). TIPRL1 directly interacts with PP2A 
C, as well as with the C subunits of the PP2A-like phosphatases PP4 
and PP6 (103). Notably, TIPRL1 may play an important role in DNA 
damage and repair signaling as it regulates PP2A enzymes that 
oppose ATM/ATR-dependent phosphorylation events (101). In 
addition, it may facilitate mTORC1 signaling and increase protein 
translation by sustaining phosphorylation of the mTORC1 substrates 
S6K1 and 4E-BP1 (104). In cancer cells, highly elevated TIPRL1 
expression was reported in hepatocellular carcinoma, correlating with 
decreased pro-apoptotic MKK7/JNK signaling and contributing to 
resistance to TRAIL-induced apoptosis (105). The physiological role 
of TIPRL1 remains, however, undefined. 
 
MITOTIC PP2A INHIBITORS: ENSA, ARPP-19, AND Bod1 
cAMP-regulated phosphoproteins ARPP-16 and ARPP-19 are splice 
variants and members of an evolutionary conserved protein family, to 
which ENSA (α-endosulfine) is closely related. ENSA and ARPP-19 
are mitotic PP2A inhibitors that promote the G2/M transition and the 
mitotic state (106,107). Intriguingly, they strongly bind to Bα and Bδ, 
but no other B-type subunits, dimeric PP2A or monomeric PP2A C, 
suggestive for a strong PP2A holoenzyme specificity (106–108) 
(Figure 4A). Moreover, these proteins require prior phosphorylation 
by the mitotic Great-wall/MASTL kinase, the Cdk1/cyclinB kinase, or 
potentially other mitotic kinases to exert their PP2A inhibitory effects 
(106,107,109,110). Phosphorylation of ARPP-19 by cAMP-dependent 
kinase (PKA) serves to keep oocytes arrested in prophase (111), but 
how this may affect PP2A inhibition is unknown. More recently, yet 
another mitotic PP2A inhibitor was identified: Bod1, a protein required 
for proper chromosome alignment at mitosis. Bod1 shares sequence 
similarity with ENSA and ARPP-19, but intriguingly, specifically 
inhibits kinetochore- and centrosome-associated PP2A-B’ 
holoenzymes. Again, a phosphorylation of Bod1 by Cdk1/cyclinB is 
required to promote interaction with and inhibition of PP2A-B’ (112). 
Although many more needs to be discovered about the biochemistry 
and physiological roles of these mitotic PP2A inhibitors, they currently 
represent an exemplary mechanism of holoenzyme (family)-specific 
PP2A inhibition. 
 
EXPRESSION OF PP2A INHIBITORS IN HEMATOLOGIC 
TISSUES  
As for the PP2A subunits (Figure 2) and the regulators of PP2A 
holoenzyme assembly (Figure 3B), we have analyzed mRNA 
expression of the above PP2A inhibitors in mouse spleen (n=3), 
thymus (n=3), and bone marrow (n=4) ( Figure 4B). Expression of
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SET, CIP2A, and ANP32e appears significantly higher in all three 
hematologic tissues analyzed, as opposed to terminally differentiated 
brain and heart tissues. In fact, CIP2A expression is completely 
undetectable in brain and heart, consistent with the idea that its 
expression is tightly coupled to cell proliferation, and potentially, 
stemness (90). Bod1 expression shows the opposite behavior and is 
significantly less expressed in spleen, thymus, and bone marrow as 
opposed to brain and heart, while TIPRL1, ANP32a, ENSA, and 
ARPP-19 expression is comparable in tissues analyzed (Figure 4B). 
 
PP2A ABERRATIONS IN HEMATOLOGIC MALIGNANCIES  
 
Several mechanisms of PP2A dysfunction in hematologic 
malignancies have been reported, including changes in expression of 
PP2A subunits and inhibitors (by epigenetic or other mechanisms), 
genomic alterations in PP2A subunit and regulator encoding genes 
(including mutations, deletions, splicing errors, chromosomal 
translocations), and alterations in subunit modifications affecting 
PP2A activity. 
 
ALTERATIONS IN PP2A SUBUNITS  
Although both PPP2R1A (Aα) and PPP2R1B (Aβ) have been 
identified as genuine tumor suppressor genes in solid cancers (17, 
25), few reports have currently documented their inactivation in 
hematologic malignancies. Decreased A subunit expression is 
observed in myeloid cells expressing activated c-KIT mutants (113), 
while loss of Aβ function occurs with low frequency in ALL (G90D 
mutation, 3/150) (114), B-CLL (exon skipping and reduced mRNA 
expression) (115,116), and AML (117). Decreased expression of Cα 
is one of the hallmarks of del(5q) myelodysplastic syndromes (MDS) 
and AML, and interestingly, predicts a favorable therapy response to 
lenalidomide (118), suggestive for its use as a stratification marker. 
Increased Y307 phosphorylation of PP2A C occurred in 29/37 AML 
cases, correlating with significantly decreased PP2A activity toward 
Akt and ERK (117).  
PP2A B-type subunit alterations occur more frequently, 
particularly in AML. Reduced expression of Bα in AML blasts, 
correlating with increased Akt, p70S6K, and PKCα phosphorylation 
and deregulated expression of specific microRNAs (miRs), is 
associated with significantly reduced complete remission duration 
(119,120). In c-KIT mutant AML, reduced expression of Bα is 
observed, along with decreased expression of several B’ subunits 
(α,γ,δ), correlating with overall decreased PP2A activity (113). 
Genomic deletion of PPP2R5B/C (B’β,γ) (117) and downregulation of 
B’ε by an elusive non-genomic mechanism (121) do also frequently 
occur in AML, correlating with increased oncogenicity of the leukemic 
cells. In lymphocytic leukemia, PPP2R5C (B’γ) downregulation is a 
hallmark of progressive as opposed to stable B-CLL (122), while in 
Notch-induced T-ALL, PPP2R5E (B’ε) was identified as one of the 
targets for miR-19, an oncomiR that promotes leukemogenesis in 
vivo (123). In childhood T-ALL and B-ALL, PPP2R3A (B’’α) is 
epigenetically inactivated by increased methylation with high 
frequency (69 and 82%, respectively) (124). Genomic deletion of 
PPP2R2A/B (Bα,β) is sporadically observed in primary plasma cell 
leukemia and multiple myeloma (125,126). 
 
ALTERATIONS IN PP2A REGULATORS  
The large majority of PP2A aberrations in hematologic malignancies 
involve abnormalities (overexpression, genetic modifications) in the 
proto-oncogenic PP2A inhibitors CIP2A and SET. 
 
 
  
The first time deregulated CIP2A expression was linked to blood 
cancer development was through the discovery of a chromosomal 
translocation, resulting in an MLL-KIAA1524 fusion protein in an 
isolated case of infant AML (127). In this fusion, exons 1–10 of MLL 
are coupled in frame to exons 17–21 of CIP2A, encompassing the 
CIP2A coiled coil domain. In addition, CIP2A overexpression occurs 
frequently in newly diagnosed AML (54/70) and relapsed AML (11/14) 
(128). In CML, a positive feedback loop between CIP2A and 
BCR/ABL has been described, implying that CIP2A overexpression 
may promote CML pathogenesis (129,130). Importantly, and in 
contrast to expression of SET, CIP2A expression is a clear 
determinant of disease progression to blast crisis (129) and thus 
confers a poor prognosis in these patients. Mechanistically, high-
CIP2A levels in primary CML correlate with high levels of S62-
phosphorylated c-Myc (129) and increased resistance to bortezomib-
induced apoptosis (131). Analysis of CIP2A expression levels in a 
panel of 105 B-cell lymphomas further demonstrated a link with 
clinical aggressiveness of the subtypes, with weak or absent CIP2A 
expression in indolent B-cell lymphomas and strongly positive signals 
in the more aggressive diffuse large B-cell and Burkitt lymphoma 
subtypes (132). 
  
Increased SET expression is found in CML, where it correlates 
with blast crisis and resistance to therapeutic BCR/ABL tyrosine 
kinase inhibitors (TKI) (82), in Philadelphia chromosome-positive 
(Ph)-ALL (133), (c-KIT positive) AML (113,134), and B-CLL (85). In 
AML and B-CLL, its expression is associated with disease severity 
and poor outcome. In leukemic progenitors, PP2A activity is 
substantially impaired as a result of SET overexpression (82). In CML 
and Ph-ALL, induction of SET expression is controlled by BCR/ABL 
(82), while in AML, overexpression of EVl1 or downregulation of 
miR199b may contribute (134). Restoration of PP2A activity in 
leukemic cells results in decreased phosphorylation of pRb, c-Myc, 
Stat5, ERK1/2, Akt, Bad, and Jak2, and induction of SHP1-mediated 
BCR/ABL inactivation and degradation (82,135). In atypical CML, 
lacking the BCR/ABL fusion, recurrent SETBP1 mutations are found 
in 17/70 cases, some of which abrogate a site for ubiquitination, 
resulting in increased amounts of SETBP1 and SET protein, lower 
PP2A activity, and higher proliferation rates (136). In AML, 
overexpression of SETBP1 predicts poor outcome in elderly AML 
patients (81). Finally, SET is recurrently involved in chromosomal 
rearrangements and translocations, in particular, with the 
nucleoporin-encoding Nup214 gene (also called CAN ) in AML, T-
ALL, and acute undifferentiated leukemia (137–140). 
 
 
PP2A (RE)ACTIVATION AS A NOVEL 
THERAPEUTIC STRATEGY IN HEMATOLOGIC 
MALIGNANCIES 
 
The above findings, highlighting several mechanisms of PP2A 
inactivation in patients with hematologic malignancies, substantially 
underscore the tumor suppressor activities of (specific) PP2A 
holoenzymes and the proto-oncogenic properties of PP2A inhibitors 
CIP2A and SET. Importantly, some of these mechanisms may serve 
as biomarkers to improve current therapies (118), or may be directly 
amenable for therapeutic intervention. Several recent preclinical 
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studies have shown that pharmacological restoration of PP2A tumor 
suppressor activity by PP2A-activating drugs (PADs) indeed 
effectively antagonizes cancer development and progression 
[reviewed in Ref. (17)]. Because PP2A complexes have so many 
cellular targets, these therapies may have the additional advantage, 
not to target just a single oncogene, but rather many different 
oncogenic pathways, contributing to their therapeutic efficacy. On the 
other hand, it is obvious that not all mechanisms of PP2A inhibition 
are suitable for restoration, particularly when subunit mutations are 
involved. Likewise, the development of small-molecule protein–
protein interaction inhibitors targeting PP2A–SET or PP2A–CIP2A 
complexes remains, although attractive, extremely challenging.  
Neviani et al. were the first to highlight the therapeutic relevance 
of using PP2A activators, such as FTY720 and forskolin, to target 
leukemia cells (82,133). These observations prompted many others 
to test these compounds successfully in their own leukemic models 
(85,113,117,141,142). Treatment of AML patients with forskolin, in 
combination with standard induction therapy, gave an additive effect, 
highlighting therapeutic potential of PP2A activators in combination 
with standard chemotherapy (117). The mechanism of PP2A 
activation by these compounds remains somewhat obscure, but may 
involve direct binding of FTY720 to a ceramide-binding domain of 
SET (143,144), resulting in SET dissociation from PP2A (143,145). 
FTY720 also reduces SET Ser phosphorylation (144) and promotes 
SET nuclear localization (145), suggesting that its therapeutic effect 
may be largely attributable to restoration of cytoplasmic PP2A 
activity. The cell penetrating SET antagonistic peptides COG112 and 
OP449 (formerly COG449) directly bind SET to prevent SET–PP2A 
inter-action and enhance PP2A activity (84). Like FTY720, they show 
significant therapeutic potential as PADs, as they induce apoptosis of 
human B-cell non-Hodgkin lymphoma and B-CLL in vitro and in vivo, 
without any discernable effects on normal B cells (85,146). In models 
of human CML and AML (147) and canine T-cell lymphomas (148), 
OP449 also shows anti-tumoral effects, especially in combination with 
ABL TKI ( 147). The latter demonstrates the added benefit of 
combining TKIs and PADs for anti-leukemic therapy (17). Very 
recently, yet another class of FDA-approved drugs, the 
phenothiazines, were shown to act as PADs in models of T-ALL 
(149). These compounds induce rapid dephosphorylation of multiple 
PP2A targets, resulting in suppressed growth and increased 
apoptosis of T-ALL cells in vitro and in vivo. Mechanistically, a direct 
interaction with the Aα subunit is involved, but how this results in 
increased PP2A activity should still be further explored. 
 
Together, these findings strongly encourage the inclusion of 
pharmacological PP2A activators with major anti-cancer activities and 
good safety profiles into current anti-cancer protocols in hematologic 
malignancies. The partially overlapping effects of existing drugs and 
PP2A stimulation predict that the inclusion of PADs in combination 
therapies with TKIs or other conventional therapeutics would 
represent particularly attractive therapeutic strategies to improve 
therapeutic outcome in these devastating malignancies. In the 
meantime, additional efforts to improve the potency and selectivity of 
existing PADs, and to identify alternative PP2A-activating strategies 
should be undertaken, in order to achieve their eventual use in the 
clinic. 
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Introduction 
Unlike protein kinases, mutations in serine/threonine (Ser/Thr) 
protein phosphatases have not commonly been associated with 
disorders of human development. There are 2 major Ser/Thr 
protein phosphatase families in the cell: protein phosphatase 1 
(PP1) and protein phosphatase 2A (PP2A), together accounting 
for more than 90% of all phospho-Ser/Thr dephosphorylations. 
PP2A consists of a catalytic subunit (C), a substrate binding regu- 
latory subunit (B), and a scaffolding subunit (A) that links B and C. 
Unlike the generally expressed A and C subunits, there is a pleth- 
ora of B subunits with different expression patterns (1). The    dif- 
 
ferential substrate preferences of the nearly 100 different PP2A 
holoenzymes that, in theory, can be formed by 2 C isoforms, 2 A 
isoforms, and at least 23 types of B subunits is largely unknown (2), 
particularly within the context of a whole organism. Apparently, 
PP2A-dependent protein dephosphorylation has a potential for 
regulation that may be just as fine-tuned as protein phosphoryla- 
tion. Unlike protein phosphorylation, associations between muta- 
tions in PP2A subunits and genetic diseases or syndromes have 
not been described until recently, when 4 de novo PPP2R5D and 
3 de novo PPP2R1A mutations were found among the first 1,133 
parent-child trios sequenced in the United Kingdom Deciphering 
   Developmental Disorders project (3). 
Here, we add clinical descriptions and functional data to  the 
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DDD findings and present 9 additional cases with de novo PP2A 
subunit mutations; 7 in PPP2R5D, encoding the regulatory B56δ 
subunit, and 2 in PPP2R1A, encoding the scaffolding Aα subunit. 
 
Here we report inherited dysregulation of protein phosphatase activity as a cause of intellectual disability (ID). De novo 
missense mutations in 2 subunits of serine/threonine (Ser/Thr) protein phosphatase 2A (PP2A) were identified in 16 
individuals with mild to severe ID, long-lasting hypotonia, epileptic susceptibility, frontal bossing, mild hypertelorism, and 
downslanting palpebral fissures. PP2A comprises catalytic (C), scaffolding (A), and regulatory (B) subunits that determine 
subcellular anchoring, substrate specificity, and physiological function. Ten patients had mutations within a highly conserved 
acidic loop of the PPP2R5D-encoded B56δ regulatory subunit, with the same E198K mutation present in 6 individuals. Five 
patients had mutations in the PPP2R1A-encoded scaffolding Aα subunit, with the same R182W mutation in 3 individuals. 
Some Aα cases presented with large ventricles, causing macrocephaly and hydrocephalus suspicion, and all cases exhibited 
partial or complete corpus callosum agenesis. Functional evaluation revealed that mutant A and B subunits were stable and 
uncoupled from phosphatase activity. Mutant B56δ was A and C binding–deficient, while mutant Aα subunits bound B56δ 
well but were unable to bind C or bound a catalytically impaired C, suggesting a dominant-negative effect where mutant 
subunits hinder dephosphorylation of B56δ-anchored substrates. Moreover, mutant subunit overexpression resulted in 
hyperphosphorylation of GSK3β, a B56δ-regulated substrate. This effect was in line with clinical observations, supporting a 
correlation between the ID degree and biochemical disturbance. 
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Table 1. De novo mutation details and the corresponding cases 
 
Cases Gene Genomic changeA cDNA changeB Protein change 
1 PPP2R5D chr6:g.42974253C>T c.157C>T p.Pro53Ser 
2–7 PPP2R5D chr6:g.42975003G>A c.592G>A p.Glu198Lys 
8–9 PPP2R5D chr6:g.42975009G>A c.598G>A p.Glu200Lys 
10 PPP2R5D chr6:g.42975013C>G c.602C>G p.Pro201Arg 
11 PPP2R5D chr6:g.42975030T>A c.619T>A p.Trp207Arg 
12 PPP2R1A chr19:g.52715971C>T c.536C>T p.Pro179Leu 
13–15 PPP2R1A chr19:g.52715979C>T c.544C>T p.Arg182Trp 
16 PPP2R1A chr19:g.52716329G>A c.773G>A p.Arg258His 
AGenomic positions are according to Build37/hg19. BcDNA reference sequences: NM_006245.2 for PPP2R5D and NM_014225.5 for PPP2R1A. 
 
Taken together, of the 11 mutations in PPP2R5D, 6 mutations  
and 2 mutations were identical; 3 of the 5 mutations in PPP2R1A 
were also identical. All Aα mutations and all but one of the B56δ 
mutations had the potential to hinder access of catalytically com- 
petent C subunits to B56δ-regulated substrates, suggesting a com- 
mon dominant-negative disease mechanism mainly affecting 
B56δ-regulated Ser/Thr dephosphorylation. 
 
Results 
In cases with intellectual disability (ID) of unknown etiology, 
parent-child trio exome sequencing was performed to find de 
novo and recessive mutations that could explain the condition. 
De novo missense mutations in 2 subunits of the Ser/Thr phos- 
phatase PP2A were identified in 16 individuals from the United 
Kingdom (7 cases), the Netherlands (7 cases), Israel (1 case), and 
Norway (1 case). 
The 7 United Kingdom cases were found among 1,133 chro- 
mosomally normal parent-child trios (3). This suggests that the 
prevalence of PP2A subunit mutations in the moderate-to-severe 
ID group without pathogenic copy number aberrations is around 
0.6%. In the United Kingdom, this was part of the large DDD proj- 
ect (http://www.ddduk.org); in other cases, this was done as part 
of routine diagnostics. In 11 cases, de novo missense mutations 
in PPP2R5D, encoding the regulatory B56δ PP2A subunit, were 
found. In 5 other cases, a de novo missense mutation in PPP2R1A, 
encoding the scaffolding Aα subunit of PP2A, was found. Six 
mutations and 2 mutations in PPP2R5D were identical, and 3 
PPP2R1A mutations were identical. Details on all mutations can 
be found in Table 1. Other trio exome sequencing results indicat- 
ing a de novo change of possible relevance or a recessive condition 
of potential interest can be found in Supplemental Table 1 (sup- 
plemental material available online with this article; doi:10.1172/ 
JCI79860DS1). In 10 cases, such findings were made, but based 
on bioinformatic evaluation of the variants and the clinical fea- 
tures of the patients, all but one of these findings could easily 
be excluded as causative factors for the phenotype. The excep- 
tion was case 15, which had heterozygosity for a TMEM67 splice 
mutation and a few signs that were compatible with a ciliopathy 
(e.g., unilateral postaxial polydactyly). However, this could also 
be a random finding, since a second TMEM67 mutation was not 
found upon Sanger sequencing. In addition, detecting the same 
de novo missense mutations in patients with identical clinical fea- 
tures is, in itself, evidence in support of causality, especially when 
supported by functional data (see below). As a crude estimation, 
the likelihood of finding 10 de novo missense mutations in the 
same 9–amino acid stretch of B56δ by chance should be less than 
10–50  (see Statistics). 
The clinical features of the 11 PPP2R5D cases and the 5 
PPP2R1A cases are summarized in Tables 2 and 3, respectively. 
Despite mutations occurring in 2 different PP2A subunit genes 
with different biochemical functions (regulatory and scaffolding), 
there are clinical similarities between the cases. All patients were 
born after a normal pregnancy, and 15/16 cases had birth weights 
within normal range. In 2 cases, breech deliveries were reported, 
and in 2 other cases, emergency cesarean sections had to be per- 
formed. After birth, ID and hypotonia were common features in 
all cases. Despite pronounced and long-lasting hypotonia, feeding 
difficulties were usually not a major problem, and only one case 
had gastrostomy. In 12/16 cases, the degree of ID was severe, and 
this correlated with very late independent walking, usually around 
age 6–7 years. The exceptions were the 4 patients with E200K, 
P201R, or W207R PPP2R5D mutations (see below for functional 
explanation), who learned to walk between 1½ and 2¼ years of 
age and had mild/moderate ID (Table 2). These 4 cases were also 
the only ones with language development beyond a few words. 
Seven out of 16 patients had epilepsy, including one of the mild ID 
cases. Only one patient had short stature (case 1 with a P53S muta- 
tion, see Table 2), and he was the only PPP2R5D case that was 
microcephalic. In the other PPP2R5D cases, head circumferences 
were from upper-normal range to pronounced macrocephaly, and 
in the latter cases, hydrocephalus was suspected. In contrast, most 
PPP2R1A cases were normocephalic or microcephalic, and hydro- 
cephalus was initially suspected in only one case (Table 3). In all 
these patients, the corpus callosum was absent or almost absent, a 
feature that distinguished PPP2R1A cases from PPP2R5D cases. In 
contrast, facial features were overlapping (Figure 1): A hypotonic 
and sometimes also elongated face with tented upper lip, mild 
hypertelorism with downslanting palpebral fissures, and frontal 
bossing in the PPP2R5D cases. 
The finding of recurrent and clustered de novo missense 
mutations in 2 PP2A subunit genes (PPP2R5D and PPP2R1A) sug- 
gested a dominant-negative– or gain-of-function–related disease 
mechanism, rather than haploinsufficiency or  loss-of-function. 
All but one of the PPP2R5D mutations (E198K, E200K, P201R, 
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Figure 1. Facial photographs. 
The display shows the facial 
features of the PPP2R5D cases 
that consented to facial pho- 
tographs being shown and the 
PPP2R1A cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and W207R) clustered in a highly conserved acidic loop that faces 
the A and C subunits (4–6). This acidic surface corresponds to the 
extended loop between α-helices 3 and 4 of HEAT domain 2 in the 
crystal structure of the highly related B56γ isoform (Figure 2A). 
Only the P53S mutation (case 1 in Table 2) localized outside this 
loop, i.e., in the B56δ-specific N-terminal domain. 
To investigate if the PPP2R5D missense mutations affected 
subunit interactions, a human embryonic kidney cell line — 
HEK293 cells, a well-known model from previous PP2A subunit 
interaction studies (7) — was transfected with EGFP-tagged WT 
or mutant B56δ subunits in order to study subunit interactions. 
All ID-associated B56δ mutants except P53S showed deficient 
holoenzyme formation, i.e., A- or C-to-B56δ association (Fig- 
ure 2B). To  check if others had discovered missense variants  
in the same acidic B56δ loop, Broad institute’s ExAC browser 
(http://exac.broadinstitute.org/) was consulted. Only 2 other 
missense variants (P196L and P201S) were reported. Interest- 
ingly, the latter variant was in the same residue as the de novo 
mutation (P201R) in case 10, although the amino acid change 
was different. Unlike P201R, we found that P201S failed to show 
any significant A or C binding defects (Supplemental Figure 1), 
further strengthening our working hypothesis that a charge 
change in the acidic B56δ loop could be  pathogenic. 
Our cellular binding assays with Glutathione S-Transferase– 
tagged (GST-tagged) B subunits and HemAgglutinin-tagged (HA-
tagged) WT or mutant Aα subunits revealed that all 3 PPP2R1A 
mutations also affected PP2A holoenzyme formation (Figure 3). 
Surprisingly, interaction with the C subunit was hindered, despite 
the Aα mutations being in HEAT domains predicted to interact with 
B (Figure 3A). The mutations’ effect on B subunit binding was com- 
plex (Figure 3B). All Aαmutants lacked significant binding to the B55 
(also called B) family members tested (isoforms B55α and B55β), as 
well as to the B56 (also called B’ or PR61) family members tested 
(B56α and B56γ). On the other hand, binding to B56δ was almost 
entirely retained, whereas B56ε bound significantly less. For PR72, 
a member of the B’’ family of PP2A regulatory subunits, binding was 
retained to Aα-P179L but was completely lost to the Aα-R182W and 
Aα-R258H mutants (Figure 3B). These (mutant) Aα binding charac- 
teristics were confirmed for endogenous B55α and B56δ subunits, 
for which good-quality, isoform-specific antibodies are available 
(Figure 4A). These data could be compatible with a dominant- 
negative effect on, notably, B56δ for all Aα mutants, and on  PR72 
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Table 2. Clinical features in cases with de novo PPP2R5D missense mutations 
 Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9 Case 10 Case 11 
Mutation P53S E198K E198K E198K E198K E198K E198K E200K E200K P201R W207R 
Age of 
examination 
53 yr 5 yr 11 yr 10 yr 15 yr 13 yr 2 yr 20 yr 4 yr 3 yr 9 yr 
Sex Male Female Male Female Male Male Female Female Female Female Female 
Delivery Normal Breech Normal Emergency C/S Emergency C/S Normal Amniotic 
rupture 
C/S Normal Breech Normal 
Birth weight Normal Normal Normal Normal Normal SGA Normal Normal Normal Normal Normal 
Hypotonia Not 
reported 
Present Present Present Present Present Present Present Present Present Present 
Walked 
unsupported 
9 yr 6 yr 6 yr Not so far 7 yr 6 yr Not so far 1½ yr 2¼ yr 1½ yr 2 yr 
Ataxic gait No Yes Yes N/A No Yes N/A No Yes Yes No 
Language No words 3–4 
words 
No words 2 words, poor 
articulation 
No words No words No words Yes, poor 
intelligibility 
A few words A few words Yes, poor 
intelligibility 
Epilepsy No No No No Multifocal Yes No No No Multifocal No 
EEG – Abnormal – Normal Abnormal Abnormal Normal Normal Not done Abnormal Normal 
ID/DD Severe Severe Severe Severe Severe Severe Severe Mild Mild Moderate Moderate 
Height 0.5  cm 10th 5th 25th 20 cm < 3rd 50th 90th 5–10th 50th 50th 50th 
< 3rd 
Head 
circumference 
1 cm < 3rd 5 cm > 97th 50th 5 cm > 97th at 
age 3½ yr 
50th 97th 99th 97th 1 cm > 97th 75th 97th 
Weight Normal Normal 50th 90th 50th 90th 30th 10 kg > 97th 75th 60th 50th 
Brain MRI – Pseudo- Normal    Hydrocephalus Mild ventricular  Mild ventricular Normal – Normal – Normal 
hydroceph 
 
Other findings Cataract  Fatigue 
Hypoglycemia 
Abnormal 
fat oxidation 
Bilateral 6th 
nerve palsies 
dilatation 
 
Narrow palate 
Mild 2/3 and 
3/4 finger 
syndactyly 
dilatation 
Small CC 
 
Scoliosis  Neonatal 
nonepileptic 
myoclonus 
 
 
Fatigue Ptosis  Fatigue 
Strabismus 
 
 
Hip dysplasia 
Gastric reflux 
 
 
Scoliosis Hip 
dysplasia 
Fatigue Mild 
mitochondrial 
dysfunction 
Height, head circumference, and weight are measured relative to centiles (the 3rd and 97th centile correspond to ± 2 SD). Abbreviations: ID/DD, intellectual 
disability/developmental delay; y, years; -, unknown or not done; SGA, small for gestational age; C/S, cesarean section; CC, corpus  callosum. 
 
for Aα-P179L, provided that C binding would be lost or dimin- 
ished in the B56δ-Aα mutant complex. To provide direct evidence 
that mutant Aα can complex with B56δ without C, we expressed 
HA-Aα mutants or HA-Aα (WT) in HEK293 cells stably expressing 
EGFP-TEV-B56δ (WT) and analyzed the presence of endogenous C 
in anti-HA immunoprecipitates from the tobacco etch virus–cleaved 
(TEV-cleaved) eluates of GFP-trapped B56δ (Figure 4B). While C 
subunit was clearly present in B56δ-Aα (WT) complex (as expected 
from normal holoenzyme formation), it was barely detectable in 
the B56δ-Aα-P179L complex, indicating that mutant Aα-P179L may 
bind B56δ but not C. In contrast, the B56δ-Aα-R182W and B56δ- 
Aα-R258H complexes still bound a significant amount of C (Figure 
4B). However, measurements of specific PP2A activity in these sam- 
ples showed a decrease in phosphatase activity for all Aα mutants 
compared with WT (Figure 4C), suggesting that the C subunit pres- 
ent in these B56δ-mutant A-C complexes is catalytically impaired. 
Because previous reports had indicated increased B56δ sub- 
unit degradation upon gradual reduction of A subunit levels (8, 9), 
we examined the stability of our mutant subunits, since unstable 
mutant proteins would preclude the interpretation of our func- 
tional data. In line with our hypothesis, we did not experience any 
 
problems expressing ID-associated B56δ subunits in cells (Fig- 
ures 2–4). Furthermore, protein-synthesis–blocking experiments 
showed that the ID-associated B56δ (P53S, E198K) or Aα (P179L, 
R182W) mutants tested appeared more long-lived than the WT 
subunits in our assay (Supplemental Figure 2). 
Taken together, for all but one (P53S in PPP2R5D) of the de 
novo mutations identified, our biochemical data are consistent with 
a common defect in PP2A-B56δ–dependent dephosphorylation. 
A-C binding–defective B56δ mutants, or C binding– but not B56δ 
binding–defective Aα-mutants, and B56δ binding Aα-mutants har- 
boring a catalytically impaired C subunit, may all block dephospho- 
rylation of PP2A-B56–specific substrates and interfere with phos- 
phorylation-dephosphorylation dynamics in the brain. In line with 
this hypothesis, overexpression of the E198K B56δ mutant or the 
R182W Aα mutant in HEK293 cells resulted in increased phospho- 
rylation of GSK-3β Ser9, an established PP2A-B56δ substrate in this 
cell line (Figure 5 and ref. 10). 
 
Discussion 
The presented work demonstrates that de novo missense mutations 
in genes encoding PP2A subunits may cause syndromic ID — and 
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probably also nonsyndromic ID, since the facial dysmorphism in 
these cases is subtle (Figure 1). The PPP2R5D and PPP2R1A  muta- 
tions disrupt B56δ-dependent dephosphorylation dynamics and 
link PP2A dysfunction to congenital brain dysfunction. 
In general, the Aα cases were more severely affected than the 
B56δ cases. All had severe ID, absent speech, diminished brain 
growth, and partial or complete agenesis of the corpus callosum 
(Table 3). This is in line with the expected greater difficulty to 
compensate for a general scaffolding (A) subunit dysfunction 
than a specific regulatory (B) subunit dysfunction, as reflected   
by our biochemical data showing additional loss or reduction of 
holoenzyme assembly of many different PP2A complexes (B55α, 
B55β, B56α, B56γ, and B56ε) for these Aα mutants (Figure 3B).  
The Aα scaffolding subunit is highly flexible, composed of 15 
tandem repeat HEAT motifs (11) that mediate interactions with   
a regulatory B subunit (HEAT repeats 1–8) and the C subunit 
(HEAT repeats 11–15)(4, 5, 12, 13). Two ID-associated PPP2R1A 
mutations (P179L and R182W) cluster in HEAT domain 5 of Aα, 
and one (R258H) occurs in HEAT domain 7; these mutations are 
involved in contacts with subunits of all B families (4, 5, 12, 13). 
However, for these mutations, loss-of-function might be less 
critical than substrate protection and altered phosphorylation 
dynamics; hence, the retained binding to PR72 for Aα-P179L 
could have additional functional consequences due to seques- 
tration of PR72 in a complex deficient in C subunit binding or 
with decreased specific activity of  C. 
 
 
Figure 2. Binding of mutant and WT B56δ to the A or C subunits. (A) 
Model of the highly conserved B56 acidic loop, harboring 4 ID-associ- 
ated B56δ missense mutations, based on crystallographic data from 
PP2A-B56γ (PDB code: 2IAE)(5). The corresponding residues in B56γ 
(highlighted in white) are displayed with amino acid numbering accord- 
ing to B56δ. Note that the E198 residue directly contacts the C subunit. 
Color code: C subunit, blue; A subunit, yellow; B56γ, red. The structure 
was analyzed and visualized with Molsoft MolBrowser 3.7. (B) Cellular 
binding assays of ID-associated B56δ mutants and endogenous A and C 
subunits. EGFP-tagged WT B56δ, 5 ID-associated B56δ mutants (P53S, 
E198K, E200K, P201R, and W207R), or EGFP alone (–) were ectopically 
expressed in HEK293 cells. Following EGFP trapping, the presence of 
endogenous A and C subunits in the trapped complexes was examined 
by immunoblotting (IB). After quantification of the band intensities 
with ImageJ software, the ratios between EGFP and C signals — and 
between EGFP and A signals — were determined and calculated relative 
to B56δ WT control. Mean values and a representative image of 4 inde- 
pendent experiments are shown (1-way multiple-comparisons ANOVA; 
*P < 0.05, **P < 0.01).  
 
Besides its scaffolding function, Aα is a major player in the 
biogenesis of active PP2A holoenzymes (14). This highly regulated 
but incompletely understood process does not only involve simple 
trimeric assembly of the A, B, and C subunits, but it also involves 
several activation steps of the C subunit, which is de novo trans- 
lated as an inactive enzyme (15). It has been suggested that some 
of these activation steps require or are facilitated by the A subunit 
(16, 17), explaining why A-subunit mutations may affect the spe- 
cific activity of the associated C subunit, as observed here within 
the B56δ-(mutant A)-C complexes (Figure 4C). Additional activity 
measurements performed directly in anti-HA immunoprecipitates 
of HA-tagged (mutated) A subunits seem to further confirm this 
hypothesis (Supplemental Figure 3). Hence, it can be further ratio- 
nalized why mutations in the A subunit have a much more severe 
effect on the PP2A system as a whole, as opposed to mutations in 
B56δ, which affect a single PP2A holoenzyme complex. 
PPP2R5D encodes the longest isoform of the B’ family of 
PP2A regulatory subunits and harbors unique N- and C-terminal 
extensions, which are predicted to be important for substrate rec- 
ognition and/or subcellular targeting (18). Ten out of 11 PPP2R5D 
mutations were located in a conserved acidic loop of B56δ needed 
for holoenzyme formation (Table 1), and all mutations introduced 
a positively charged residue (either arginine or lysine). Only one 
mutation (P53S) was atypical, and this case also had a different 
clinical picture: it was the only PPP2R5D case with short stature 
and microcephaly (Table 2). In theory, P53S in the B56δ-specific 
N-terminal domain might change the PP2A-B56δ interaction with 
relevant substrates or introduce a new phosphorylation site that 
affects regulation by protein kinases. Such changes could easily 
have a gain-of-function or dominant-negative effect. 
We also observed a correlation between the degree of bio- 
chemical disturbance and clinical severity. Among the PPP2R5D 
cases (Table 2), the 6 patients with E198K mutations were the 
most severely affected, in line with a near absence of A and C 
subunit binding. The least-affected individuals were the E200K 
cases, both with mild ID correlating with some residual A and C 
binding capability (Figure 2B). Notably, E198 is the only one of the 
5 mutated residues that directly interacts with the catalytic sub- 
unit (Figure 2A and refs. 4–6). Additionally, since all B subunits, 
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Table 3. Clinical features in cases with de novo PPP2R1A missense  mutations 
 Case 12 Case 13 Case 14 Case 15 Case 16 
Mutation P179L R182W R182W R182W R258H 
Age of examination 3½ yr 4 yr 11 yr 1 yr 5 yr 
Sex Female Female Male Female Male 
Delivery Normal Normal Normal Labor-induced (hydrocephalus) Normal 
Birth weight Normal Normal Normal Normal Normal 
Hypotonia Present Present Present Present Present 
Walked  unsupported Not so far Not so far 6 yr Not so far 3 yr 
Ataxic gait N/A N/A Yes N/A Yes 
Language No words No words No words No words ~30 words 
Epilepsy No Yes Yes, multifocal Yes Yes 
EEG – Abnormal Abnormal Abnormal Abnormal 
ID Severe Severe Severe Severe Severe 
Height ~90th ~97th 50th 75th 90th 
Head circumference 2  cm < 3rd 10th 2nd 98th    >  75th 1 cm < 2nd 
Weight  75th 97th 10th  16th  97th 
Brain MRI CC agenesis  CC hypoplasia 
Large  ventricles 
CC  hypoplasia  CC agenesis 
Delayed  myelinisation 
Large  ventricles 
CC hypoplasia 
Delayed  myelinisation 
Other findings Cortical visual 
impairment 
Scoliosis Scoliosis Hip dysplasia 
Hypermobility 
Physically strong 
Gastrostomy age 8 yr 
Cortical visual impairment 
Unilateral postaxial polydactyly 
Unilateral kidney agenesis 
Absent uterus and vagina 
Hyperactivity 
Obstipation 
Entropion of eyelids 
Height, head circumference, and weight are given relative to centiles (the 3rd and 97th centile correspond to ± 2 SD). Abbreviations: y, years; CC, corpus 
callosum; C/S, cesarean section; –, unknown or not done. 
 
 
 
except B56δ and PR72, have been shown to make stabilizing con- 
tacts with the C subunit tail (5, 19), C-subunit binding to B56δ, and 
possibly PR72, may be particularly Aα dependent. 
A brain-restricted phenotype is not unexpected for B56δ 
mutations because PPP2R5D is expressed mainly in the brain, 
particularly in the striatum (18, 20, 21). The brain-restricted phe- 
notype of the Aα mutations (P179L, R182W, and R258H) is more 
unexpected, since PPP2R1A is generally expressed as a common 
scaffolding subunit for many different PP2A holoenzymes (22). 
Nevertheless, other malformations than severe corpus callosum 
hypogenesis were not found in the 5 PPP2R1A cases (Table 3). The 
restricted phenotype may be related to our finding that mutated 
A subunits bound most tightly to B56δ and (for P179L) also PR72 
(Figure 3B), both of which are expressed in the brain, notably in 
the striatum where both B56δ and PR72 (encoded by PPP2R3A) 
control the dephosphorylation of the neural dopamine-regulated 
inhibitor of PP1 (DARPP-32) (23–25). 
Despite the severe intellectual dysfunction in most patients, 
B56δ does not appear essential for mammalian brain develop- 
ment, since Ppp2r5d knockout mice have intact learning and mem- 
ory despite ataxia and tauopathy (21). This also suggests that our 
patients’ ID was not caused by haploinsufficiency or a mere loss 
of function. It is therefore tempting to speculate that the mutated 
B56δ subunits may not only interfere in a dominant manner with 
dephosphorylation of B56δ binding PP2A substrates, as shown 
for GSK-3β in HEK293 cells (Figure 5), but also with subcellular 
anchoring of PP2A via B56δ, and thereby with control of localized 
signaling. Thus, A-Cbinding–deficient B56δmutantsmaystillform 
complexes with B56δ partners, but without promoting dephos- 
 
phorylation. Such dysphosphorylation may have far-reaching 
consequences for regulation of localized signaling. One exam- 
ple could be the signaling complex scaffolded by the neural vari- 
ant of the cAMP-dependent PKA anchoring protein  mAKAP, 
that binds B56δ and several other phosphatases (PP1, PP2B) and 
kinases (PKA, PDK1, RSK3, ERK5) (26, 27). Dephosphorylation of 
PP2A-B56 substrates may also be hindered, e.g., the transcription 
factor and PKA-substrate HAND (28), the neural cyclin-depen- 
dent kinase 5 (CDK5) activator CDK5R1 (21), and DARPP-32 (24, 
25). PKA activates DARPP-32 directly by Thr-34 phosphorylation 
and indirectly by PP2A-B56δ–dependent activation through Thr- 
75 dephosphorylation (24). B56δ has several sites for PKA phos- 
phorylation that activate PP2A-B56δ phosphatase activity (24, 29). 
Moreover, PKA-activated PP2A-B56δ–dependent dephosphoryla- 
tion of another DARPP-32 phosphorylation site (Ser-97) induces 
nuclear import — mediating dopamine-dependent epigenetic 
functions (25) — and lack of nuclear PP2A-B56δ targeting has 
been associated with juvenile myoclonic epilepsy (30). There is 
also evidence that PP2A-B56δ regulates both expression (30) and 
activity (31) of tyrosine hydroxylase, the rate-limiting enzyme in 
catecholamine synthesis. Which of these candidate substrates will 
eventually be of pathologic relevance in our ID patients remains to 
be further determined in appropriate cellular and animal models. 
A model for a common dominant-negative effect of mutant B56δ 
and Aα subunits is depicted in Figure 6. This model explains 
whyall our biochemical findings are compatible with B56δ- 
dependent PP2A dysregulation. Our model  is also supported 
by a recent paper showing that Aα can form a tight complex in 
vitro with members of the B’’ subunit family, including PR72,  in 
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Figure 3. Binding of mutant and WT Aα to C and B subunits. (A) PP2A-C subunit binding assays: HA-tagged WT Aα, 3 ID-associated Aα mutants (P179L, 
R182W, and R258H), or an empty HA-vector (–) were transfected into HEK293 cells. Following anti-HA immunoprecipitation, the presence of endoge-  
nous C subunit in the immunoprecipitates was examined by immunoblotting (IB). After quantification of the band intensities with ImageJ software, the 
ratios between HA and C signals were determined and calculated relative to WT Aα control. Mean values and a representative image of 3 independent 
experiments are shown (1-way multiple-comparisons ANOVA, **P < 0.01). (B) PP2A B subunit binding assays: Several GST-tagged B subunits, belonging    
to 3 different families (B55 or B, B56 or B’, and B’’) or GST alone (–) were coexpressed in HEK293 cells with HA-tagged WT Aα, or ID-associated Aα-P179L, 
R182W, and R258H mutants. The presence of HA-Aα (WT or mutant) in the complete lysates and the isolated GST pulldown complexes was determined   
by IB. After quantification of the band intensities with ImageJ software, the ratios between GST and HA signals were determined and calculated relative 
to WT Aα control (which were set to 100% for each B-type subunit pulldown). Mean values and a representative image of 3 independent experiments are 
shown (1-way multiple-comparisons ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 4. Analysis of Aα mutant complexes. (A) Endogenous B subunit binding assays: HA-tagged WT 
Aα, Aα mutants (P179L, R182W, and R258H), or an empty HA-vector (–) were transfected into HEK293 
cells. Following anti-HA immunoprecipitation, presence of endogenous B56δ and B55α subunits in the 
immunoprecipitates was examined by immunoblotting (IB). (B) Formation of B56δ-(mutant Aα)-C com- 
plexes: HEK293 cells stably expressing EGFP-TEV-B56δ were transfected with HA-Aα, HA-Aα mutants,     
or empty HA-vector (–). Following EGFP-trapping and cleavage of the trapped complexes with TEV pro- 
tease, the eluates were subjected to HA immunoprecipitation and the immunoprecipitates analyzed by 
IB with anti-HA, anti-C, and anti-B56δ antibodies. After quantification of the band intensities (ImageJ), 
the ratios between C and HA signals were determined and calculated relative to WT Aα control (set to 
100% in each IP-on-IP experiment). Mean values and a representative image of 4 independent experi- 
ments are shown (1-way multiple-comparisons ANOVA; *P < 0.05). (C) PP2A activity measurements in 
B56δ-(mutant Aα)-C complexes. The pmol number of released phosphate from K-R-pT-I-R-R phospho- 
peptide (350 μM) was determined by Malachite Green for each B56δ-(mutant Aα)-C complex (retrieved 
as in B). To obtain specific C activities, this number was divided by the amount of C in the respective 
samples, as determined by IB and following quantification by ImageJ software. All specific activities  
were eventually recalculated relative to WT Aα control (set to 100%). Mean values and one representa- 
tive image of 3 independent experiments are shown (1-way multiple-comparisons ANOVA; **P < 0.01). 
 
the most prevalent mutations. A growth 
advantage may also explain mutation 
recurrence if these de novo mutations 
turn out to be solely paternal (40). Since 
88% of the cancer-associated Aα muta- 
tions are of the missense-variant, a 
dominant-negative effect also in cancer 
promotion is likely. None of our patients 
have been diagnosed with or treated for 
cancer. The cancer risk might not be 
increased, in line with what is usually  
the case for  congenital  gain-of-func- 
tion mutations in other cancer-related 
pathways like the RAS/MAPK pathway 
or the PI3K/AKT cascade. Only further 
patients and patient follow-ups will 
answer this question, but a major cancer 
risk seems unlikely. 
The tumor-suppressor effect of  
PP2A may operate by KRAS/MAPK 
cascade inhibition, KRAS/ARF/TP53 
cascade inhibition, or PI3K/AKT/TP53 
cascade inhibition (33). Somatic mosaic 
activation of the PI3K/AKT cascade 
causes the megalencephaly-capillary 
malformation-polymicrogyria (MCAP) 
and megalencephaly-polymicrogyria- 
polydactyly-hydrocephalus (MPPH) 
group of overgrowth syndromes (41). 
These patients have variable ID, a ten- 
dency to develop hydrocephalus and 
epilepsy, and dysmorphic facial fea- 
tures, including frontal bossing with 
hypotonia, tented upper lip, and deep- 
set eyes. The latter features are shared 
with several of our patients (Figure 1). It 
is therefore relevant to consider B56δ- 
dependent PP2A dysregulation syn- 
drome (which we propose to be desig- 
nated B56deltopathies) among the dif- 
ferential diagnoses to the MCAP/MPPH 
group of syndromes, at least in some 
cases. It is conceivable that the B56δ 
mutations may affect  only  a  subgroup 
of  PP2A  substrates  located  distally   in 
the absence of the C subunit (32). It may be of interest to study    
if fingolimod (FTY720), a PP2A activator and immunosuppres- 
sant that is licensed for treatment of multiple sclerosis (33–35), or 
FDA-approved compounds of the phenothiazine family that were 
recently discovered as PP2A activators (36) may improve brain 
function in these patients. 
For future evaluation of de novo mutation origin (paternal 
or maternal)(37), it is of interest that all 3 PPP2R1A mutations 
also are found in the Sanger Institute’s Catalogue of Somatic 
Mutations in Cancer (the COSMIC database; http://cancer. 
sanger.ac.uk/cosmic), mainly in endometrial and ovarian can- 
cers (38, 39). Aα P179L/P179R, R182W, and R258H are by far 
the PIK3 signaling cascade — such as GSK-3β Ser9, a well-estab- 
lished Akt phosphorylation site — since the proximal steps do not 
appear to be subject to B56δ-dependent dephosphorylation (42). 
In summary, we have demonstrated that de novo missense 
mutations in the PPP2R5D and PPP2R1A genes encoding PP2A 
subunits represent a new mechanism for ID, due to disrupted B56δ- 
dependent dephosphorylation dynamics and PP2A dysfunction. 
 
Methods 
Case detection. There were 7 Dutch patients (from RUMC: cases 1,  8–
9, and 11; from UMC Utrecht: cases 7,  15, and 16). Six of these  cases 
were identified through routine diagnostic exome  sequencing
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Figure 5. Increased phosphorylation of GSK-3β Ser9 upon expression of B56δ-E198K or Aα-R182W. GFP-tagged WT B56δ, E198K mutant B56δ, or GFP 
alone (–) (left); or HA-tagged WT Aα, R182W mutant Aα, or HA alone (–) (right) were expressed in HEK293 cells, and the effect on GSK-3β phosphorylation 
determined by immunoblotting (IB) with the indicated antibodies. Total GSK-3β and phospho-Ser9 GSK-3β signals were determined on different blots, 
which were both developed for vinculin to correct for loading differences. In cells expressing the ID-associated mutants, higher phospho/total GSK-3β 
ratios were found, relative to cells transfected with empty expression vector (in which case, this ratio was set to 100%) or cells expressing WT subunits. 
Mean values and one representative image of 3 independent experiments are shown (1-way multiple-comparisons ANOVA; *P < 0.05, **P < 0.01). 
of patient-parent trios. These patients showed no pathogenic copy 
number changes (high-resolution copy number array). Putative de 
novo variants were validated by Sanger sequencing of blood DNA.  
In 4 of 7 cases, other de novo variants were identified, but none of 
these were likely to cause the phenotype (Supplemental Table 1). A 
possible exception was case 16, in which heterozygosity for a likely 
pathogenic mutation in the TMEM67 was  identified.  The  patient 
had clinical features partly consistent with a ciliopathy (unilateral 
postaxial polydactyly, unilateral kidney agenesis, and absent uterus). 
However, a second TMEM67 mutation was not identified after 
Sanger sequencing. Cases 1 and 11 have been previously published  
as part of studies showing the power and impact of next-generation 
sequencing–based (NGS-based) technologies in a clinical diagnostic 
setting without clinical details on the patients’ phenotypes or func- 
tional evaluation of the mutations (43, 44). Case 8 was identified as 
part of large-scale resequencing study of candidate ID genes using 
molecular inversion probes (MIPs). PPP2R5D was one of 42 candi- 
date ID genes tested in 1,300 cases with a clinical diagnosis of ID and 
in whom previous molecular diagnostic tests were negative. 
The 7 United Kingdom patients (cases 3–5, 10, and 12–14 in 
Tables 2 and 3) were recruited to the DDD study by the United King- 
dom National Health Service or the Republic of Ireland Regional 
Genetics Service (3). Recruitment criteria were patients with neu- 
rodevelopmental disorders and/or congenital anomalies, abnormal 
growth parameters, dysmorphic features, and unusual behavior. 
DNA samples from patients and parents were analyzed by the Well- 
come Trust Sanger Institute using high-resolution microarray anal- 
ysis (array-CGH and SNP-genotyping) to investigate copy     number 
variations (CNVs) in the child, and exome sequencing to investi- 
gate single nucleotide polymorphisms (SNPs) and small insertions/ 
deletions (indels). Putative de novo sequence variants were vali- 
dated using targeted Sanger sequencing of blood-sample DNA. All 
genomic variants were annotated with the most severe consequence 
predicted by Ensembl Variant Effect Predictor (VEP) (45) and their 
minor allele frequencies observed in diverse population samples. 
Likely, diagnostic variants were fed back to referring clinical genet- 
icists for validation and discussion with the family via the patient’s 
record in Database of Chromosomal Imbalance and Phenotype in 
Humans Using Ensembl Resources (DECIPHER; Ensembl) (46), 
where they can be viewed in an interactive genome browser. Full 
genomic datasets were also deposited under accession number 
EGAS00001000775 in the European Genome-Phenome Archive 
(www.ebi.ac.uk/ega). 
The de novo PPP2R5D mutations in the Norwegian (case 2) and 
Israeli (case 6) patients were identified by exome sequencing of 
parent-child trios in a diagnostic setting. Only the PPP2R5D variant 
remained as true de novo after filtering and verification by Sanger 
sequencing of blood DNA, and no pathogenic copy number changes 
were detected by a high-resolution copy number array. 
Biochemical investigations. To study the functional consequences  
of the de novo missense mutations, WT Aα and B56δ (isoform 1) 
cDNAs were cloned into HA-tag (pMB001) and EGFP-tag (pEGF- P-
C1) eukaryotic expression vectors, respectively. The different PP2A 
B-subunit cDNAs were in a GST-tag eukaryotic expression vector, as 
described (19). PCR-based site-directed mutagenesis  (Stratagene)  
was performed directly in the pMB001 or pEGFP vectors with proof- 
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reading Pwo polymerase (Roche Applied Science) and complemen- 
tary DNA oligonucleotide primers (Sigma-Aldrich) containing the 
desired point mutations (primer sequences in Supplemental Table 2). 
All mutations were confirmed by sequencing (LGC Limited). There- 
after, HEK293 cells (ATCC) were transfected with PEI transfection 
reagents according to standard protocol. Forty-eight hours after 
transfection, cells were rinsed with PBS, lysed in 200 μl NET buffer 
(50 mM Tris pH 7.4, 150 mM NaCl, 15 mM EDTA, and 1% Nonidet P-
40) containing protease and phosphatase inhibitor cocktail (Roche 
Applied Science), and centrifuged for 15 minutes at 13,000 g. In case 
phosphatase activity needed to be measured, phosphatase inhibitors 
were omitted from the lysis buffer. 
For EGFP trapping, cell lysates were incubated at 4°C for 1 hour 
with wash buffer (10 mM Tris-HCl pH 7.5, 0.5 mM EDTA, and 150 mM 
NaCl) and 15 μl GFP-trap-A beads (ChromoTek GmbH) on a rotating 
wheel. The beads were washed 4 times with 0.3 ml of wash buffer. 
For GST pulldown, cell lysates were incubated at 4°C for 1 hour 
with NENT100 buffer (20 mM Tris-HCl pH 7.4, 1 mM EDTA, 0.1% 
Nonidet P-40, 25% glycerol, and 100 mM NaCl) containing 1 mg/ml 
bovine serum albumin and 25 μl glutathione-Sepharose beads (GE 
Healthcare) on a rotating wheel. The beads were washed 2 times with 
0.3 ml of NENT100 containing 1 mg/ml bovine serum albumin, and 2 
times with 0.3 ml of NENT containing 300 mM NaCl. 
For HA immunoprecipitation, the lysates were precleared with 
Protein A-Sepharose beads (GE Healthcare) for 1 hour, and incubated 
on a rotating wheel at 4°C for 2 hours with 1 μg HA antibody (Sig- 
ma-Aldrich)  in  TBS/1%  Nonidet  P-40.  Protein  A-Sepharose   beads 
were added for 1 hour, and beads were washed 2 times in NENT300 and 
2 times in TBS/0.1% Nonidet P-40. Alternatively, 25 μl HA-agarose 
beads (Sigma-Aldrich) were directly added to the lysates and incu- 
bated on a rotating wheel in 500 μl TBS/0.1% Nonidet P-40 for 1.5 
hours at 4°C. Beads were washed 4 times in TBS/0.1% Nonidet P-40. 
In all cases, bound proteins were eluted by the addition of NuPAGE 
sample buffer (Invitrogen) and boiling. The eluted proteins were sub- 
sequently analyzed by SDS-PAGE on 4%–12% (wt/vol) Bis-Tris gels 
(Bio-Rad) and Western blotting. The membranes were blocked in 5% 
milk solution in TBS/0.1% Tween 20 for 1 hour at room temperature 
and subsequently incubated  with the primary antibody overnight   at 
 
 
 
 
Figure 6. Mechanistic model. Top  panels model the physiological   
situation in which the B-type subunit dictates subcellular targeting, 
substrate specificity, and substrate dephosphorylation by the C subunit. 
Conceivably, certain B subunits (like B56δ) or A-B dimers could dock     
to substrates independent of holoenzymes (alternatives labeled with 
question  marks).  Bottom  panel  displays  the  pathological situation 
in which (i) a B subunit mutation hindering interaction of the A and    
C subunit, (ii) an A subunit mutation hindering interaction of the C 
subunit but not the B subunit, or (iii) an A subunit mutation resulting in  
the incorporation of a catalytically impaired C subunit into the trimeric 
complex result in protection of B subunit–directed substrate dephos- 
phorylation  by  a  competition-based,  dominant-negative mechanism. 
The common feature in all ID cases described here is hindered access of 
the PP2A activity to B56δ-specific PP2A substrates. S,  substrate; 
P, phosphate. 
 
4°C. The following primary antibodies were used: mouse monoclonal 
anti-GST (Sigma-Aldrich), anti-HA (Sigma-Aldrich), anti-GFP (Corn- 
ing), anti–PP2A-A subunit (supplied by S. Dilworth, Middlesex Univer- 
sity, London, United Kingdom), anti–PP2A-C subunit (BD Biosciences); 
and rabbit polyclonal anti-B55α (Cell Signaling Technology), and anti- 
B56δ (20). After washing in TBS/0.1% Tween 20, the membranes were 
incubated at room temperature for 1 hour with horseradish peroxidase– 
conjugated secondary antibodies (Dako) and developed using a Pierce 
enhanced chemiluminescence detection system (Thermo Fisher Scien- 
tific). All densitometric quantifications were done with ImageJ software. 
For the IP-on-IP approach, a polyclonal population of HEK293 
cells stably expressing EGFP-TEV-B56δ was used   (selected with 
2 μg/ml puromycin). The EGFP-TEV expression vector was a gift of 
E. Heroes (KU Leuven, Leuven, Belgium). Forty-eight hours after 
transfection with HA-Aα (pMB001) or HA-mutant Aα (pMB001), 
EGFP trapping was performed, and the trapped complexes were 
incubated overnight at 4°C with 0.2 μg/μl of recombinant TEV 
protease in TEV cleavage buffer (TBS, 1 mM DTT, 0.5 mM EDTA). 
Following addition of  EDTA  (1  mM),  PMSF  (1  mM),  and  TLCK 
(1 mM), the TEV eluates were subjected to HA immunoprecipitation 
with HA-agarose beads and the washed immunoprecipitates were 
analyzed by immunoblotting with anti-HA, anti–PP2A-C, and anti- 
B56δ  antibodies  (20, 21). 
For PP2A activity measurements, the HA-agarose beads were 
washed once more with 20 mM Tris HCl pH 7.4 plus 1 mM DTT, and 
finally resuspended in 60 μl enzyme dilution buffer (catalog 20-169, 
Millipore). All assays were performed with 20 μl of this phosphatase 
suspension and 4.5 μl of 2 mM stock of K-R-pT-I-R-R phosphopeptide 
(catalog 12-219, Millipore) for 10–60 minutes at 30°C (still in the lin- 
ear range of the assay). The released free phosphate was determined 
by the addition of malachite green solution (10/1 mix of solution A 
[catalog 20-105, Millipore] and solution B [catalog 20-104, Milli- 
pore]). After 15 min incubation at room temperature, absorbance at 
630 nm was measured in a multi-channel spectrophotometer. Pico- 
molar amounts of phosphate released were calculated by comparison 
with a standard curve of known KH2PO4 concentrations, as outlined 
in the manufacturer’s instructions (Ser/Thr Phosphatase Assay Kit 1, 
Millipore). Specific phosphatase activity was obtained by correcting 
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these absolute values for amount of C present in the samples, as 
determined by immunoblotting with anti-C antibodies and quantifi- 
cation of the signals by ImageJ software. 
For protein-stability analysis, HEK293 cells were  transfected  
with    EGFP-B56δ    (WT);    with    EGFP-B56δ-P53S    or EGFP-B56δ- 
E198K mutants (pEGFP-C1); or with HA-Aα (WT), HA-Aα-R182W,  
or HA-Aα-P179L mutants (pMB001), one 10 cm plate per plasmid. 
Twenty-four hours after transfection, each 10-cm plate was split over 
6 wells on a 6-well plate, in which eventually 50 μM cycloheximide 
(CHX, Sigma-Aldrich) was added per well to block translation. Fol- 
lowing incubation with CHX for different time points (0, 10, and 24 
hours), whole-cell lysates were prepared in NET lysis buffer and fur- 
ther analyzed by immunoblotting with anti-vinculin mouse monoclo- 
nals (Sigma-Aldrich), anti-HA, or anti-GFP antibodies. Band intensi- 
ties were quantified using ImageJ software. 
Statistics. Statistical analysis of biochemical data was done with 
1-way multiple-comparisons ANOVA, and P < 0.05 was considered to 
be significant. 
The calculation of the chance likelihood for finding 10 de novo 
mutations in the same 9–amino acid stretch of B56δ was based on the 
following assumptions: The target size is <10–6 of the total ORF size, 
the number of random missense changes per generation is on average 
1, and the index is removed from the equation. This gives a chance 
likelihood of less than (10–6)9, or <10–54, not taking the lack of similar 
variants in ExAC into account. The chance of finding a similar vari- 
ant in the whole ID dataset by chance is about 2 × 10–3, assuming that 
about 2,000 ID cases were tested. In that case, the phenotype should 
also be random, and this was not the case. 
Study approval. The DDD study has UK Research Ethics Commit- 
tee (REC) approval (10/H0305/83, granted by the Cambridge South 
REC, and GEN/284/12 granted by the Republic of Ireland REC). In 
other cases, ascertainment of patients was part of the clinical routine. 
All patients’ families have consented to publication of clinical find- 
ings. Written informed consent was also obtained for publication of 
all facial photographs presented in Figure 1. 
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Supplementary Figure 1: Cellular binding assay of the B56δ P201S SNP 
found in the EVS database.  
EGFP-tagged wild-type B56, B56 P201S, or EGFP alone (-) were ectopically expressed in HEK293 cells. 
Following EGFP-trapping, the presence of endogenous PP2A A and C subunits in the trapped complexes 
was examined by immunoblotting (IB). After quantification of the band intensities with Image J, the ratios 
between EGFP and C, and between EGFP and A signals were determined, and calculated relative to B56 
wild-type control. The graphs that show A or C binding abilities displays mean values of 6 independent 
experiments (all shown). 
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Supplementary Figure 2: Stability of ID-associated B56 and A mutants 
HEK293 cells were transfected with EGFP-B56δ (wild-type), EGFP-B56-P53S or EGFP-B56-E198K mutants 
(upper panels), or with HA-Aα (wild-type), HA-A- R183W or HA-A-P179L mutants (lower panels), and 
incubated with 50 µM cycloheximide (CHX) for different time points (0h, 10h and 24h). After lysis, the protein 
extracts were analyzed by immunoblotting (IB) with anti-vinculin, anti-HA or anti-GFP antibodies. Band 
intensities were quantified using ImageJ software. 
Relative HA/vinculin or GFP-vinculin levels were calculated from three independent experiments and the mean 
values +/- standard deviation plotted in a graph defined by linear regression (and with relative PP2A 
subunit/vinculin levels at time point 0h designated as 100%). 
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Supplementary Figure 3: Reduced specific PP2A C activity in HA-(mutant)Aα-C 
complexes.  
In panel A, binding of C to the HA-tagged (mutant) A subunits is determined (as described in Figure 3A). In panel B, 
the pmole number of released phosphate from the K-R-pT-I-R-R phosphopeptide (350 µM in assay) was determined 
by Malachite Green assay for each of the HA- -C complexes. The assay was done at 30°C for 10 minutes. 
Specific C activities were obtained by dividing the absolute amount of pmoles released by the amount of C in the 
resp. samples, as determined by immunoblotting (IB) and following quantification by Image J. All specific activities 
were eventually recalculated relative to Aα wild-type control (which was set to 100%). 
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Supplementary Table 1: Overview of additional exomic alterations of potential 
interest. 
 
Case Gene Genomic change Prediction / evaluation 
1 MEP1B De novo missense variant Polymorphism 
2 - No other plausible findings - 
3 ABCB7D Inherited missense variant Polymorphism 
4 COG1 Compound heterozygous 
missense variants 
The phenotype was incompatible 
with CDG type IIG 
5 OCRL Inherited missense variant The phenotype was incompatible 
with Lowe syndrome 
6 ? No information available  
7 TMEM204 
SUV420H2 
De novo missense variants No known disease association 
8 ? Unknown – detected by 
targeted (MIP) assay 
- 
9 - No other plausible findings - 
10 - No other plausible findings - 
11 ELMO2 De novo missense variant No known disease association 
12 - No other plausible findings - 
13 PKHD1 Compound heterozygous 
missense variants 
The phenotype was incompatible 
with ARPKD 
14 LST1 De novo missense variant No known disease association 
15 TMEM67 Heterozygous inherited splice 
mutation 
Phenotype was partly reminiscent 
of a ciliopathy, but a second 
   mutation was not detected. 
16 - No other plausible findings - 
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Supplementary Table 2: Oligonucleotides used for site-directed mutagenesis 
 
 
 
Primers B56δ mutations 
P53S Forward 5’-GTCTCAGCCATCGTCATCCAAC-3’ 
P53S Reverse 5’-GTTGGATGACGATGGCTGAGAC-3’ 
E198K Forward 5’-GACCCAGAGAAAGATGAGCCC-3’ 
E198K Reverse 5’-GGGCTCATCTTTCTCTGGGTC-3’ 
E200K Forward 5’-GACCCAGAGGAAGATAAGCCCACCCTGGAAGCTGC-3’ 
E200K Reverse 5’-GCAGCTTCCAGGGTGGGCTTATCTTCCTCTGGGTC-3’ 
P201R Forward 5’-GACCCAGAGGAAGATGAGCGCACCCTGGAAGCTGCTTGGCC-3’ 
P201R Reverse 5’-GGCCAAGCAGCTTCCAGGGTGCGCTCATCTTCCTCTGGGTC-3’ 
P201S Forward 5’-GACCCAGAGGAAGATGAGAGCACCCTGGAAGCTGCTTGGCC-3’ 
P201S Reverse 5’-GGCCAAGCAGCTTCCAGGGTGCTCTCATCTTCCTCTGGGTC-3’ 
W207R Forward 5’-GCCCACCCTGGAAGCTGCTAGGCCACATCTCCAGCTCG-3’ 
W207R Reverse 5’-CGAGCTGGAGATGTGGCCTAGCAGCTTCCAGGGTGGGC-3’ 
Primers Aα mutations 
P179L Forward 5’-GCTCAGATGACACCCGCATGGTGCGGCGGGC-3’ 
P179L Reverse 5’-GCCCGCCGCACCATGCGGGTGTCATCTGAGC-3’ 
R182W Forward 5’-   ACCCCCATGGTGTGGCGGGCCGCA-3’ 
R182W Reverse 5’-   TGCGGCCCGCCACACCATGGGGGT-3’ 
R258H Forward 5’-AAGACAAGTCCTGGCACGTCCGCTACATGGT-3’ 
R258H Reverse 5’-ACCATGTAGCGGACGTGCCAGGACTTGTCTT-3’ 
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ABSTRACT 
 
Somatic PPP2R1A missense mutation is one of only a few genomic alterations occurring with 
high frequency in serous endometrial carcinoma and carcinosarcoma, both clinically 
aggressive subtypes of uterine cancer with few therapeutic options. PPP2R1A encodes the 
scaffolding Aα subunit of protein phosphatase 2A (PP2A), a major family of Ser/Thr 
phosphatases increasingly recognized to belong to the critical human tumor suppressors. 
Previously studied cancer-associated Aα mutants exhibited defects in binding to other PP2A 
subunits and were suggested to contribute to cancer development through a mechanism of 
functional haploinsufficiency. Here, we report on the biochemical and functional 
consequences of eleven recurrent endometrial carcinoma-associated PPP2R1A mutations 
clustering into Aα HEAT-repeats 5 and 7. Besides the predicted loss-of-function effects on 
formation of some PP2A holoenzymes, we uncover two novel mechanisms-of-action, 
consistent with dominant-negative and gain-of-function effects. Dominant-negative Aα 
mutants retain binding to specific subunits of the B’/B56 family, but form substrate-trapping 
complexes with impaired phosphatase activity due to increased recruitment of the PP2A 
inhibitor TIPRL1. Gain-of-function A mutants show significantly increased binding to 
B”’/STRN and several STRIPAK components. In accordance with these mechanisms, ectopic 
expression of A mutants in endometrial carcinoma cells increases anchorage-independent 
growth and tumor formation in vivo, and causes hyperphosphorylation of oncogenic PP2A-
B’/B56 substrates in the Akt and mTOR/p70S6K signaling pathways, while phosphorylation of 
ERK, a STRIPAK target, was decreased. Our data reveal how PPP2R1A mutations affect PP2A 
function and oncogenic signaling during endometrial cancer development, providing a 
molecular basis for improved design of targeted therapies. 
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INTRODUCTION 
 
Although not as common as endometrioid carcinoma (type I), serous uterine carcinoma 
(type II) is a highly aggressive disease characterized by high mortality due to a tendency for 
early metastasis and resistance to conventional chemotherapy (1). While genome-wide 
molecular changes in low grade endometrioid carcinomas have been revealed through The 
Cancer Genome Atlas research initiative (2), the molecular changes associated with serous 
endometrial cancer pathogenesis have only recently started to emerge. Several studies have 
consistently shown that, besides TP53 mutation (occurring in up to 80-95% of cases), 
relatively few additional molecular genetic aberrations can be found in this cancer type, the 
most prevalent being alterations in PPP2R1A, PIK3CA, FBXW7, CCNE1 and CHD4 (3,4,5). 
Amongst these, PPP2R1A appears by far the most frequently altered, in 18.4 up to 43.2% of 
cases, depending on the study (2,3,4,5,6,7,8,9) (Suppl. Table S1). PPP2R1A aberrations 
already occur early during progression in the pre-invasive intraepithelial precursor lesions 
(3), are distinctive for the serous subtype (6), and clearly distinguish the uterine serous 
carcinomas from the clinicopathological similar ovarian high-grade serous carcinomas (1,7 
,8). In addition, in the very aggressive uterine carcinosarcoma PPP2R1A mutation is a 
frequent event, occurring in 21.4% up to 26.8% of cases (6, 
http://www.cbioportal.org/study.do?cancer_study_id=ucs_tcga), as well as in the highly 
malignant undifferentiated endometrial carcinoma (20% of cases) (10) (Suppl. Table S1). 
PPP2R1A encodes the A subunit of type 2A protein phosphatases (PP2A), suggesting a 
prominent, but so far unexplored, role for PP2A in the etiology of these uterine cancers. 
PP2A phosphatases are well-recognized to belong to the critical tumor suppressors in a 
large variety of human cancers (11,12,13). Structurally, these enzymes are highly diverse; 
they consist of a catalytic C subunit (or PP2Ac), a structural A subunit and one of multiple (at 
least 23) regulatory B-type subunits, the latter defining substrate specificity and subcellular 
localization of the holoenzyme (14,15). Since different isoforms exist of A, B and C subunits, 
their combination can result in at least 96 different PP2A holoenzymes, each with different 
signaling functions in transcription, translation, DNA replication, responses to extracellular 
growth and stress factors, apoptosis, and cell cycle control (16,17,18). The PP2A A subunit 
plays a major role in holoenzyme assembly, as it forms the scaffold between the C and B-
type subunits. It is a highly flexible molecule (19), composed of 15 tandemly repeated HEAT 
(Huntington, Elongation Factor 3, PR65/A, TOR) motifs (20). Biochemical and structural 
studies have demonstrated that interaction with a regulatory B-type subunit is mediated by 
HEAT-repeats 1-8, while interaction with the C subunit occurs through HEAT-repeats 11-15 
(21,22,23,24,25,26,27,28). Despite these different interaction domains, C and B subunit 
binding to the A subunit do not necessarily occur independently from each other (29). For 
instance, N-terminal deletions of A inhibit C binding (21), and PR55/Bα and PR61/B’γ3 do 
not bind to a C-terminally truncated A (22,30), while B”/PR72 does (30). This is all 
indicative for cooperativity between specific B-type subunits and the C subunit in binding the 
A subunit, while other B-type subunits may bind the A subunit independently from C (31). In 
particular, it has been shown that the highly conserved C-terminal tail of the C subunit 
provides additional, stabilizing contacts with B/PR55 and most B’/PR61 subunits, but not 
B’/PR61, B”/PR72 or B”’/striatin subunits, to promote holoenzyme assembly 
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(25,32,33,34,35). Thus, the determinants governing PP2A holoenzyme assembly seem to be 
significantly dependent on the nature of the B-type subunit that needs to be incorporated. 
While some PP2A complexes may be proto-oncogenic (36,37,38), an overwhelming 
amount of evidence rather underscores their ability to suppress various (proto)oncogenes 
and oncogenic signaling pathways (17,39,40,41,42). In accordance, it was found that 
inhibition of PP2A – together with expression of oncogenic RasV12 – is an absolute 
requirement to achieve full transformation of a large panel of human epithelial cells 
immortalized by overexpression of the telomerase catalytic subunit and the SV40 large T 
antigen (39,42,43,44,45,46), highlighting the major role specific PP2A complexes play in 
protecting human cells from oncogenic transformation. Hence, there is currently plenty of 
evidence for deregulation of PP2A activity or expression in a variety of human solid cancers 
and hematological malignancies (47,48,49,50). Particularly, cancer-associated missense point 
mutations have been reported in both PPP2R1A and PPP2R1B, encoding the non-redundant 
PP2A Aα and A subunits respectively. Inactivating A mutations occur with relatively high 
frequency in lung (6-15%) (51) and colon cancers (10-15%) (51,52,53), while Aα mutations 
have less frequently been reported in lung carcinoma (4%), melanoma (7%) and breast 
carcinoma (2%) (54). Biochemical analyses have shown that most A and all Aα point 
mutations affect PP2A holoenzyme formation, either by interrupting interaction between A 
and C subunits, between A and all or specific B-type subunits, or both (39,45,55,56). For the 
Aα missense mutants characterized so far (E64D, E64G and R418W), these binding defects 
result in a state of functional haploinsufficiency that promotes cell transformation via 
activation of the PI3K/Akt pathway (45). In accordance, heterozygous A E64D/G knockin 
mice show increased susceptibility to benzopyrene-induced lung cancerogenesis (57).  
Here, we have characterized 11 of the more recently discovered, but not yet biochemically or 
functionally characterized, PPP2R1A missense mutants, identified with high frequency in 
serous uterine carcinoma and carcinosarcoma (P179R, R182W, R183G/Q/W, R249H, 
S256F/Y, W257C/G, R258H). All these Aα mutations are heterozygous, cluster in HEAT-
repeats 5 or 7, and many of them are recurrent in uterine cancer (Suppl. Table S1), but 
sporadically also occur in other cancer types (58,59). Such high degree of recurrence rather 
suggests a dominant mechanism-of-action for these mutants, rather than haploinsufficiency. 
We found that a subset of PP2A holoenzymes is affected by HEAT domain Aα mutants in a 
dominant-negative manner, whereas another subpopulation of PP2A complexes is affected 
by a gain-of-function mechanism. Accordingly, expression of HEAT domain Aα mutants in an 
endometrial cancer cell line harboring two wild-type PPP2R1A alleles, triggers activation of 
p70 S6 kinase and Akt signaling pathways and promotes anchorage-independent growth and 
tumor growth in vivo. 
 
 
MATERIALS AND METHODS 
 
Site-directed mutagenesis. Wildtype Aα coding region was cloned into an HA-tag 
eukaryotic expression vector (pMB001). PCR-based site-directed mutagenesis (Stratagene) to 
generate eleven recurrent serous uterine carcinoma-associated A mutants (P179R, R182W, 
R183G, R183Q, R183W, R249H, S256F, S256Y, W257C, W257G, R258H) and the melanoma-
associated R418W mutant was performed directly in the pMB001 vector with proofreading 
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Pwo polymerase (Roche Applied Science) and complementary DNA oligonucleotide primers 
(Sigma Genosys) containing the desired point mutations (primer sequences in Suppl. Table 
S2). The Aα deletion mutant containing HEAT repeats 1-10 (A aa1-410) was generated by 
introduction of a stop codon at amino acid 411 (Suppl. Table S2). The mutant (P179R, 
R182W, R183G, R183Q and S256F) and WT Aα coding regions were subcloned in the pLA 
CMV N-Flag vector via the In-Fusion® HD cloning kit (Clontech Laboratories). All Aα 
mutations were confirmed by sequencing (LGC genomics). The different PP2A B-type subunit 
coding regions were cloned in a GST-tag eukaryotic expression vector as described (33). The 
B’ε coding region was cloned in pEGFP-C1 vector. Bα, B’γ1 and B’ (60) were additionally 
subcloned in pEGFP-TEV. STRN3 cDNA (clone HsCD00623024) was obtained from DNASU 
repository (The Biodesign Institute/Arizona State University) (61) and subcloned into pEGFP-
TEV vector using In-Fusion® HD technology (Clontech Laboratories). TIPRL cDNA (isoform 
1) was obtained by RT-PCR on mRNA isolated from HEC-1-A cells, and cloned into pGMEX-T, 
pEGFP-TEV and pET15b vectors. 
Lentiviral transduction. HEK293T cells (ATCC, Manassas, VA, USA) were 
transfected in a 6-well plate with Aα WT or mutant cloned into the lentiviral pLA CMV N-Flag 
vector, in the presence of pCMV-deltaR8.91 and pMD.G-VSVG, using Turbofect transfection 
reagent (Thermo Scientific). 24h later, the complete supernatant was used to transduce 
HEC-1-A endometrial carcinoma cells (ATCC, Manassas, VA, USA) and generate cells stably 
expressing FLAG-tagged WT A or mutant proteins. 
Cellular PP2A subunit binding assays. HEK293 cells (ATCC, Manassas, VA, USA) 
were transfected with appropriate PP2A subunit expression vectors using PEI transfection 
reagens according to standard protocol. 48h after transfection, cells were rinsed with 
phosphate-buffered saline (PBS), lysed in 200μl NET buffer (50 mM Tris.HCl pH 7.4, 150 mM 
NaCl, 15 mM EDTA and 1% Nonidet P-40) containing protease and phosphatase inhibitor 
cocktail (Roche Applied Science) and centrifuged for 15' at 13,000 g.  
For GST pull down (from transiently transfected HEK293 cells) and FLAG pull down 
(from virally transduced HEC-1-A cells), cell lysates were incubated at 4°C for 1h with 
NENT100 buffer (20 mM Tris-HCl pH 7.4, 1 mM EDTA, 0.1% Nonidet P-40, 25% glycerol, 100 
mM NaCl) containing 1 mg/ml bovine serum albumin (BSA) and 25 μl glutathione-Sepharose 
beads (GE Healthcare) or anti-FLAG M2 affinity gel (Sigma Aldrich Corp.) on a rotating 
wheel. The beads were washed 2 times with 0.3 ml of NENT100 containing 1 mg/ml BSA, and 
2 times with 0.3 ml of NENT300 containing 300 mM NaCl.  
For HA pull down, 25 μl anti-HA agarose beads (Sigma Aldrich Corp.) were directly 
added to the lysates and incubated on a rotating wheel in 500 μl TBS for 1 hour at 4°C. 
Beads were washed 4 times in TBS. 
For GFP trapping, cell lysates were incubated at 4°C for 1h with wash buffer (10 mM 
Tris-HCl pH 7.5, 0.5 mM EDTA and 150 mM NaCl) and 15 μl GFP-trap-A beads (Chromotek) 
on a rotating wheel. The beads were washed 4 times with 0.5 ml of wash buffer.  
In most cases, bound proteins were eluted by addition of 2x NuPage sample buffer 
(Invitrogen) and boiling. The eluted proteins were subsequently analyzed by SDS-PAGE on 
4–12% (w/v) gels (BioRad) and Western blotting. The membranes were blocked in 5% milk 
solution in TBS/0.1% Tween-20 for at least 1h at room temperature. Antibodies used for 
immunoblotting in this study are: mouse monoclonal anti-GST, anti-HA, anti-FLAG, anti-GFP 
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and anti-vinculin antibodies (all from Sigma-Aldrich Corp.); mouse monoclonal anti-PP2A-A 
and anti-PP2A-C (generously supplied by Dr. S. Dilworth, University of Middlesex, London, 
UK); rabbit polyclonal anti-B’δ antibody (62); rabbit polyclonal anti-B’γ2,3 and anti-B’ε 
antibodies (generously shared by Dr. B Hemmings, Friedrich Miescher Insitute, Basel, CH); 
rabbit polyclonal anti-B’ (Abcam); rabbit polyclonal anti-B subunit (#4953, Cell Signaling 
Technology); mouse monoclonal anti-STRN3 (Acris Antibodies); and rabbit polyclonal anti-
TIPRL1 (Abcam). The following antibodies were purchased from Cell Signaling Technology: 
rabbit polyclonal anti-phospho-p70S6 kinase (T389), rabbit monoclonal anti-phospho-S6 
Ribosomal Protein (Ser235/236), rabbit monoclonal anti-S6, rabbit monoclonal anti-phospho-
Akt (T308), rabbit monoclonal anti-Akt, rabbit monoclonal anti-phospho-GSK-3β (Ser9), 
rabbit monoclonal anti-GSK-3β, anti-phospho-ERK1/2 (Thr202/Tyr204), rabbit polyclonal 
anti-ERK1/2 and rabbit polyclonal anti-phospho-MEK1/2 (Ser217/221). Immunoblot signals 
were visualized through horseradish peroxidase-coupled secondary antibodies (DAKO) and 
enhanced chemiluminescence detection (Westernbright ECL-HRP substrate kit, Isogen Life 
Science). All densitometric quantifications were done with ImageJ software. For statistical 
analysis, we applied one-way multiple comparisons ANOVA to the average values of all 
quantified bands of a given condition on a given gel. P-values below 0.05 were considered to 
be significant.  
“IP-on-IP” approach. HEK293 cells were transiently co-transfected (PEI) with 
expression vectors for EGFP-TEV-B56, and HA-A (WT or mutant). 48h after transfection, 
GFP-trapping was performed, and the trapped complexes were incubated overnight at 4°C 
with 0.2µg/µl of recombinant Tobacco Etch Virus (TEV) protease in TEV cleavage buffer 
(TBS, 1mM DTT, 0.5 mM EDTA). Following addition of EDTA (1mM), PMSF (1mM) and TLCK 
(1mM), the TEV eluates were subjected to HA-pull down with HA-agarose beads, and the 
washed immunoprecipitates analyzed by immunoblotting and/or assayed for PP2A activity.  
PP2A activity measurements. HA-agarose beads from HA pull downs according to 
the IP-on-IP approach, were washed once more with 20mM Tris.HCl pH 7.4 + 1mM DTT, 
and finally resuspended in 60µl enzyme dilution buffer (catalog # 20-169, Millipore). All 
assays were performed with 20µl of this ‘phosphatase suspension’ and 9 µl of 2mM stock of 
R-R-A-pT-V-A phosphopeptide for 10 to 60 minutes at 30°C (still in the linear range of the 
assay). The released free phosphate was determined by addition of malachite green solution 
(100/1 mix of solution A (catalog # 20-105, Millipore) and solution B (catalog # 20-104, 
Millipore)). After 15 minutes incubation at RT, absorbance at 630 nm was measured in a 
multi-channel spectrophotometer. Pmole amounts of phosphate released were calculated by 
comparison with a standard curve of known KH2PO4 concentrations, as outlined in the 
manufacturer’s instructions (Ser/Thr Phosphatase Assay Kit 1, Millipore). Specific 
phosphatase activity was obtained by correcting these absolute values for amount of C 
present in the samples - as determined by immunoblotting with anti-C antibodies and 
quantification of the signals by ImageJ.  
Expression and purification of recombinant TIPRL1. N-terminally His-tagged 
TIPRL1 (pET15b) was expressed in E. coli BL21 cells for 3h at 37°C, and purified from the 
soluble fraction of the bacterial lysate via metal affinity purification using Ni-NTA beads 
(Affiland), following the manufacturer’s standard protocol. After five washes in 50 mM 
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Tris.HCl pH 8.0, 300 mM NaCl and 13 mM imidazole, and elution in the same buffer with 250 
mM imidazole, the purified protein was dialysed against 20 mM Tris.HCl pH 7.4/ PEG 10,000, 
and stored in 60% glycerol at -80°C. Final protein concentration was determined by 
absorbance at 280 nm (NanoDrop 2000, Thermo Scientific). 
 
PPP2R1A exome sequencing in HEC-1-A cells. RNA was isolated using TRIzol 
reagent (LifeTechnologies), reverse-transcribed with MuLV RT (New England BioLabs Inc.), 
and PCR-amplified with primers Forw 5’-ATGGCGGCGGCCGACGGCGACG-3’ and Rev 5’-
TCAGGCGAGAGACAGAACAGTCAG-3’ using PWO proofreading DNA polymerase (Roche). The 
purified fragment (Illustra GFX PCR DNA purification kit, GE Healthcare) was subjected to 
Sanger sequencing using the same primers (LGC Genomics). 
Mass spectrometry experiments. FLAG-tagged WT or mutant A were isolated 
from HEC-1-A transduced cells by FLAG pull down (see above). HEC-1-A cells transduced 
with an empty pLA vector were used as a negative control. After several wash steps as 
described above, the FLAG-tagged proteins were eluted by addition of 1.5 µg/µl FLAG 
peptide (23 aa: MDYKDHDGDYKDHDIDYKDDDDK) in 50mM Tris.HCl pH 8.0, containing 
50mM NaCl. The eluates were subjected to trypsin digestion and desalting by C18 ZipTip 
pipette tips (Millipore) before analysis on a hybrid quadrupole-orbitrap mass spectrometer (Q 
Exactive, Thermo Fisher Scientific). Relative quantification of the interactomes of mutant 
versus WT A was executed with Progenesis software (Nonlinear Dynamics) incorporating 
protein identifications obtained with the MASCOT (Matrix Science) search engine using the 
uniprot_swprot (release 07/15/2015, Homo sapiens, 20,279 entries). Proteins with an 
abundance that was at least 3 times higher in any of the experimental conditions than in the 
‘FLAG-only’ control were considered as true interaction partners (100 proteins) and were 
retained for further calculations. Only abundances of peptides with a MASCOT score of 25 
and above (significance threshold) were taken into account. Resulting protein abundances of 
interacting proteins in each experimental condition were subsequently normalized according 
to A input abundance. From those values, relative quantification to WT A was determined. 
A HEAT-map of differential interactions was made with GENE-E software. 
Soft agar colony assay. 1x104 cells/well were seeded in triplicate into 0.35% top 
agar/0.5% base agar (Sigma Aldrich) supplemented with 2µg/µl Fungizone (Invitrogen) in 6-
well plates. Every 2-3 days, fresh medium (DMEM + 10% fetal calf serum) was dropped on 
top. After four weeks, colonies were counted (Motic AE31 microscope, 4x magnification). 
Xenograft assay. 5x106 cells in 200µl PBS were subcutaneously injected in 6-week-
old female NMRI-nu (nu/nu) nude mice. Xylazine (Kompun)/ ketamine (Imalgene) was used 
as a local anaesthetic. Per condition, three mice were injected in both flanks (n=6). All 
procedures were approved by the local KU Leuven Animal Ethical Committee (project 
number P104/2012). The number of tumors was determined approximately one month after 
injection. Tumor size was calculated using the following formula: tumor width2 x (tumor 
length/2). 
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RESULTS 
 
Cancer-associated Aα mutations dramatically affect PP2A holoenzyme 
formation 
All recurrent serous uterine cancer-associated Aα mutations are heterozygous and missense, 
and cluster into HEAT-repeat 5 (P179L, P179R, R182W, R183G, R183Q, R183W) and HEAT-
repeat 7 (R249H, S256F, S256Y, W257C, W257G, R258H). To investigate how these Aα 
mutations affect PP2A holoenzyme assembly, we first evaluated their binding to PP2Ac. HA-
tagged wildtype (WT) A, the PP2Ac-binding deficient R418W A mutant (45,55) and the 11 
uterine cancer-associated Aα mutants were expressed in HEK293 cells, and interaction with 
endogenous PP2Ac was studied after HA pull down. All mutants, but R249H, show reduced 
PP2Ac binding, when compared to WT Aα (Figure 1).  
 
 
Figure 1: PP2Ac subunit binding to cancer-associated A mutants. 
WT Aα, the melanoma-associated R418W A mutant and 11 endometrial cancer-associated Aα 
mutants (all HA-tagged), or an empty HA vector (-) were transfected into HEK293 cells. Following HA 
pull down, interaction with endogenous PP2Ac subunit was examined by immunoblotting (IB). After 
quantification of the band intensities with Image J, the ratios between HA and C signals were 
determined and calculated relative to Aα WT control (set to 100%). Mean values and a representative 
image of four independent experiments are shown (*, p < 0.05; **, p < 0.01). 
 
 
Next, we determined binding of the mutant HA-tagged Aα proteins with GST-tagges B-type 
subunits of the B, B’ and B” families in GST pull down assays (Figure 2). The single A 
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mutant that retained PP2Ac binding, R249H, also showed normal binding to all B-type 
subunits tested (Figure 2A). All other A mutants showed varying binding alterations to at 
least one B-type subunit (Figure 2A-2F, Table 1). The most pronounced defects in binding 
were observed for the PR55/B family members, Bα and B. In fact, all of the remaining 10 
A mutants no longer (or hardly, 11%) bound to these B subunits anymore (Table 1). Also 
the B’ and B” family members primarily showed binding defects, but in a much more 
heterogeneous way as compared to the B family members. For example, PR72/B” was found 
to bind efficiently to R183G, R183W and W257C, but it lost binding or bound significantly 
less (<30%) to R182W, R183Q, S256F, S256Y, W257G and R258H. Binding to P179R was, 
although decreased by half, not significantly different from the WT (Table 1). These data 
already indicate that a single mutation in either of the two affected A HEAT-repeats can 
have an impact on PR72 binding, and that not just the mutated residue determines the 
binding deficiency, but also the amino acid in which it is substituted (e.g. compare R183G 
with R183Q).  
 
Similar conclusions could be drawn from the results of the binding experiments obtained for 
the B’ subunits (Table 1), although in these cases, remarkable isoform-specific differences in 
binding behavior to a single cancer-derived Aα mutant were additionally found. The latter 
finding is especially clear for the B’δ isoform which overall shows the least binding defects, 
while B’γ1, showed the most pronounced binding defects in this assay. In fact, none of the 
binding differences observed between WT and the 10 A mutants reached statistical 
significance for B’ (although binding to P179R, R182W, R183G, R183W, S256F/Y and R258H 
was only retained for 40-65%), while B’γ1 lost binding or bound significantly less (<30%) to 
8 A mutants and to R183G (46%), and only retained binding to R183Q (75%). B’β lost 
binding (0%) to all HR5 mutants (P179R, R182W and R183G/W/Q) and R258H, bound 
significantly less (10-30%) to S256Y and W257C/G, and only retained binding to S256F 
(47%). B’ bound significantly less (20%) to 5 A mutants (P179R, R182W, R183W, S256Y 
and R258H), showed moderate binding defects (30-50%) to 3 others (R183G, W257C and 
W257G), and retained binding to R183Q (85%) and S256F (45%). B’ε showed severe loss of 
binding to only 2 A mutants (R183W and R258H), moderately lost binding (30-50%) to 4 
others (P179R, R182W, R183G and W257G), and retained binding to S256F/Y (45-60%), 
R183Q and W257C (both 100%). The binding defects of the melanoma-associated R418W 
mutant were largely as reported before (Figure 2G) (45,55,63).  
 
Binding of HA-tagged mutant A binding to the B”’ subunits was monitored in GFP trapping 
assays with GFP-tagged STRN3 (SG2NA) (Figure 3). Intriguingly, we found that upon STNR3 
co-expression, several A mutants were significantly more expressed (Figure 3A,B), while 
this was not observed when the mutants were co-expressed with any of the B, B’ or B” 
subunits tested (Figure 2). This suggested that STRN3 might have a stabilizing effect on the 
mutants, due to a better binding to this B subunit. Indeed, when we analyzed the GFP-
trapped complexes for HA-A binding, all but one (R249H) of the A mutants tested bound 
obviously better to GFP-STRN3 as compared with WT A (Figure 3A). When the increase in 
binding was normalized to the levels of expression , two A mutants, S256F and R258H, 
were found to statistically significantly bind better to STRN3 as compared with WT A 
(Figure 3C).  
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Figure 2: Binding of B-type subunits (B, B’ and B”) to endometrial 
cancer-associated A mutants. 
GST-tagged B subunits or empty GST vector (-) were co-expressed in HEK293 
cells with HA-tagged WT or mutant Aα. The following 11 endometrial cancer-
associated A mutants were tested: R249H and R183Q (panel A), R138G and 
R183W (panel B), P179R and R182W (panel C), S256F and S256Y (panel D), 
W257C and W257G (panel E), R258H (panel F) and the previously tested 
melanoma-associated R418W mutant (45,55) (panel G). The HA signal in the 
complete lysates and in the isolated GST pull down complexes was determined by 
immunoblotting (IB). After quantification of the band intensities with Image J, 
ratios were determined between the GST and HA signals and calculated relative 
to Aα WT control (set to 100% for each B-type subunit pull down). Mean values 
and a representative image of three independent experiments are shown (*, p < 
0.05; **, p < 0.01). 
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Figure 3: Binding of B”’ subunit STRN3 to endometrial cancer-related A mutants. 
A. GFP-tagged STRN3 or GFP alone (-) were co-expressed with HA-tagged WT or mutant A in 
HEK293 cells. The HA signal in the complete lysates and in the isolated GFP-trapped complexes was 
determined by immunoblotting (IB). After quantification of the band intensities with Image J, ratios 
were determined between the GFP and HA signals in the GFP-trapped complexes, and between the 
vinculin and HA signals in the lysates. B. Mean values of quantified HA/vinculin ratios in the lysates, 
calculated relative to Aα WT control (set to 100%), from three independent experiments (*, p < 0.05; 
**, p < 0.01). C. Mean values of quantified HA/GFP ratios in the GFP-trapped complexes, calculated 
relative to Aα WT control, and further corrected for differences in expression with Aα WT control 
(panel B). Results are derived from three independent experiments (*, p < 0.05). 
 
To provide further insights into the obviously different binding behavior of the A mutants to 
resp. the B, B’ and B” subunits (unaltered, decreased or loss-of-binding), and the B”’/striatins 
(increased binding), we co-expressed HA-tagged WT A or A mutants (R182W, R183G/Q 
and S256F) with GFP-tagged B-type subunits (B, B’γ1, B’, B’ε, STRN3), and evaluated the 
presence of endogenous PP2Ac and the HA-tagged A subunits in the GFP-trapped 
complexes (Figure 4). Unfortunately, anti-A immunoblotting could not unambiguously reveal 
the presence of endogenous A because of insufficient resolution of the HA-tagged A and 
endogenous A bands on the SDS-PAGE gel (data not shown). Nevertheless, we found that 
the PP2Ac binding patterns in all cases completely mimicked those of the GFP-B-type 
subunits’ inputs, while the anti-HA signals were completely different, but fully consistent with 
our other binding assays (Figures 2 and 3). Taken together, these data indicate that all B-
type subunits likely bound a mixture of HA-tagged and endogenous A subunits. Only for 
STRN3, the fraction of bound mutant A was significantly higher than bound WT, providing 
additional proof for a gain-of-binding of STRN3 to the A mutants. B’ bound comparable 
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amounts of mutant and WT A. B’γ1 and B’ε showed lower affinity to mutant A compared 
to WT, and B did not bind any mutant A at all. 
 
 
Figure 4: Comparative analysis of binding of A mutants and endogenous PP2Ac to GFP-
tagged B-type subunits. 
GFP-tagged B, B’γ, B’, B’ε and STRN3 were co-expressed with HA-tagged WT or mutant A in 
HEK293 cells. The presence of HA-tagged A variants and endogenous PP2Ac in the GFP-trapped 
complexes was determined by immunoblotting. For the anti-C immunoblot, two different exposures 
(‘exp.’) are shown. Asterisks indicate the GFP-STRN3 and GFP-B bands resp. 
 
In summary, our binding assays in HEK293 cells revealed that cancer-associated Aα 
mutations differentially affect binding of Aα to different PP2A subunits. 
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Table 1. Summary of mutant A binding defects. 
‘   ‘ : A mutant binding is highly and significantly decreased as compared to WT (<30%); 
‘   ‘ : A mutant binding is modestly, but significantly decreased as compared to WT 
(>30%); 
‘   ’ : A mutant binding does not significantly differ from WT A;  
‘   ’ : A mutant is significantly increased as compared to WT A 
‘numbers’ indicate percentage of residual A mutant binding compared to WT A (set at 
100%) 
 
Interactome of WT and mutant Aα in endometrial cancer cells 
To validate and extend our targeted PP2A subunit binding assays to a pathological more 
relevant context, we expressed WT A and 5 selected A mutants (P179R, R182W, R183G, 
R183Q and S256F) as N-terminally FLAG-tagged proteins in the endometrial cancer cell line 
HEC-1-A by a lentiviral approach. HEC-1-A cells expressing FLAG peptide alone were used as 
a negative control. Following anti-FLAG pull down and subsequent elution by FLAG peptide, 
we analyzed the trapped complexes and their putative interaction partners by mass 
spectrometry (MS) in a semi-quantitative way. Besides validation of changes in the assembly 
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of the subset of PP2A holoenzymes expressed in endometrial epithelial cells, this approach 
also allowed identification of potential gain-of-function or loss-of-function alterations in the 
broader A interactome in an unbiased, non-targeted way. 
 
Using this approach, we identified 96 cellular proteins as specific co-eluting (direct or 
indirect) interaction partners of A (Figure 5). 42 of these had previously been reported in 
PP2A interactome studies from HEK293 cells (64,65,66) (Figure 5A), while the remaining 54 
are potentially novel (Figure 5B). Details on the MS data, quantifications and normalizations 
can be found in Suppl. Data S3 (Excel file). The known interaction partners include 12 
established PP2A subunits (C, C, R2A/B, R2D/B, R5A/B’, R5A/B’β, R5C/B’γ, R5D/B’, 
R5E/B’ε, the B”’ subunits STRN, STRN3 and STRN4), 2 PP4 subunits (C and R1), a reported 
cellular PP2A inhibitor (67) (TIPRL1), a number of well-established B-type subunit interactors 
(nine components of the STRIPAK complex (64,65,68), the B’γ/B’ interactors PPFIA1/2 
(liprin 1/2) (69,70)), and a number of poorer characterized (indirect) A binding partners 
(ten subunits of the Integrator complex, ANKLE2, CCDC6, CCT5, FECH, FGFR1OP and 
TMPO). Overall, the R183Q and S256F mutants show the most pronounced binding 
deficiencies to several of the interactors identified, followed by the R183G and R182W 
mutants, and finally, the P179R mutant which shows the least binding deficiencies when 
compared to WT A. Notably, the MS data revealed that the Aα mutants showed lower 
binding affinity for the PP2A C, B and B’ subunits, suggesting that these mutations are loss-
of-function (Figure 5A). This was further confirmed by direct immunoblotting of the anti-
FLAG pull downs with available isoform-specific PP2A subunit antibodies (Figure 5C). 
However, these immunblots also revealed sustained binding of specific Aα mutants to 
specific B’ subunits (Figure 5C), consistent with our binding assays in HEK293 cells (Figure 
2). In contrast, the MS data suggested either largely unaltered, or increased binding to the 
A mutants for the PP2A B”’/STRN subunits, rather indicating gain-of-function effects of 
these A mutations (Figure 5A). This result was also validated by direct immunoblotting 
(Figure 5D). Thus, the (mutant) A interactome data from HEC-1-A cells largely confirm 
results from our binding assays in HEK293 cells with ectopically expressed A and B-type 
subunits (Table 1). The reliability of the MS data is further underscored by the observation 
that interactors belonging to one and the same multi-protein complex (e.g. STRIPAK, 
Integrator) show an identical differential binding behavior to the different A mutants. 
Finally, the MS data revealed the most obvious and strongest gain-of-function effect of the 
Aα mutants for the PP2A inhibitor TIPRL1 (Figure 5A). We validated the enhanced interaction 
of Aα mutants to TIPRL1 by immunoprecipitation and TIPRL1 immunoblotting (Figure 5D). 
Taken together, we observed bidirectional effects of Aα mutations on the formation of 
specific complexes, making it challenging to define their mode of action as loss-of-function or 
gain-of-function.
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Figure 5: Mass spectrometry-based identification of WT and mutant A interactomes in 
HEC-1-A endometrial cancer cells. 
A,B. Semi-quantitative heat maps of WT and mutant A interactomes in HEC-1-A cells. Putative A 
interacting proteins were identified by mass spectrometry in FLAG peptide eluates of FLAG pull down 
assays, performed on lysates of HEC-1-A cells stably expressing N-terminally FLAG-tagged A 
variants, or FLAG-tag alone. To be scored as a potentially genuine interaction partner, the overall 
peptide abundance of a given protein should be at least 3 times as abundant as in the FLAG alone 
control. This resulted in 96 putative A interaction partners. Heat maps display the relative abundance 
of each interaction partner in the different A pull downs: regardless of absolute abundances, the 
interactor occurring in the highest abundance is given a dark red color and the lowest abundant 
partner is given a dark blue color. Data interpretation, therefore, needs to be done with caution, 
preferably with the list of absolute abundances at hand (Excel file Suppl. Data S3), as small 
differences in abundance can be similarly displayed as marked differences in abundance. Panel A 
displays previously reported PP2A interactome constituents; panel B displays putatively novel A 
interactors. C. Validation of endogenous PP2Ac binding and of several endogenous PP2A B and B’ 
subunits to mutant A. The presence of the indicated PP2A subunits in anti-FLAG pull downs (left) and 
total cell lysates (right) of the transduced HEC-1-A cells was determined by immunoblotting (IB) with 
available isoform-specific antibodies. * indicates FLAG-tagged A in the lysates. Quantifications 
represent the calculated ratios between the IB:C or B signals and the IB:FLAG signal for a given A 
mutant in the anti-FLAG pull downs. D. Validation of gain of TIPRL1 and STRN3 binding to mutant A. 
Same approach as in panel C to determine endogenous TIPRL1 and STRN3 levels in anti-FLAG 
(mutant) A pull downs. 
 
 
Cancer-associated Aα mutants increase anchorage-independent growth 
and xenograft growth in vivo of endometrial carcinoma cells 
We next analyzed whether ectopic expression of the mutant Aα proteins in HEC-1-A cells 
affected the oncogenic properties of these endometrial cancer cells. First, we confirmed that 
both PPP2R1A alleles in HEC-1-A cells are wildtype by Sanger sequencing (data not shown). 
The growth-inducing potential of the Aα mutants was tested in soft agar assays in vitro and 
xenograft assays in immune-compromised mice (Figure 6). These functional studies revealed 
that all A mutants tested show an increased tumorigenic potential vs. WT A upon their 
expression in HEC-1-A cells. This is particularly clear for R183G, R183Q and S256F since the 
size and number of colonies grown in soft agar (Figure 6A) and the number and the size of 
xenografted tumors in mice (Figure 6B) was significantly increased compared to WT Aα 
expressing cells and negative control (parental HEC-1-A cells). The effect for P179R and 
R182W mutants was weaker (Figure 6A,B), although for P179R this might be related to its 
markedly lower expression levels (Figure 5C).  
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Figure 6: Tumorigenic phenotypes of endometrial cancer cells expressing A mutants. 
A. Anchorage-independent growth of HEC-1-A cells, ectopically expressing mutant or WT Aα subunit. 
The pictures give an idea about the number and size of colonies obtained for each condition at a given 
time point after seeding. The data in the graph represent the mean (±SD) of the colony number from 
3 replicates and 6 measurements. Data were analyzed via the ANOVA test (**p < 0.01; *** p < 
0.001). B. Tumor growth of xenografted HEC-1-A cells. Size (graph) and number of tumors (n) are 
indicated for each condition (n=6). Differences in tumor size were analyzed via the ANOVA test (* p < 
0.05; ** p < 0.01; *** p < 0.001). 
 
Cancer-associated Aα mutants promote hyperphosphorylation of the Akt 
and mTOR/p70S6K signaling pathways and decrease phosphorylation of the 
MAPK pathway 
To determine the effects of mutant or WT Aα expression on oncogenic signaling, we 
performed immunoblotting analysis using antibodies directed against several established 
cancer-related PP2A substrates and components of cancer-associated signaling pathways 
(Figure 7). These experiments revealed significantly increased oncogenic signaling in cells 
expressing the strong tumorigenic mutants R183G/Q and S256F, as demonstrated by 
hyperphosphorylation of phospho-p70S6 kinase and phospho-S6 (Figure 7A,D), phospho-
GSK3β and phospho-Akt T308 (Figure 7B,D). For the P179R and R182W mutants, an effect 
on only phospho-GSK3β was seen (Figure 7B,D), consistent with their milder tumorigenic 
phenotype in the functional assays (Figure 6). Remarkably, we found that 
activity/phosphorylation of ERK1/2 was decreased in all cases (Figure 7C,D). These results 
suggest that increased tumorigenic potential induced by Aα mutants could be triggered by 
up-regulation of the Akt, GSK-3β and mTOR signaling pathways.
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 Figure 7: Effects of mutant Aα expression on oncogenic signaling pathways in HEC-1-A cells. 
Cell lysates of WT or mutant A expressing HEC-1-A cells were subjected to immunoblotting (IB) with the indicated antibodies and signals were quantified 
using ImageJ. ‘Total’ and ‘Phospho’ signals were determined on different blots, which were both redeveloped for vinculin to correct for loading differences. 
Differences with WT are indicated in color: green for an increase as compared with WT; red for a decrease as compared with WT. Representative images of 
one of three independent (i.e. three different lentiviral transductions) experiments are shown (A,B,C). D. Mean values of quantified Phospho/Tot ratios in the 
lysates, calculated relative to Aα WT control (set to 100%) from three independent experiments (ANOVA test; *, p < 0.05; **, p < 0.01).
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Mutant Aα proteins act in a dominant manner through formation of 
substrate-trapping, catalytically deficient AB’C complexes 
Since we observed increased oncogenicity upon mutant Aα expression, without prior 
reduction of endogenous Aα in HEC-1-A cells (Figures 6 and 7), it seemed very unlikely that 
the tested cancer-associated Aα mutants acted by a mechanism of haploinsufficiency. In 
addition, we did not observe a clear correlation between the number of B-type subunit 
binding deficiencies for a given mutant (Table 1, Figure 2B, Figure 3, Figure 5C,D) and the 
degree of their oncogenic behavior in tumor growth (Figure 6) or oncogenic signaling (Figure 
7). On the other hand, such correlation was more obvious for the observed gain-of-binding 
of the Aα mutants to STRN3 and TIPRL1 (Figure 3, Figure 5D), although it was still not 
entirely consistent (e.g. compare R183G with R182W or P179R). Particularly, a gain of 
function of PP2A-STRN is difficult to reconcile with decreased dephosphorylation of the 
oncogenic kinases GSK3β, Akt and p70 S6K (Figure 7A,B), which are actually reported 
substrates of PP2A-B’β, B’γ and B’δ isoforms (42,45,71,72,73,74). On the other hand, ERK 
phosphorylation could be negatively regulated by PP2A-STRN through 
inactivation/dephosphorylation of Mst kinases (75,76,77,78), and this might explain the 
observed decrease in ERK phosphorylation (Figure 7C), but not the increase in cancer cell 
growth. Therefore, our data eventually emerged in the hypothesis that the Aα mutants might 
exert their tumorigenic effect through a dominant-negative mechanism: by retaining binding 
to certain B-type subunits, in particular to B’β, B’γ and B’δ, the Aα mutants might form 
substrate trapping complexes with decreased PP2A activity that are capable to compete with 
active, WT Aα-containing PP2A-B’β/γ/δ trimers for substrate binding. Indeed, as overall 
PP2Ac binding to the Aα mutants was decreased (Figure 1), these dominant complexes 
might be mutant A-B complexes devoid of C subunit, or alternatively, as the PP2A inhibitor 
TIPRL1 showed marked gain-of-binding to all Aα mutants (Figure 5A,D), these dominant 
complexes might be mutant A-B-C holoenzymes with catalytically impaired C subunit through 
increased recruitment of TIPRL1. 
 
To experimentally test whether B-type subunits can form A-B complexes without C, we first 
expressed an HA-tagged Aα deletion mutant (Aα aa1-410), lacking the PP2Ac binding domain 
(HEAT-repeats 11 to 15) in HEK293 cells, and determined its binding to several GST-tagged 
Btype subunits (B, B’ and B”) and GFP-tagged STRN3 (B”’) (Figure 8). While anti-PP2Ac 
immunoblots of HA pull downs confirmed that Aα aa1-410 does indeed no longer bind PP2Ac 
(Figure 8A), GST pull down and GFP trapping experiments show that only B’γ1, B’δ, PR72 
and STRN3 retain significant binding to Aα aa1-410, while Bα, Bβ, B’α and B’ε do not (Figure 
8B,C). These findings further contribute to the notion that remarkable differences exist 
between different B-type subunits and subunit isoforms in their binding behavior to the A 
subunit, and that specific B-type subunits may indeed form A-B complexes without C. 
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Figure 8: Select B-type subunits can bind A independently of A–C interaction. 
Multiple GST-tagged representatives from the B, B’ and B” subunit families, or GFP-tagged STRN3 
(B”’) were co-transfected in HEK293 cells with the Aα deletion mutant containing HEAT repeats 1-10 
(amino acids 1-410) and thus lacking the PP2Ac binding domain. A. Lack of PP2Ac binding to A aa1-
410. The presence of PP2Ac in HA pull downs from HEK293 cells expressing HA-tagged A aa1-410 
was determined by immunoblotting (IB). B. Binding characteristics of several PP2A B-type subunits to 
HA-tagged A aa1-410. Upon GST pull down (left) or GFP trapping (right), interaction with the A 
deletion mutant was examined by immunoblotting (IB) with anti-HA antibody. C. After quantification 
of the band intensities with Image J, ratios were determined between the GST/GFP and HA signals 
and calculated relative to Aα WT control (set to 100% for each B-type subunit pull down). Mean 
values of two independent experiments are shown. 
 
To further substantiate these findings in isolated mutant A-B complexes, we performed serial 
pull downs (“IP-on-IP”) on GFP-TEV-B’δ and several HA-tagged Aα mutants, and compared 
their ability to bind C subunit with the WT A-B’δ complex (Figure 9). Apparently, all mutant 
Aα-B’δ tested (R183G, R183Q and S256F) still bound PP2Ac in comparable amounts as WT 
Aα-B’δ (Figure 9A, left, ratio C/HA). When the same experiment was repeated in the 
presence of ectopically expressed TIPRL1, relatively more PP2Ac was retrieved in the mutant 
Aα-B’δ complexes than in WT Aα-B’δ (Figure 9A, right). Moreover, TIPRL1 itself was also 
present in the trimeric complexes (Figure 9A). Interestingly, when phosphatase activities in 
the retrieved complexes was measured, specific PP2Ac activity was found to be decreased in 
the mutant Aα-B’δ-C complexes when TIPRL1 was co-expressed with GFP-TEV-B’δ and HA-
Aα (Figure 9B). 
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Figure 9: Biochemical characterization of mutant A-B’ complexes. 
EGFP-TEV-B’ was co-expressed with HA-tagged WT or mutant A, with or without GST-tagged 
TIPRL1. A. Following serial pull down (“IP-on-IP”, details in materials and methods), the presence of 
PP2Ac and TIPRL1 in the A-B’ complexes was analyzed by immunoblotting (IB) with PP2Ac or 
TIPRL1 antibodies. After quantification of the band intensities with Image J, the ratios between C and 
HA signals were determined and calculated relative to Aα WT (set to 100%). B. PP2A activity 
measurements in isolated A-B’ complexes (IP-on-IP). For activity measurements, the pmole number 
of released phosphate from the R-R-A-pT-V-A phosphopeptide (750µM in assay) was determined by 
Malachite Green assay. For calculation of specific PP2A activities, each activity measurement was 
corrected for the amount of C present in the isolated complexes, determined via immunoblotting (IB) 
and quantified by ImageJ. All specific activities were eventually recalculated relative to Aα WT (set to 
100%). 
 
To provide further insights into the inhibitory effects of TIPRL1 on different PP2A complexes, 
we purified recombinant TIPRL1 from bacteria (Figure 10A), and assayed its effect on 
isolated PP2A complexes of different composition in vitro. We observed the strongest 
inhibitory effect on the isolated PP2A core dimer (Figure 10B), while, at the same 
concentration, TIPRL1 failed to show any discernable inhibitory effects on isolated B’γ1- and 
B’δ-containing PP2A trimers (Figure 10C). Remarkably, however, when the same trimers, 
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now harboring a mutant Aα protein (R183Q or R183G) instead of WT Aα were assayed in the 
presence of TIPRL1, a clear inhibition of PP2A activity could be observed (Figure 10D,E). 
Thus, our data reveal that Aα mutation, through increased affinity for the PP2A inhibitor 
TIPRL1, suppresses phosphatase activity of specific PP2A trimers. These catalytically 
impaired trimers that, despite Aα mutation, can still be assembled and that are characterized 
by the presence of a specific B-type subunit, may subsequently interfere with normal 
dephosphorylation by WT Aα-containing trimers, harboring the same B-type subunit, through 
a competition mechanism for binding to B-type subunit targeted substrates. This clearly 
explains their ability to increase cancer cell growth and oncogenic signaling upon their 
ectopic expression in HEC-1-A cells harboring two WT PPP2R1A alleles, and underscores their 
contribution to endometrial cancer development by a dominant-negative mechanism-of-
action. 
 
 
Figure 10: Effects of recombinant TIPRL1 on different PP2A complexes 
A. Coomassie Brilliant Blue (CBB) stained SDS-PAGE gel of His-TIPRL1, purified from E. coli.               
B. TIPRL1 efficiently inhibits the PP2A core dimer. De novo purified PP2AD (Millipore) (1/80 in 20μl 
enzyme dilution buffer) was pre-incubated for 15’ at 30°C with 20μl enzyme dilution buffer alone, or 
with 0.5 μg or 2 μg recombinant TIPRL1 in 20μl enzyme dilution buffer. PP2A activity was determined 
on R-R-A-pT-V-A phosphopeptide, and calculated relative to the condition without addition of TIPRL1 
(set at 100%). C. Same experiment as in panel B, but instead of PP2A dimer, PP2A-B56γ1 and PP2A-
B56δ trimers, isolated from GFP-B56γ1 and GFP-B56δ expressing HEK293 cells by GFP-trapping, were 
used. D-E. Same experiment as in panel B with PP2A-B56δ trimers harboring HA-tagged WT or 
mutant Aα, isolated by ‘IP-on-IP’ approach from GFP-TEV-B56δ expressing HEK293 cells (D.), or with 
PP2A-B56γ1 trimers harboring HA-tagged WT or mutant Aα, isolated by ‘IP-on-IP’ from HEK293 cells 
expressing GFP-TEVB56γ1 (E.). 
 
 
 117 
 
DISCUSSION 
 
Heterozygous missense mutation of PPP2R1A appears to be a recurrent event in human 
cancer. There is a prevailing view that PPP2R1A mutations are loss-of-function due to 
impairment of PP2A holoenzyme formation. This can be either due to loss of PP2Ac binding 
and reduced binding to all B-type subunits (R418W) (45,55,63), or to decreased or loss of 
binding to all B’ subunits (E64D/G) (45,55,57,63). This results in haploinsufficieny of Aα, 
primarily affecting holoenzyme formation with B-type subunits which no longer bind to 
mutant Aα and show the least binding affinity for WT Aα, and therefore, lose the competition 
with other B-type subunits to bind with the remaining 50% WT Aα and form PP2A trimers. 
When tested in HEK293 cells, particularly formation of PP2A-B’γ trimers becomes significantly 
impaired under these circumstances, resulting in Akt hyperphosphorylation and increased 
tumor growth (45). However, our current results strongly indicate that this model, which is 
based on the characterization of a few, sporadically occurring Aα mutants, cannot be 
generalized. Indeed, we found that 10 of 11 recurrently occurring endometrial cancer-
associated Aα mutants affect PP2A activity by a completely different mechanism. All these 
heterozygous mutants harbor a single amino acid substitution clustering in HEAT-repeat 5 
(P179L, P179R, R182W, R183G, R183Q, R183W) or HEAT-repeat 7 (R249H, S256F, S256Y, 
W257C, W257G, R258H). Such clustering and the recurrence of these mutations, not only in 
endometrial cancers patients, but sporadically also in patients of other cancer types, 
represent strong genetic evidence for a dominant-negative or gain-of-function mechanism-
of-action, rather than haploinsufficiency. 
 
Our binding assays with ectopically expressed Aα mutants and B-type subunits in HEK293 
cells, as well as with ectopically expressed Aα mutants and endogenous B-type subunits in 
HEC-1-A cells, showed an unexpectedly complicated picture of diverse binding defects to 
10/11 mutants tested. Only Aα mutant R249H largely behaved like WT, and may therefore 
be a nonpathological passenger mutant. Published crystallographic data of different PP2A 
trimers support this view, revealing that the R249 residue is buried inside the protein, while 
all other mutated residues face the B and C subunits (27). All other Aα mutants showed loss 
of binding to B55 subunits (isoforms α and β in HEK293 cells; isoforms α and δ in HEC-1-A 
cells); thus, a single missense mutation in either HR5 or HR7 suffices to severely affect 
binding to probably all isoforms of this PP2A subunit class. For the B56 and B” subunits, a 
completely different picture emerged. In this case, the binding deficiencies were much more 
diverse. Only one subunit, B56δ, still appeared to bind all Aα mutants tested in comparable 
amounts as WT, both in HEK293 and HEC-1-A cells. In contrast, for the B’’’/striatin family 
members, our binding data revealed for the first time a gain-of-binding to Aα mutant 
proteins, demonstrated again in both cell models. Increased binding of the striatins to the Aα 
mutants may in part be an indirect consequence of their generally decreased binding to 
subunits of other subclasses (B55, B56 and B”). STRN3 may also have a stabilizing effect on 
the mutants, because they bind better. 
 
We also found a general decrease in PP2Ac binding to 10/11 Aα mutants. In accordance, Aα 
deletion mutants of HR 5 and 7 were previously reported to show reduced binding to the C 
subunit (21). This highlights a complex relationship between B and C subunits within the 
holoenzyme: not only B subunits may require stabilizing contacts with PP2Ac to bind A and 
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form stable PP2A trimers (22,30,32,33,34), also the reverse can be true, i.e. stable PP2Ac 
binding to A can be dependent on the presence of the B subunit. Therefore, we presume 
that the overall reduced binding of PP2Ac to the Aα mutants, is an indirect consequence of 
the reduced or loss of binding of specific B-type subunits. However, some B-type subunits, in 
particular, B’γ1, B’δ, PR72 and STRN3, can form stable A-B complexes without C, as 
illustrated by their binding to Aα aa1-410, lacking the PP2Ac binding HEAT-repeats 11 to 15. 
This finding is consistent with earlier data, demonstrating that neither B’δ, PR72 or the 
striatins require any contacts with the six carboxyterminal residues of the PP2Ac tail to 
assemble into a PP2A holoenzyme, while all other B’ subunits (α,β, ε isoforms) clearly do (B’γ 
was not tested) (33,35), and with recent structural data on formation of a stable A-B” dimer 
(31). Despite these findings, our subsequent IP-on-IP data with B’δ did not support 
formation of mutant A-B’δ complexes devoid of PP2Ac for any of the Aα mutants tested 
(R183G/Q, S256F). 
 
Instead, an unbiased MS-based approach to identify differences in mutant Aα binding to 
constituents of the broader Aα interactome in HEC-1-A cells, unexpectedly, revealed TIPRL1, 
a previously reported cellular PP2A inhibitor (67), as the only cellular protein that showed 
significant gain-of-binding to all Aα mutants tested (P179R, R182W, R183G, R183Q, S256F). 
Subsequently, we showed that TIPRL1 co-expression or addition of recombinant TIPRL1 in 
vitro, resulted in decreased PP2A activity in isolated mutant Aα-B’δ-C complexes when 
compared with WT Aα-B’δ-C complexes, suggesting that increased TIPRL1 binding could 
result in the formation of catalytically impaired, mutant Aα containing PP2A trimers, which 
might act as dominant-negatives towards WT Aα containing trimers. The dominant-negative 
nature of the mutants was significantly further underscored by increased cell and tumor 
growth, and corresponding increased oncogenic signaling (hyperphosphorylation of p70S6K 
and S6, Akt T308, GSK3β) upon their ectopic expression in HEC-1-A cells, without any prior 
downregulation of endogenous Aα. This definitely argues against a mechanism of 
haploinsuffciency, and virtually eliminates the putative involvement of the observed loss-of-
binding to specific B-type subunits (e.g. to B55 and others) as a major cause of the observed 
phenotype. Expression of R183G, R183Q and S256F resulted in a more severe phenotype 
than expression of P179R and R182W. For the R182W mutant, the number of tumors in the 
mice was higher compared to WT Aα, and especially in the early days after injection, the 
tumors grew faster, although the difference did not reach statistical significance. The soft 
agar assay showed a slight, but statistically non-significant, elevated number of colonies. 
Xenograft assays with P179R expressing HEC-1-A cells resulted in the formation of more 
tumors compared to WT Aα expressing cells, without any discernable difference in size. We 
suspect however, that the minimally increased tumorigenic potential of the P179R mutant 
may in part be due to its poorer expression following lentiviral transduction. The functional 
differences between the mutants were reflected well at the signaling level: 
hyperphosphorylation of p70S6K (and S6), Akt T308 and GSK3β S9 was clearly seen for 
R183G, R183Q and S256F and of GSK3β for R182W and P179R. Hyperactivation of these 
pathways indeed stimulates protein translation, cell growth/proliferation and survival. 
Although all mutants showed increased binding to STRN3, a gain-of-function of PP2A-STRN3 
complexes cannot explain the observed hyperphosphorylation of the above oncogenic 
kinases. Instead, Akt, GSK-3β and p70S6K are reported substrates of PP2A-B’ complexes in 
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several cellular contexts, particularly of B’β, B’γ- and B’δ-containing PP2A trimers 
(42,45,71,72,73,74,79). Accordingly, in HEC-1-A cells, the R183Q mutant, causing the most 
severe tumor phenotype, retains binding to B’γ2, B’γ3 and B’δ, and based on the MS data, 
also to B’β. This mutant also shows the strongest interaction with TIPRL1. For the other 
mutants, a similar reasoning could be applied, whereby the severity of the observed growth 
phenotype may eventually be the combinatory result of (1) the specific kind of B’ subunit 
that still retains binding, (2) the number of B’ subunits that retain binding, (3) the absolute 
strength of the retained binding (or binding affinity) to a specific B’ subunit, and finally, (4) 
the binding efficiency to TIPRL1. Notably, the more B’ subunits retain binding to an Aα 
mutant to form different substrate-trapping complexes, the better potential functional 
redundancies between different trimers for dephosphorylation of a given substrate will be 
avoided, therefore, contributing to a more severe phenotype. This also provides a 
mechanistic explanation for the apparent lack of correlation between the number of B-type 
subunit binding deficiencies of a given Aα mutant and the severity of the growth phenotype 
seen upon its ectopic expression. Rather, the growth phenotypes in our model seem to 
depend on the number of remaining B’ subunit binders, their absolute degree of binding to a 
given Aα mutant, and the gain-of-binding of Aα mutants to TIPRL1. 
 
Although STRN3 gain-of-binding to mutant Aα could not explain hyperphosphorylation of Akt, 
p70S6K or GSK3β in mutant Aα expressing HEC-1-A cells, it remains still possible that this 
gain-of-function mechanism may contribute to the increased oncogenic phenotype of these 
cells. The role of PP2A-striatins within several identified STRIPAK complexes is indeed 
considered to be oncogenic, via dephosphorylation of Mst1/2 and Mst3/4 kinases [76], 
impacting e.g. on regulation of NF-κB (80), Hippo (36,37) and MEK/ERK signaling (75,77,78). 
Also the recently reported role of PP2A-striatins in regulating cancer cell migration and 
invasion (81) remains worthwhile to follow-up in future functional assays with mutant Aα 
expressing HEC-1-A cells, particularly given the known high metastatic potential of serous 
uterine tumors and carcinosarcomas. The observed reduced phosphorylation of ERK in our 
HEC-1-A model, found in all mutant Aα expressing cells, would in any case be consistent with 
a disturbed phosphorylation/dephosphorylation balance within STRIPAK due to enhanced 
STRN3-PP2A function. 
 
It still remains unclear how changes in the broader (mutant) Aα interactome might 
additionally contribute to the observed differences in anchorange-independent or tumor 
growth. Although some of these interaction partners have reported links with cancer 
pathology, e.g. CCDC6, ANKLE2, TMPO, PP4 and liprin α1/2, this awaits future dedicated 
functional studies. Likewise, the so far unexplored function of PP2A as an interaction partner 
of the Integrator complex, a U-rich small nuclear RNAs (UsnRNAs) 3’-end processing factor 
and RNA polymerase II interacting complex (82), remains worthwhile to further follow-up. 
 
In summary, our data provide biochemical and functional evidence that cancer-associated Aα 
mutants trigger cancer cell growth of serous uterine carcinoma through a novel dominant 
negative mechanism dependent on retained binding to tumor suppressive B’ subunits, such 
as B’β, B’γ and B’δ, and gain-of-binding to the TIPRL1 inhibitor. Although the biochemistry of 
 120 
 
TIPRL1 remains largely unexplored, it has been hypothesized that TIPRL1 might play a role 
in PP2A biogenesis as one of the proteins that controls the activity of the newly translated 
PP2Ac, or alternatively, that it might play a role in PP2Ac inhibition after PP2A holoenzyme 
disassembly following cellular stresses, such as DNA damage (83). Our current data may 
support a role of TIPRL1 in the biogenesis of active PP2A trimers through an interaction with 
Aα. Notably, overexpression of TIPRL1 was reported to result in hyperphosphorylation of 
p70S6K and 4E-BP (84), consistent with our data in HEC-1-A cells, ectopically expressing Aα 
mutants with TIPRL1 gain-of-binding. In addition, cBioportal data indicate TIPRL 
overexpression at moderate frequency, and TIPRL mutation at low frequency, in several 
human cancer types (58,59). This all supports a novel pathological role of TIPRL1 in the 
biology of PPP2R1A mutated endometrial cancers, and identifies TIPRL1 as a novel 
therapeutic anti-cancer target in these hard-to-treat tumors. In this respect, our functional 
data also clearly highlight the therapeutic potential of treating PPP2R1A mutant tumor cells 
with kinase inhibitors directed against components of the Akt and mTOR/p70S6K signaling 
pathways, either as monotherapies, or in combination. Our observations predict a good 
therapeutic efficiency for Akt/mTOR inhibitors and might suggest stratification of patients 
based on mutant or WT Aα status of the tumor. This opens interesting perspectives for the 
use of PPP2R1A as a therapeutic biomarker, and improved clinical management of these 
tumors. 
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Table S1: Overview of PPP2R1A mutations found in gynaecological cancers 
Endometrial Ovarian 
Endometrioid Serous Carcinosarcoma Undifferentiated Endometrioid Serous Clear-cell 
ref. 1       7.1%(3/42) 
 
R183G (1) 
R183W (1) 
R182W (1) 
ref. 2 5% (3/60) 
 
R183Q (2) 
R249H (1) 
40.8% (20/49) 
 
P179R (6) 
P179L (3) 
R182W (1) 
R183W (2) 
S256F (6) 
S256Y (1) 
W257G (1) 
  12.2% (5/41) 
 
P179R (1) 
R183W (2) 
S256Y (1) 
W257G (1) 
0% (0/62) 4.1% (2/49) 
 
R183W (1) 
W257C (1) 
R258C (1) 
ref. 3 6.7% (2/30) 
 
R183W (1) 
R182W (1) 
19.2% (5/26) 
 
S256Y (1) 
P179R (1) 
S256F (2) 
W257G (1) 
  10% (4/40) 
 
R183W (2) 
R183Q (1) 
R182W (1) 
0% (0/91) 9.1% (4/44) 
 
R183W (3) 
R183Q (1) 
ref. 4 6.9% (19/276) 
Low-grade 
 
R183Q (4) 
R183W (4) 
H87Y (2) 
R249H (1) 
R48Q (1) 
S256F (1) 
P179L (1) 
S219L (1) 
Q237R (1) 
S219L (1) 
VE99del (1) 
182insV (1) 
 
10% (3/30) 
High-grade 
 
R182W (1) 
R221W (1) 
R183W (1) 
43.2% (16/37) 
 
 
P179R (8) 
S256F (4) 
T102K (1) 
R183W (1) 
P179L (1) 
V182M (1) 
21.4% (9/42) 
 
 
P179R (4) 
S256F (2) 
V229M (1) 
W257C (1) 
N312H (1) 
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Table S1: continued 
Endometrial Ovarian 
Endometrioid Serous Carcinosarcoma Undifferentiated Endometrioid Serous Clear-cell 
ref. 5 2.5% (3/118) 
 
W257C (1) 
E216K (1) 
R258Y (1) 
32% (8/25) 
 
R258H (1) 
P179R (3) 
R258Y (1) 
P179L (2) 
W257C (1) 
     
ref. 6  18.4% (14/76) 
 
P179R (7) 
R183W (3)  
S256Y (1) 
W257G (1) 
S256F (1) 
W257C (1) 
 
     
ref. 7  20% (6/30) 
 
P179R (4) 
S256F (2) 
     
ref. 8     6.6% (1/15) 
High-grade 
 
P179R (1) 
4.5% (1/22) 
 
 
R183W (1) 
4.5% (1/22) 
 
 
R183Q (1) 
ref. 9     2.7% (1/37) 
 
W257C (1) 
0% (0/76)  0% (0/43)  
ref. 10  25% (13/52) 
 
P179R (5) 
S256F (3) 
W257S (1) 
W257C (3) 
L286P (1) 
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Table S1: continued 
Endometrial Ovarian 
Endometrioid Serous Carcinosarcoma Undifferentiated Endometrioid Serous Clear-cell 
ref. 11 4.5% (14/307) 
 
S256F (1) 
R183W (2) 
R258C (1) 
R258H (1) 
R221W (1) 
L173M (1) 
A41T (1) 
A164V (1) 
R105Q (1) 
R28C (2) 
A114V (1) 
R144C (1) 
V298L (1) 
A136T (1) 
Q237R (1) 
27.9% (12/43) 
 
S256F (2) 
P179R (7) 
S256Y (1) 
L_27splice (1) 
V220M (1) 
     
ref. 12,13   26.8% (15/56) 
 
P179R (4) 
S219L (2) 
R183W (2) 
Q217K (1) 
P179L (1) 
S146L (1) 
R48Q (1) 
R183Q (1) 
S256F (1) 
S256Y (1) 
E413K (1) 
Q288H (1) 
    
ref. 14    20% (4/20) 
 
R183W (1) 
R182W (1) 
A252V (1) 
22984C>T (1) 
   
 
 
 
 128 
 
References: 
1. Jones S, Wang TL, Shih IeM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330:228–231. 
2. McConechy MK, Anglesio MS, Kalloger SE, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol 2011; 223:567–
573. 
3. Shih IeM, Panuganti PK, Kuo KT, et al. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol 2011; 178:1442–1447. 
4. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 2012; 228:20–30. 
5. Nagendra DC, Burke J 3rd, Maxwell GL, Risinger JI. PPP2R1A mutations are common in the serous type of endometrial cancer. Mol Carcinog 2012; 51:826–
831. 
6. Kuhn E, Wu RC, Guan B, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 
2012; 104:1503–1513. 
7. Zhao S, Choi M, Overton JD, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S 
A 2013; 110:2916–2921. 
8. Rahman M, Nakayama K, Rahman MT, et al. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes. Anticancer Res 2013; 
33:113–118. 
9. Wang F, Zou Y, Liu FY, et al. Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer. Mol Med Rep 2013; 7:1826–1830. 
10. Le Gallo M, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling 
and ubiquitin ligase complex genes. Nat Genet 2012; 44:1310–1315. 
11. The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497:67–73. 
12. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer 
Discov 2012; 2:401–404. 
13. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6(269):pl1. 
DOI: 10.1126/scisignal.2004088. 
14. Kuhn E, Ayhan A, Bahadirli-Talbott A, Zhao C, Shih IeM. Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma. 
Am J Surg Pathol 2014; 38:660–665.
 129 
 
Table S2: oligonucleotides used for site-directed mutagenesis 
Primers Aα mutations 
 
P179R Forward 5’- GCTCAGATGACACCCGCATGGTGCGGCGGGC -3’ 
P179R Reverse 5’- GCCCGCCGCACCATGCGGGTGTCATCTGAGC -3’ 
R182W Forward 5’- ACCCCCATGGTGTGGCGGGCCGCA -3’ 
R182W Reverse 5’- TGCGGCCCGCCACACCATGGGGGT -3’ 
R183G Forward 5’- CCCATGGTGCGGGGGGCCGCAGCC -3’ 
R183G Reverse 5’- GGCTGCGGCCCCCCGCACCATGGG -3’ 
R183W Forward 5’- ACCCCCATGGTGCGGTGGGCCGCAGCCTCCA -3’ 
R183W Reverse 5’- TGGAGGCTGCGGCCCACCGCACCATGGGGGT -3’ 
R183Q Forward 5’- CCCCCATGGTGCGGCAGGCCGCAGCCTCCAA -3’ 
R183Q Reverse 5’- TTGGAGGCTGCGGCCTGCCGCACCATGGGGG -3’ 
R249H Forward 5’- TGATGCCCACTCTGCACCAGGCCGCTGAAGA -3’ 
R249H Reverse 5’- TCTTCAGCGGCCTGGTGCAGAGTGGGCATCA -3’ 
S256F Forward 5’- CCGCTGAAGACAAGTTCTGGCGCGTCCGCTA -3’ 
S256F Reverse 5’- TAGCGGACGCGCCAGAACTTGTCTTCAGCGG -3’ 
S256Y Forward 5’- CCGCTGAAGACAAGTACTGGCGCGTCCGCTA -3’ 
S256Y Reverse 5’- TAGCGGACGCGCCAGTACTTGTCTTCAGCGG -3’ 
W257C Forward 5’- TGAAGACAAGTCCTGTCGCGTCCGCTACATG -3’ 
W257C Reverse 5’- CATGTAGCGGACGCGACAGGACTTGTCTTCA -3’ 
W257G Forward 5’- GCTGAAGACAAGTCCGGGCGCGTCCGCTACA -3’ 
W257G Reverse 5’- TGTAGCGGACGCGCCCGGACTTGTCTTCAGC -3’ 
R258H Forward 5’- AAGACAAGTCCTGGCACGTCCGCTACATGGT -3’ 
R258H Reverse 5’- ACCATGTAGCGGACGTGCCAGGACTTGTCTT -3’ 
R418W Forward 5’- GACGCCAAGTGGTGGGTGCGGCTGG -3’ 
R418W Reverse 5’- CCAGCCGCACCCACCACTTGGCGTC -3’ 
L/A410stop forward 5’- GTTCCAGATTACGCTTCTAGAATGGCGGCGGCCGA 
CGGCGACG -3’ 
L/A410stop reverse 5’- TATCTTATCATGTCTGGATCCTCACAGCTCCACAATG 
GCAGGGAGC -3’ 
 
 
 
 
 
 
 
 
 
 
S3: Excel spreadsheet, with raw and processed data from MS Orbitrap experiments 
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Normalized abundance 
    
Ratios mutant as to WT       Ratios normalized for PPP2R1A input    
 
WTAalfa P179R R182W R183Q R183G S256F WTAalfa P179R R182W R183Q R183G S256F WTAalfa P179R R182W R183Q R183G S256F 
SSR4 2,94E+05 2,61E+05 1,23E+06 2,48E+05 1,76E+05 3,99E+05 1,0 0,9 4,2 0,8 0,6 1,4 1,00 1,76 2,20 0,21 0,54 0,62 
CNIH4 1,85E+05 1,00E+05 9,83E+05 1,23E+05 1,07E+05 2,63E+05 1,0 0,5 5,3 0,7 0,6 1,4 1,00 1,08 2,80 0,16 0,52 0,65 
INT9 5,04E+05 2,43E+05 1,54E+05 4,74E+05 5,72E+05 3,49E+05 1,0 0,5 0,3 0,9 1,1 0,7 1,00 0,96 0,16 0,23 1,03 0,32 
STK24 2,55E+05 2,24E+05 2,88E+05 2,82E+05 3,04E+05 2,74E+05 1,0 0,9 1,1 1,1 1,2 1,1 1,00 1,75 0,59 0,27 1,08 0,49 
CNN2 1,75E+05 2,65E+05 3,55E+05 1,38E+05 1,36E+05 4,00E+05 1,0 1,5 2,0 0,8 0,8 2,3 1,00 3,00 1,06 0,19 0,70 1,04 
TFRC 2,81E+05 2,05E+05 1,91E+05 6,26E+04 1,20E+05 2,26E+05 1,0 0,7 0,7 0,2 0,4 0,8 1,00 1,45 0,36 0,05 0,38 0,37 
PPIA 3,01E+05 7,67E+04 1,06E+05 8,66E+04 8,74E+04 3,22E+05 1,0 0,3 0,4 0,3 0,3 1,1 1,00 0,51 0,19 0,07 0,26 0,49 
S100A11 4,31E+05 9,77E+05 4,65E+05 2,14E+05 2,63E+05 5,93E+05 1,0 2,3 1,1 0,5 0,6 1,4 1,00 4,52 0,57 0,12 0,55 0,63 
MYO1C 1,82E+05 2,13E+05 1,66E+06 3,51E+05 3,28E+05 8,24E+05 1,0 1,2 9,1 1,9 1,8 4,5 1,00 2,33 4,79 0,47 1,62 2,06 
OMA1 1,92E+04 3,42E+04 1,12E+06 5,29E+04 2,89E+04 4,52E+04 1,0 1,8 58,3 2,8 1,5 2,4 1,00 3,55 30,70 0,68 1,36 1,07 
TIPRL 5,84E+04 7,34E+04 2,76E+05 1,63E+06 2,44E+05 2,08E+05 1,0 1,3 4,7 27,9 4,2 3,6 1,00 2,51 2,49 6,86 3,77 1,62 
SLC27A2 1,44E+05 2,11E+05 8,13E+05 1,62E+05 1,25E+05 1,91E+05 1,0 1,5 5,6 1,1 0,9 1,3 1,00 2,91 2,96 0,28 0,78 0,60 
PREB 7,52E+04 3,34E+03 4,13E+03 2,52E+05 3,35E+04 6,61E+03 1,0 0,0 0,1 3,4 0,4 0,1 1,00 0,09 0,03 0,82 0,40 0,04 
DDOST 7,97E+04 4,86E+04 1,79E+05 3,30E+04 1,58E+04 1,37E+05 1,0 0,6 2,3 0,4 0,2 1,7 1,00 1,21 1,18 0,10 0,18 0,78 
POR 2,10E+04 1,27E+04 2,58E+04 1,86E+04 1,10E+03 4,44E+04 1,0 0,6 1,2 0,9 0,1 2,1 1,00 1,21 0,65 0,22 0,05 0,97 
OSBPL8 3,68E+04 1,38E+04 6,14E+04 1,07E+05 3,18E+04 6,52E+03 1,0 0,4 1,7 2,9 0,9 0,2 1,00 0,75 0,88 0,72 0,78 0,08 
HSD17B10 8,34E+04 8,40E+04 5,12E+04 4,24E+04 1,65E+04 8,99E+04 1,0 1,0 0,6 0,5 0,2 1,1 1,00 2,00 0,32 0,12 0,18 0,49 
TMEM205 8,99E+04 5,76E+04 8,55E+04 3,87E+04 1,82E+04 1,47E+05 1,0 0,6 1,0 0,4 0,2 1,6 1,00 1,28 0,50 0,11 0,18 0,74 
LACTB 3,60E+05 1,04E+05 7,75E+04 4,98E+04 5,20E+04 1,30E+05 1,0 0,3 0,2 0,1 0,1 0,4 1,00 0,58 0,11 0,03 0,13 0,17 
TMX3 7,11E+04 6,56E+04 3,66E+05 0,00E+00 1,45E+04 8,04E+04 1,0 0,9 5,1 0,0 0,2 1,1 1,00 1,84 2,71 0,00 0,18 0,52 
RAB10 1,56E+03 2,75E+03 0,00E+00 0,00E+00 1,26E+03 1,07E+05 1,0 1,8 0,0 0,0 0,8 68,3 1,00 3,51 0,00 0,00 0,73 31,17 
HADHB 2,12E+04 2,94E+04 2,60E+04 9,77E+03 6,60E+03 5,27E+04 1,0 1,4 1,2 0,5 0,3 2,5 1,00 2,75 0,64 0,11 0,28 1,13 
PPP2R5B 9,67E+04 1,00E-01 1,96E+03 0,00E+00 7,02E+01 1,35E+04 1,0 0,0 0,0 0,0 0,0 0,1 1,00 0,00 0,01 0,00 0,00 0,06 
DHX15 1,00E+00 4,48E+02 6,33E+02 0,00E+00 0,00E+00 5,46E+04 1,0 447,7 632,7 0,0 0,0 54561,3 1,00 891,24 332,90 0,00 0,00 24899,10 
KPNA4 8,27E+04 1,15E+04 3,58E+04 1,31E+04 4,90E+03 2,45E+04 1,0 0,1 0,4 0,2 0,1 0,3 1,00 0,28 0,23 0,04 0,05 0,14 
SLC3A2  4,00E+03 1,87E+03 1,12E+05 2,43E+03 2,93E+03 1,12E+04 1,0 0,5 28,1 0,6 0,7 2,8 1,00 0,93 14,79 0,15 0,66 1,28 
DHRS7B 2,49E+04 1,38E+04 1,28E+05 5,80E+03 3,37E+03 2,31E+04 1,0 0,6 5,1 0,2 0,1 0,9 1,00 1,11 2,69 0,06 0,12 0,42 
ATP5O 1,45E+04 3,64E+04 3,62E+04 0,00E+00 3,46E+03 0,00E+00 1,0 2,5 2,5 0,0 0,2 0,0 1,00 4,98 1,31 0,00 0,21 0,00 
RHOF 3,00E+03 4,37E+03 1,60E+05 0,00E+00 5,98E+03 5,11E+03 1,0 1,5 53,3 0,0 2,0 1,7 1,00 2,90 28,03 0,00 1,80 0,78 
CAPN1 9,51E+03 3,67E+02 5,56E+02 2,04E+02 2,31E+02 8,26E+04 1,0 0,0 0,1 0,0 0,0 8,7 1,00 0,08 0,03 0,01 0,02 3,96 
PIGS 2,90E+03 6,84E+03 8,04E+04 1,85E+03 2,74E+02 0,00E+00 1,0 2,4 27,8 0,6 0,1 0,0 1,00 4,70 14,61 0,16 0,09 0,00 
ALDH18A1 3,99E+04 2,43E+04 2,72E+04 1,24E+04 8,34E+03 5,56E+04 1,0 0,6 0,7 0,3 0,2 1,4 1,00 1,21 0,36 0,08 0,19 0,64 
PPFIBP1 1,17E+05 8,61E+03 6,40E+04 0,00E+00 4,72E+03 5,95E+04 1,0 0,1 0,5 0,0 0,0 0,5 1,00 0,15 0,29 0,00 0,04 0,23 
PA2G4 6,36E+04 5,49E+04 5,79E+04 2,80E+04 1,75E+04 1,34E+05 1,0 0,9 0,9 0,4 0,3 2,1 1,00 1,72 0,48 0,11 0,25 0,96 
OPA1 2,51E+04 3,14E+03 2,13E+04 3,24E+03 1,37E+04 4,42E+04 1,0 0,1 0,8 0,1 0,5 1,8 1,00 0,25 0,45 0,03 0,49 0,80 
SHMT2 9,95E+04 1,19E+05 9,00E+04 4,06E+04 3,94E+04 1,52E+05 1,0 1,2 0,9 0,4 0,4 1,5 1,00 2,39 0,48 0,10 0,36 0,70 
S100A6 3,10E+05 1,02E+05 1,54E+05 7,30E+04 7,67E+04 3,08E+05 1,0 0,3 0,5 0,2 0,2 1,0 1,00 0,66 0,26 0,06 0,22 0,45 
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Normalized abundance 
    
Ratios mutant as to WT       Ratios normalized for PPP2R1A input    
 
WTAalfa P179R R182W R183Q R183G S256F WTAalfa P179R R182W R183Q R183G S256F WTAalfa P179R R182W R183Q R183G S256F 
PDCD10 1,78E+05 1,17E+05 1,22E+05 1,08E+05 1,44E+05 1,15E+05 1,0 0,7 0,7 0,6 0,8 0,7 1,00 1,31 0,36 0,15 0,73 0,30 
GRSF1 8,80E+04 2,10E+05 1,06E+05 4,30E+04 7,86E+04 8,24E+04 1,0 2,4 1,2 0,5 0,9 0,9 1,00 4,76 0,63 0,12 0,81 0,43 
AIML1L 5,32E+05 3,38E+04 3,97E+04 5,80E+04 2,62E+04 1,81E+05 1,0 0,1 0,1 0,1 0,0 0,3 1,00 0,13 0,04 0,03 0,04 0,16 
HSD17B11 9,94E+04 5,79E+04 3,32E+05 6,56E+04 5,23E+04 1,35E+05 1,0 0,6 3,3 0,7 0,5 1,4 1,00 1,16 1,76 0,16 0,47 0,62 
BSG 4,62E+04 5,14E+04 1,86E+05 2,89E+05 4,41E+04 2,40E+05 1,0 1,1 4,0 6,3 1,0 5,2 1,00 2,21 2,11 1,54 0,86 2,37 
RHBDD2 2,28E+03 1,82E+04 5,18E+05 2,79E+03 1,56E+04 0,00E+00 1,0 8,0 227,4 1,2 6,8 0,0 1,00 15,94 119,63 0,30 6,17 0,00 
SSR1 9,97E+04 1,12E+05 6,49E+05 8,89E+04 1,91E+04 6,39E+04 1,0 1,1 6,5 0,9 0,2 0,6 1,00 2,24 3,42 0,22 0,17 0,29 
QPCTL 1,75E+04 4,60E+04 2,84E+05 4,24E+04 4,02E+04 4,51E+04 1,0 2,6 16,2 2,4 2,3 2,6 1,00 5,23 8,53 0,59 2,07 1,18 
INTS3 1,27E+05 1,99E+05 1,57E+04 2,37E+04 2,20E+05 3,86E+04 1,0 1,6 0,1 0,2 1,7 0,3 1,00 3,11 0,06 0,05 1,56 0,14 
FGFR1OP 2,84E+05 5,07E+04 6,33E+04 1,78E+05 9,93E+04 2,56E+05 1,0 0,2 0,2 0,6 0,4 0,9 1,00 0,36 0,12 0,15 0,32 0,41 
INTS4 1,40E+06 1,00E+06 5,52E+05 1,41E+06 1,99E+06 8,24E+05 1,0 0,7 0,4 1,0 1,4 0,6 1,00 1,42 0,21 0,25 1,28 0,27 
PPP2R5E 1,03E+07 2,54E+05 7,67E+05 2,07E+05 2,02E+05 3,13E+06 1,0 0,0 0,1 0,0 0,0 0,3 1,00 0,05 0,04 0,00 0,02 0,14 
SLC25A5 8,03E+05 6,94E+05 2,89E+06 5,86E+05 4,78E+05 9,41E+05 1,0 0,9 3,6 0,7 0,6 1,2 1,00 1,72 1,89 0,18 0,54 0,53 
INTS6 1,23E+06 7,76E+05 3,12E+05 1,80E+06 2,04E+06 7,46E+05 1,0 0,6 0,3 1,5 1,7 0,6 1,00 1,26 0,13 0,36 1,49 0,28 
PPP2R2D 1,25E+06 1,27E+04 3,61E+04 5,36E+04 1,39E+04 6,53E+04 1,0 0,0 0,0 0,0 0,0 0,1 1,00 0,02 0,02 0,01 0,01 0,02 
PPP2R5A 5,27E+06 8,00E+04 1,31E+05 1,22E+05 8,38E+04 5,35E+05 1,0 0,0 0,0 0,0 0,0 0,1 1,00 0,03 0,01 0,01 0,01 0,05 
RPN2 1,80E+06 1,72E+06 3,53E+06 7,32E+05 6,52E+05 2,45E+06 1,0 1,0 2,0 0,4 0,4 1,4 1,00 1,90 1,03 0,10 0,33 0,62 
IDH3B 4,88E+05 5,83E+05 9,85E+06 4,68E+05 2,04E+06 9,41E+05 1,0 1,2 20,2 1,0 4,2 1,9 1,00 2,38 10,61 0,24 3,77 0,88 
STRN3 4,55E+06 3,36E+06 9,52E+06 9,80E+06 8,36E+06 8,02E+06 1,0 0,7 2,1 2,2 1,8 1,8 1,00 1,47 1,10 0,53 1,66 0,80 
ATP1A1 6,57E+05 4,86E+05 2,43E+06 5,08E+05 3,36E+05 9,07E+05 1,0 0,7 3,7 0,8 0,5 1,4 1,00 1,47 1,94 0,19 0,46 0,63 
SLC25A6 2,24E+05 2,59E+05 1,56E+06 1,58E+05 1,64E+05 2,58E+05 1,0 1,2 7,0 0,7 0,7 1,2 1,00 2,30 3,67 0,17 0,66 0,53 
ALDH3A2 1,84E+05 2,00E+05 1,11E+07 2,32E+05 1,66E+05 1,23E+06 1,0 1,1 60,5 1,3 0,9 6,7 1,00 2,16 31,81 0,31 0,81 3,05 
SLC25A3 3,86E+05 3,09E+05 1,94E+06 3,80E+05 2,14E+05 3,16E+05 1,0 0,8 5,0 1,0 0,6 0,8 1,00 1,59 2,65 0,24 0,50 0,37 
PPFIA1/2 7,05E+06 5,01E+05 4,51E+06 4,10E+06 1,15E+06 6,15E+06 1,0 0,1 0,6 0,6 0,2 0,9 1,00 0,14 0,34 0,14 0,15 0,40 
MYH9 8,22E+06 7,80E+06 3,43E+06 1,07E+06 6,41E+06 2,29E+06 1,0 0,9 0,4 0,1 0,8 0,3 1,00 1,89 0,22 0,03 0,70 0,13 
PPP2R5D 4,46E+07 7,87E+06 2,30E+07 4,70E+07 1,39E+07 2,49E+07 1,0 0,2 0,5 1,1 0,3 0,6 1,00 0,35 0,27 0,26 0,28 0,26 
PPP4R1 2,55E+06 3,01E+06 6,78E+05 1,50E+06 1,18E+06 2,48E+07 1,0 1,2 0,3 0,6 0,5 9,7 1,00 2,36 0,14 0,14 0,42 4,45 
PPP2R2A/B 3,47E+07 3,37E+05 2,94E+05 3,21E+05 3,08E+05 5,30E+05 1,0 0,0 0,0 0,0 0,0 0,0 1,00 0,02 0,00 0,00 0,01 0,01 
PPP2R1A 3,21E+09 1,60E+09 6,06E+09 1,33E+10 3,53E+09 7,10E+09 1,0 0,5 1,9 4,1 1,1 2,2 1,00 0,99 0,99 1,02 0,99 1,01 
STRN 1,70E+07 1,27E+07 2,87E+07 3,25E+07 2,89E+07 2,82E+07 1,0 0,7 1,7 1,9 1,7 1,7 1,00 1,48 0,89 0,47 1,53 0,75 
CCDC6 1,80E+07 2,13E+07 7,16E+06 1,67E+07 1,16E+07 1,20E+08 1,0 1,2 0,4 0,9 0,6 6,6 1,00 2,36 0,21 0,23 0,58 3,03 
STRIP1/2 3,73E+06 4,01E+06 8,67E+06 7,62E+06 7,37E+06 5,75E+06 1,0 1,1 2,3 2,0 2,0 1,5 1,00 2,14 1,22 0,50 1,78 0,70 
SLMAP 7,58E+06 6,83E+06 1,51E+07 1,37E+07 1,40E+07 1,22E+07 1,0 0,9 2,0 1,8 1,8 1,6 1,00 1,79 1,05 0,44 1,67 0,73 
ANKLE2 1,97E+06 1,44E+06 1,20E+06 1,08E+06 2,27E+07 1,44E+06 1,0 0,7 0,6 0,6 11,5 0,7 1,00 1,45 0,32 0,14 10,42 0,33 
STRN4 6,12E+06 4,85E+06 1,19E+07 1,25E+07 1,00E+07 9,37E+06 1,0 0,8 1,9 2,0 1,6 1,5 1,00 1,58 1,02 0,50 1,48 0,70 
FECH 1,58E+07 5,54E+05 3,09E+06 4,92E+07 2,87E+07 3,37E+07 1,0 0,0 0,2 3,1 1,8 2,1 1,00 0,07 0,10 0,76 1,64 0,98 
PPP2CA 1,40E+05 8,86E+03 5,69E+04 7,82E+05 2,82E+04 2,05E+06 1,0 0,1 0,4 5,6 0,2 14,6 1,00 0,13 0,21 1,37 0,18 6,68 
INTS1 2,24E+06 1,66E+06 7,96E+05 2,52E+06 3,80E+06 1,20E+06 1,0 0,7 0,4 1,1 1,7 0,5 1,00 1,47 0,19 0,28 1,53 0,24 
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Normalized abundance 
    
Ratios mutant as to WT       Ratios normalized for PPP2R1A input    
 
WTAalfa P179R R182W R183Q R183G S256F WTAalfa P179R R182W R183Q R183G S256F WTAalfa P179R R182W R183Q R183G S256F 
PPP2CB 3,49E+06 1,56E+06 1,46E+06 4,10E+06 2,12E+06 4,79E+06 1,0 0,4 0,4 1,2 0,6 1,4 1,00 0,89 0,22 0,29 0,55 0,63 
PPP2R5C 1,06E+07 2,96E+05 1,91E+06 2,81E+06 8,71E+05 2,60E+06 1,0 0,0 0,2 0,3 0,1 0,2 1,00 0,06 0,09 0,06 0,07 0,11 
PPP4C 3,43E+05 1,91E+05 1,78E+04 2,50E+05 6,95E+04 2,70E+06 1,0 0,6 0,1 0,7 0,2 7,9 1,00 1,11 0,03 0,18 0,18 3,59 
TMEM43 4,67E+05 3,06E+05 1,92E+06 5,37E+05 6,15E+05 8,52E+05 1,0 0,7 4,1 1,2 1,3 1,8 1,00 1,30 2,17 0,28 1,19 0,83 
MOB4 3,19E+06 2,36E+06 6,32E+06 8,57E+06 6,50E+06 4,69E+06 1,0 0,7 2,0 2,7 2,0 1,5 1,00 1,48 1,04 0,66 1,84 0,67 
FKBP8 3,25E+05 1,94E+05 5,45E+05 1,63E+05 1,29E+05 1,43E+05 1,0 0,6 1,7 0,5 0,4 0,4 1,00 1,19 0,88 0,12 0,36 0,20 
CTTNBP2NL 4,67E+05 2,20E+05 6,13E+05 5,62E+05 5,03E+05 5,01E+05 1,0 0,5 1,3 1,2 1,1 1,1 1,00 0,94 0,69 0,30 0,97 0,49 
CCT5 4,68E+05 5,43E+05 9,34E+05 3,53E+05 3,17E+05 6,91E+05 1,0 1,2 2,0 0,8 0,7 1,5 1,00 2,31 1,05 0,18 0,61 0,67 
TMPO 5,25E+05 7,04E+05 8,72E+05 3,70E+05 5,35E+05 4,11E+05 1,0 1,3 1,7 0,7 1,0 0,8 1,00 2,67 0,87 0,17 0,92 0,36 
QSOX2 3,98E+05 2,23E+05 1,56E+06 7,11E+05 1,89E+05 6,47E+05 1,0 0,6 3,9 1,8 0,5 1,6 1,00 1,12 2,06 0,44 0,43 0,74 
NCEH1 2,54E+05 2,99E+05 4,85E+05 2,63E+05 1,76E+05 3,65E+05 1,0 1,2 1,9 1,0 0,7 1,4 1,00 2,35 1,01 0,25 0,63 0,66 
ARF4 1,78E+05 1,35E+05 4,01E+05 9,54E+04 9,95E+04 1,72E+05 1,0 0,8 2,2 0,5 0,6 1,0 1,00 1,50 1,18 0,13 0,50 0,44 
FGFR1OP2 1,82E+06 1,42E+06 3,52E+06 3,66E+06 3,28E+06 2,38E+06 1,0 0,8 1,9 2,0 1,8 1,3 1,00 1,56 1,02 0,49 1,63 0,60 
INTS7 7,08E+05 5,89E+05 2,60E+05 6,02E+05 1,01E+06 3,75E+05 1,0 0,8 0,4 0,9 1,4 0,5 1,00 1,66 0,19 0,21 1,28 0,24 
INTS5 3,42E+05 3,75E+05 8,96E+04 3,95E+05 8,27E+05 2,03E+05 1,0 1,1 0,3 1,2 2,4 0,6 1,00 2,18 0,14 0,28 2,18 0,27 
INTS8 8,78E+05 6,72E+05 1,91E+05 9,62E+05 1,28E+06 4,43E+05 1,0 0,8 0,2 1,1 1,5 0,5 1,00 1,52 0,11 0,27 1,32 0,23 
INTS2 7,55E+05 5,78E+05 5,05E+05 7,42E+05 9,05E+05 6,13E+05 1,0 0,8 0,7 1,0 1,2 0,8 1,00 1,52 0,35 0,24 1,08 0,37 
ATP2A2/1 7,22E+05 6,03E+05 2,66E+06 5,22E+05 4,32E+05 8,83E+05 1,0 0,8 3,7 0,7 0,6 1,2 1,00 1,66 1,94 0,18 0,54 0,56 
CPSF3L 8,16E+05 6,10E+05 4,28E+05 7,48E+05 1,25E+06 4,08E+05 1,0 0,7 0,5 0,9 1,5 0,5 1,00 1,49 0,28 0,23 1,38 0,23 
ASPH 2,37E+06 1,91E+06 4,05E+06 1,99E+06 1,20E+06 3,24E+06 1,0 0,8 1,7 0,8 0,5 1,4 1,00 1,60 0,90 0,21 0,46 0,62 
SIKE1 1,17E+06 7,24E+05 1,61E+06 1,75E+06 1,41E+06 2,36E+06 1,0 0,6 1,4 1,5 1,2 2,0 1,00 1,24 0,73 0,37 1,09 0,92 
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GENERAL CONCLUSIONS AND DISCUSSION  
 
PP2A represents one of the major protein phosphatase families in the cell. Each of the about 
100 different PP2A heterotrimeric phosphatases is comprised of a catalytic subunit bridged 
by the A scaffold subunit to a specific regulatory B subunit, the later determining the 
physiological function, the tissue distribution and the subcellular localization of the 
holoenzyme. Alterations in PP2A function and/or activity have been reported in many human 
pathologies [9-12]. In this thesis, we report the biochemical and functional 
characterization of PP2A aberrations found in patients suffering from ID and 
endometrial cancer. The co-occurrence of identical Aα mutations in both pathologies 
suggested a common underlying disease mechanism. Indeed, we provide evidence for a 
common dominant-negative mode-of-action of these mutations.  
 
 
PP2A dysfunction, a new causative mechanism for ID  
 
Recently, large whole exome (and genome) sequencing projects have revealed de novo 
mutations in coding regions as an important cause of severe ID. In collaboration with a large 
European consortium of clinical geneticists, we identified and biochemically characterized 
mutations in PPP2R5D (P53S, E198K, E200K, P201R and W207R), encoding the regulatory 
B’δ subunit, and in PPP2R1A (P179L, R182W and R258H), encoding the Aα subunit, in 16 
individuals with a distinct form of ID. The main clinical features were mild to severe ID, long-
lasting hypotonia, susceptibility for epilepsy, frontal bossing, mild hypertelorism and 
downslanting palpebral fissures, and for the PPP2R5D cases (except P53S), macrocephaly. 
The mutations, identified via parent-child trio exome sequencing, appear clearly clustered 
and some are recurrent. Moreover, for several patients, the PP2A mutation was the only 
unique aberration identified in the affected child, all highly suggestive for causality [165]. For 
all but one (P53S) of the discovered de novo mutations, our biochemical data are consistent 
with a common dominant-negative disease-causing mechanism, affecting PP2A B’δ-
dependent dephosphorylation. All PPP2R5D mutants (except P53S) indeed no longer bound 
PP2A A and C subunits, while all PPP2R1A mutants remarkably retained binding to B’δ, but 
formed catalytically impaired complexes with this subunit. Therefore, the hypothesis 
emerged that A-C binding defective B’δ mutants (except P53S), or catalytically impaired 
mutant Aα-B’δ complexes, may indeed block dephosphorylation of B’δ-specific substrates and 
interfere with phosphorylation-dephosphorylation dynamics in the brain by a competition 
mechanism with the WT B’δ and WT Aα containing PP2A trimers.  
 
The B’δ mutant P53S is atypical and this case also had a different clinical picture including a 
short stature and microcephaly. The P53 residue localizes in the B’δ-specific N-terminal 
domain, a region likely involved in substrate binding. So in theory, P53S might change the 
interaction of B’δ with relevant substrates or might introduce a new phosphorylation site that 
affects regulation by protein kinases. Such changes could also easily have a gain-of-function 
or dominant-negative effect. All other ID-associated B’δ mutant residues (E198K, E200K, 
P201R and W207R) cluster in an acidic loop directly facing the A and C subunits. The E198 
residue makes direct contact with the C subunit and the mutation of this residue, the most 
recurrent PPP2R5D mutation identified, shows also the most severe biochemical defects and 
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the most severe phenotype in the patients. Therefore, a clear correlation exists between the 
ID degree and the biochemical disturbance of PP2A. Remarkably, mutations have been 
reported in this conserved loop in other regulatory B subunits, B’β and B’γ (S161L in 
PPP2R5B and T157del in PPP2R5C), in overgrowth patients [152]. This again underscores 
the importance of this conserved loop in PP2A holoenzyme formation and likely expands the 
involvement of PP2A in ID and overgrowth pathogenesis to multiple B’ regulatory subunits, 
although, until now, the B’β and B’γ mutations have only been found in single cases. The 
future biochemical and functional characterization of both overgrowth-associated B’β and B’γ 
mutants should provide further insight in this. 
 
 
Potential PP2A substrates affected in ID 
 
PPP2R5D encodes the longest isoform of the B56/PR61/B’ family of PP2A regulatory subunits 
and is highly expressed in brain, particularly in the striatum [37]. B’δ also localizes both to 
the nucleus and the cytoplasm. Some physiological roles of B’δ in the brain are well 
documented: 
(1) In concordance with a previous report [59, 166], we show that overexpression of mutant 
B’δ or mutant Aα causes hyperphoshorylation, and thus inactivation, of GSK3β in HEK293 
cells, suggesting that PP2A-B’δ is a GSK3β Ser9 phosphatase in these cells. While PI3K-Akt3 
inactivates GSK3β via Ser9 phosphorylation, PP2A-B’δ may thus be the counteracting GSK3β 
phosphatase in brain. Cyclin D2 (CCND2), which can stimulate neuronal progenitor cells to 
progress through the cell cycle, is an important neuronal substrate of GSK3β, with its 
phosphorylation leading to degradation [167]. Interestingly, de novo mutations at different 
levels of the PI3K-Akt3-GSK3β-cyclin D2 signaling pathway cause megalencephaly 
syndromes (Figure 6). Germline mutations of PIK3R2 and AKT3 result in megalencephaly-
capillary malformation syndrome (MCAP), postzygotic mutations of PIK3CA and germline 
mutations in CCND2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus 
syndrome (MPPH), and postzygotic mutations of PIK3CA and AKT3 cause isolated 
hemimegalencephaly. All these aberrations eventually cause accumulation of Cyclin D2 
leading to brain overgrowth (Figure 6) [167]. Phenotypically, MCAP/MPPH patients share 
several characteristics with the mutant B’δ and Aα cases, for example ID, hypotonia, 
tendency to develop epilepsy, and several dysmorphic facial features like tented upper lip 
and deep-set eyes, suggesting that in B56deltopathy patients, inactivation of GSK3β may 
also result in increased cyclin D2 expression. In contrast, our patients lack polymycrogyria 
and vascular abnormalities [168]. All together, this suggests an important involvement of 
defective B’δ-dependent GSK3β control in B56deltopathy patients, but also highlights the 
possible involvement of other dysfunctional PP2A-B’δ substrates given the similar, but non-
identical features compared to MCAP/MPPH.  
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Figure 6: Overview of the PI3K-Akt3-GSK3-cyclin D2 signaling pathway, indicating the mutated 
proteins leading to megalencephaly syndromes. Figure adapted from [167]. 
 
(2) B’δ stimulates dopaminergic signaling by dephosphorylating dopamine & cAMP regulated 
phosphoprotein of 32kDa (DARPP32), both in the nucleus and in the cytoplasm. DARPP32 
plays a critical role in the functions of dopamine (motor behavior and reward-driven 
learning), but also of antipsychotic drugs and drugs of abuse. In the cytoplasm, stimulation 
of dopamine 1 receptors increases the level of cAMP resulting in PKA activation and 
DARPP32 phosphorylation at Thr34 [169]. This activating phoshorylation stimulates DARPP32 
to inhibit PP1 resulting in increased phosphorylation of substrates like ion pumps, protein 
kinases, voltage-gated ion channels, etc. Cdk5-mediated phosphorylation of Thr75 blocks the 
Thr34 phosphorylation by PKA under basal conditions. After D1R stimulation, PKA 
phosphorylates B’δ at Ser566 which stimulates B’δ-mediated dephosphorylation of DARPP32 
Thr75. In the nucleus, B’δ Ser566 phoshorylation by cAMP/PKA results in dephosphorylation 
of DARPP32 Ser97 and its nuclear accumulation [170]. In addition, PP2A-PR72 mediates 
Ca2+-dependent dephosphorylation of DARPP-32 Thr-75 upon activation of α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) or N-methyl-D-aspartate 
receptors (NMDA) receptors, both glutamate receptors and non-selective cation channels 
[171]. Thus, PP2A-B’δ plays a major role in dopaminergic signaling and control of DARPP32 
function in the striatum, which may be affected in B56deltopathy patients. 
 
(3) Studies in B’δ knockout mice revealed that the microtubule-associated tau protein 
becomes hyperphosphorylated at pathological residues in restricted brain areas (mainly brain 
stem and upper spinal cord), accompanied by pretangle conformation but without 
neurofibrillary tangle formation [59]. PP2A-B’δ is a poor tau phosphatase in vitro, arguing 
against a direct effect. Rather, the cellular activator of CDK5, p35, was strikingly absent in 
the affected brain areas, resulting in decreased activity of CDK5. In contrast to tau, p35 is 
an excellent in vitro PP2A-B’δ substrate. Behavioral tests indicated impaired sensorimotor but 
normal cognitive functions, which is in contrast with the severe ID seen in most 
B56deltopathy patients. The appearance of very discrete neurological phenotypes in the KO 
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mouse (in contrast to the widespread distribution of B’δ in WT brain) indicates functional 
redundancy of other PP2A complexes. Accordingly, KI of the ID-associated B’δ and A 
mutations might indeed be more severe than complete B’δ KO, because in these cases, the 
substrate-trapping mutant proteins may actively protect/shield substrates from redundant 
phosphatases.  
 
(4) B’δ controls Tyrosine Hydroxylase (TH), the rate-limiting enzyme for dopamine (and 
other catecholamines), both at the protein and gene expression levels. It was shown that 
PKCδ-mediated phoshorylation of B’δ Ser566 stimulates dephosphorylation of the Ser40 
residue of TH, resulting in its inhibition [172]. PP2A redundancy occurs toward TH, since the 
B’β isoform is also able to dephosphorylate TH Ser40 [173]. Furthermore, nuclear 
translocation of B’δ is triggered by activation of voltage-gated calcium signals of which a 
subunit, β4, can bind B’δ and brings it into the nucleus. Together with accessory proteins, 
B’δ binds the TH promotor, dephosphorylates Histon H3 and represses gene expression of 
TH [174]. It remains to be determined whether TH function and/or expression are affected 
in B56deltopathy patients. 
 
(5) The Nerve Growth Factor (NGF) signaling pathway controls neuronal development, 
survival and plasticity of most neuronal populations [175]. Within this pathway, B’δ- and B’β-
containing PP2A complexes are able to dephosphorylate the NGF receptor, tropomyosin-
related kinase A (TrkA), at Ser and Thr residues, potentiating the intrinsic Tyr kinase activity 
of TrkA. This enhances NGF signaling via Akt and Ras pathways to promote neuritogenesis 
and neuronal differentiation. B’δ dysfunction may therefore impair NGF signaling. 
 
(6) Phosphorylation/dephosphorylation events regulate the dimerisation and function of 
HAND 1 and HAND 2 transcription factors, which are required for neuronal, limb, vascular, 
heart and extraembryonic development [176]. While HAND phosphorylation is mediated by 
PKA and PKC, PP2A-B’δ is responsible for their dephosphorylation. B’δ is abundant in 
undifferentiated embryonic cells and is downregulated during differentiation. Moreover, 
overexpression of HAND factors in de developing limbs of chick and mice causes polydactyly, 
a condition in which more than 10 finger or toes are developed. This condition was also 
found in one Aα case. Nevertheless, overall brain development seems largely unaffected in 
the majority of B56deltopathy cases. 
 
(7) Finally, B’δ also constitutes part of the neural variant of the muscle cAMP-dependent PKA 
anchoring protein (mAKAP) complex. The mAKAP scaffold protein also binds several other 
phosphatases (PP1, PP2B) and kinases (PKA, PDK1, RSK3, ERK5), integrating local signaling 
events. In response to elevated levels of cAMP, PKA is able to phosphorylate the alternatively 
spliced type 4 phosphodiesterase isoform D3 (PDE4D3), stimulating its activity. On the other 
hand, PKA also phosphorylates B’δ, enhancing its dephoshorylation activity towards PDE4D3, 
and subsequently inhibiting it [177]. mAKAPα and mAKAPβ are two alternatively spliced 
isoforms of mAKAP expressed in the heart and the brain, respectively. The presence of B’δ in 
mAKAPβ, once again, suggests an important regulatory role of this PP2A subunit in 
dopaminergic signaling. 
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The identification of the physiological PP2A-B’δ substrates, whose phosphorylation-
dephosphorylation dynamics may be deregulated in B56deltopathy patients, clearly awaits 
further biochemical analyses (for instance, through identification of B’δ interacting proteins in 
neurons), and definitely, establishment of appropriate cellular and in vivo models of the 
disease (cfr. Future perspectives), which can be further studied in great detail. 
 
 
Therapeutic options for B56deltopathy patients? 
 
Given the known redundancy of B subunits for several (neuronal) substrates, it is still unclear 
which substrates are primarily affected by B’δ and Aα mutations and, hence, are crucial to 
the pathology. This hampers the development of treatment protocols to alleviate symptoms 
and provide ID patients with a better quality of life. Nevertheless, since overall brain 
development of the B56deltopathy patients seems largely unaffected, there is perhaps hope 
to restore or improve dysfunctional phosphorylation-dephosphorylation dynamics through 
administration of specific pharmaca. While use of kinase inhibitors has clearly a proven 
clinical benefit in certain diseases (particularly cancer), more and more phosphatase 
modulators with a therapeutic potential are currently being discovered [178]. Recent 
developments in the PP2A field have led to the discovery of PP2A activating drugs (‘PADs’), 
such as FTY720, phenothiazines and their derivates [116, 162]. It would be of enormous 
therapeutic interest to test whether these compounds, all already FDA-approved, might 
improve brain functions or restore neuronal signaling in the B56deltopathy patients. In 
addition, we speculate that specific kinase inhibitors (potentially in combination with a PAD) 
may also be excellent candidate-drugs to normalise phosphorylation of dysregulated PP2A-
B56 substrates. This however awaits identification of the kinases whose function is 
counteracted by PP2A-B’δ in brain. 
 
 
PPP2R1A mutations function via a dominant-negative mode-of-action in uterine 
cancer 
 
The co-occurrence of identical Aα mutations in both ID and serous endometrial cancer 
suggested a common underlying dominant-negative disease mechanism, which we further 
and more extensively investigated in the cancer context.  
Our cellular binding assays in HEK293 and HEC-1-A cells, ectopically expressing Aα mutant 
and WT proteins, reveal some very interesting observations, shaking up the traditional way 
we think about PP2A complex formation.  
(1) Isoform-specific differences in binding behavior to cancer-derived Aα mutants exist 
within members of the same B-type subunit family. This is especially true for the 
B56/PR61/B' family since B’δ seems to behave differently than the other members; in fact, 
B’δ is the only B-type subunit that still significantly binds all mutant proteins, while the other 
family members show a more heterogeneous binding pattern. This observation, 
subsequently, warns about generalization of binding behavior of a given B subunit, based on 
the binding behavior of a single related subunit of the same family.  
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(2) It seems that not just the specific Aα residue that is mutated determines the binding 
pattern to B-type subunits, but especially the amino acid in which it is substituted. This 
is demonstrated most clearly by the differences in B-type subunit binding of the R183G/Q/W 
mutants. For example, R183G and R183W both still interact with PR72, while R183Q is 
completely unable to do so.  
(3) Although the mutations cluster in B subunit-binding HEAT-repeats 5 and 7, the PP2Ac 
interaction is decreased (except for R249H which shows WT binding to PP2Ac and B 
subunits). In agreement, Aα deletion mutants of HEAT-repeats 5 and 7 show reduced 
binding to the C subunit [23]. Together, these data point towards a complex relationship 
between B and C subunits within the holoenzyme in which stable C subunit binding to Aα 
is dependent on the presence of the B subunit. 
(4) In contrast, B’γ, B’δ, PR72 and STRN3 can interact with a mutant Aα protein containing 
HEAT-repeats 1 to 10 (amino acids 1 to 410) and unable to interact with PP2Ac, to form 
B’γ/B’δ/PR72/STRN3-Aα dimeric complexes. Formerly, only proof existed for a PR72-
Aα complex without PP2Ac in the format of a crystal structure [25]. For the B’δ, PR72, PR70 
and the striatin [74, 75] subunits, however, it was previously shown that they are able to 
associate with a deletion mutant of the entire PP2Ac C-tail, already suggesting that these B-
type subunits do not need stabilizing contacts with the catalytic subunit to form trimeric 
holoenzymes. For B'γ, the PP2Ac C-terminal determinants facilitating its incorporation in the 
holoenzyme were not reported before. Bα/β and B'α/β/ε subunits do require contacts with 
PP2Ac, in particular with the conserved C-terminal tail, to form a stable holoenzyme [74].  
(5) Finally, we show for the first time gain-of-binding of the B’’’ STRN family members 
and of the cellular PP2A inhibitor TIPRL1 to Aα mutant proteins. 
 
Furthermore, the dominant mechanism-of-action, brought to light by the characterization of 
the ID-associated Aα mutations, was further substantiated upon ectopic expression of 
P179R, R182W (ID-associated), R183G, R183Q and S256F mutants in the endometrial 
cancer cell line HEC-1-A. This resulted in a severe phenotype for R183G/Q and S256F and a 
milder phenotype for P179R and R182W when evaluating AIG and tumor formation in mice. 
So, these mutations indeed must function via a dominant effect, rather than via 
haploinsufficiency. For the latter, a phenotype only emerged when WT Aα levels were first 
reduced by half, and was completely dependent on the loss of certain trimeric holoenzymes 
(particularly, PP2A-B'γ) [96]. In contrast, the cancer phenotype within our model is not 
dependent on the loss of binding of regulatory B subunits, but rather on the B subunits that 
maintained binding to mutant Aα (Figure 7). Indeed, the mutants could still form substrate-
trapping complexes with these B subunits, with impaired catalytic activity and able to 
compete with WT Aα containing, active complexes for substrate binding. Moreover, the 
severity of the phenotype may be linked to the number of B subunits present in these 
inactive complexes, as well as by their absolute binding abilities, shown by the interaction 
data in HEK293 and HEC-1-A cells. In this regard, the mutant showing the strongest 
tumorigenic potential, R183Q, interacts the best with several B56/PR61B’ family members, 
especially B’γ and B’δ, and binds most TIPRL1. Important to emphasize, the more B subunits 
are incorporated in substrate-trapping, inactive complexes, the less redundancy there will be 
for dephosphorylation of a given substrate and the more severe the cancer phenotype will 
manifest, as demonstrated by our biochemical and functional data. In support of this view, 
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suppression of individual B-type subunits could only partially transform HEK-TER cells and 
overexpression of B’γ could only partially rescue the SV40 st tumorigenic phenotype [86]. 
 
 
 
Figure 7: The upper panel shows the disease-associated PPP2R1A mutations, which result in the 
formation of dominant-negative complexes containing TIPRL1, leading to hyperactivation (↑ ) of 
components within the Akt/GSK3β and mTOR/p70S6K signaling pathways. The severity of the cancer 
phenotype is linked to the number of B subunits present in these inactive complexes, because the 
more B subunits are incorporated, the less redundancy there will be for dephosphorylation of a given 
substrate (lower panel). Gain-of-binding of PP2A to STRN3 might be responsible for the inhibition (↓ ) 
seen on the Ras/Raf/MEK pathway. Figure adapted from [131]. 
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Incorporation of TIPRL1 in dominant-negative mutant Aα complexes 
Our data suggest a novel pathological function of TIPRL1 via gain-of-binding to endometrial 
cancer- and ID-associated mutant Aα proteins, and resulting in formation of dominant-
negative PP2A complexes. This was brought to light by the MS-based approach in HEC-1-A 
and validated by immunoblotting. Furthermore, we were able to show the existence of 
TIPRL1-(mutant Aα)-C complexes and proved TIPRL1 incorporation in B’δ-containing 
holoenzymes, resulting in a lower activity of B’δ-(mutant Aα)-C complexes. Moreover, 
addition of recombinant TIPRL1 to isolated B’γ/δ-(mutant Aα)-C complexes resulted in 
decreased C activity, compared to WT complexes. TIPRL1 is a ubiquitously expressed PP2A 
inhibitory protein, of which the physiological function is largely unknown, but that appears 
overexpressed at moderate frequency or mutated at low frequency in several human cancer 
types (cBioportal). The PP2A inhibitory activity resides in the C-terminal part that is lacking in 
the shorter TIPRL splice variant, TIPRL2, which does not interact with or inhibit PP2A. 
TIPRL1 was shown to bind PP2Ac, without the presence of WT A or any B-type subunit 
[179]. It has been hypothesized that TIPRL1 might play a role in PP2A biogenesis as one of 
the proteins that controls the activity of the newly translated PP2Ac, similar to PME1 [62]. 
Alternatively, it might rather play a role in PP2Ac capturing and inhibition after PP2A 
holoenzyme disassembly following cellular stresses, like DNA damage [62]. However, these 
hypotheses are highly speculative and formulated based on fragmented and even 
contradicting results. Our data might give support though for a role of TIPRL1 in the 
biogenesis of active PP2A trimers through an interaction with Aα. Although TIPRL1 
biochemistry is poorly understood, it was reported that TIPRL1 has a positive effect on 
mTORC1 signaling through association with PP2Ac, and that TIPRL1 overexpression results 
in hyperphosphorylation of p70S6K and 4E-BP [180]. Notably, we also found increased 
p70S6K phosphorylation upon ectopic expression of mutant Aα (showing gain-of-binding to 
TIPRL1). 
 
In summary, our data identify TIPRL1 gain-of-binding to B-(mutant Aα)-C substrate-trapping 
complexes as a likely cause of increased endometrial cancer cell growth. By extension, such 
increased recruitment of TIPRL1 into ID-associated mutant Aα-B’δ-C complexes may provide 
the mechanistic explanation for the observed decrease in specific PP2Ac activity in these 
complexes as well.   
 
 
Expression of dominant-negative Aα mutants correlates with increased 
mTOR/p70S6K and Akt signaling, but with decreased ERK signaling 
 
The hyperactivation of Akt and mTOR pathway members Akt, GSK3β, p70S6K and S6 
supports a dominant-negative effect on the B56/PR61/B' family members, particularly on B’β-
, B’γ- and B’δ-containing PP2A trimers (Figure 6). In Hela cells, B’γ, but not B’δ, was reported 
to be responsible for dephosphorylation of p70S6K, since siRNA-mediated knockdown of 
PPP2R5C (but not PPP2R5D) resulted in hyperphoshorylation of p70S6K [181]. Also, 
Drosophila PP2A-B’, for which B’γ and B’δ are the human orthologues, interacts with and 
dephosphorylates p70S6K [181]. Furthermore, B'γ was identified as an important tumor 
suppressive B-type subunit, since its knockdown (partially) replaced SV40st in the HEK-TER 
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system for human cell transformation [86, 87]. B'γ knockdown was accompanied by Akt and 
Wnt pathway activation [87]. Several PP2A holoenzymes can interact with and 
dephosphorylate Akt, depending on the context [30]. However, studies in mammalian cells, 
Drosophila and C. elegans convincingly linked PP2A PR61/B’ subunits to Akt 
dephosphorylation, in particular the PR61/B’β and B’γ isoforms. Mainly PR61/B’β 
dephosphorylates Akt in liver and was shown to be regulated by insulin/IGF signaling [30]. 
Additional tumor suppressive functions have been reported for B’γ. B’γ3 was shown to be 
enriched in the nucleus during S phase where it regulates CDK inhibitor p27KIP1 to restrain 
cell cycle progression [182]. B’γ 1 and 3 isoforms also promote p53 stability through Thr55 
dephosphorylation during DNA damage [183]. So, multiple pieces of evidence firmly establish 
B’γ as a major tumor suppressive B subunit. Furthermore, unpublished data from our lab 
identified B’δ as a tumor suppressor in vivo, since Ppp2r5d KO mice spontaneously develop 
several primary tumors, with high incidence of HCC and lymphoma. In this model, lack of B’δ 
also results in hyperphosphorylation of GSK3β and, subsequently, in increased oncogenicity 
of the c-Myc oncogen. Indeed, inactivation of GSK3β results in lack of Thr58 phosphorylation 
in the oncogenic c-Myc form (phosphorylated on Ser62) and this leads to c-Myc stabilization 
[166]. In proliferative vascular smooth muscle cells, a functional redundancy has been 
reported between PP2A-B’γ and PP2A-B’δ towards GSK3β [184]. More controversy exists on 
which regulatory B subunit is responsible for dephosphorylating ERK, with some reports 
identifying the B56/PR61/B' family members B’β and B’γ, but not the B55/PR55/B family 
members [185, 186], while others disprove the role of B56/PR61/B' family members in ERK 
dephosphorylation and put forward Bα and Bδ as the responsible phosphatases [187]. This 
nicely illustrates how the action of PP2A phosphatases on a given substrate may be 
particularly dependent on the cellular context and the specific repertoire of PP2A B-type 
subunits present in a given cell or tissue. 
 
 
All Aα mutants tested show gain-of-binding to the striatins (B”’ subunits) 
 
It is very well possible that the STRN3 gain-of-binding to mutant Aα might also contribute to 
the observed phenotype in the endometrial cancer cells. The obtained Aα interactomes from 
the mutant and WT HEC-1-A cells highlighted the presence of multiple STRIPAK components, 
including all three striatin family members (STRN, STRN3 and STRN4), Mammalian Sterile 
20-like kinase 3 (MST3), Striatin Interacting Protein 1/2 (STRIP1/2, also FAM40A/B), STRIP2-
interactor MYH9, sarcolemmal membrane–associated protein (SLMAP), cerebral cavernous 
malformation 3 (CCM3), phocein (Mob4, also PREI3), suppressor of IKKε (inhibitor of NF-κB 
kinase ε) (SIKE),  fibroblast growth factor receptor 1-oncogenic partner 2 (FGFR1OP2) and 
Cortactin Binding Protein 2 N-Terminal Like (CTTNBP2NL). STRIPAK and STRIPAK-like 
complexes are multiprotein signaling complexes involved in the regulation of the cell cycle, 
cell growth and transformation, cell polarity, apoptosis, cell survival, Golgi assembly, and cell 
migration [50]. Consistent with this wide range of functions, over 100 different variants of 
STRIPAK complexes have been predicted from different combinations of STRIPAK 
components. To date, PP2A A and C subunits are the only striatin family-associated proteins 
found in nearly all identified complexes [50]. Striatins form homodimers that interact with A 
and C as a 2:2:2 heterohexamer, and homodimerization is essential for interaction with PP2A 
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subunits [188]. However, the functions of PP2A within the different STRIPAK complexes are 
only beginning to emerge:  
 
(1) Very recently, a paper reports the function of a STRIPAK complex containing multiple 
members identified in our (mutant) Aα interactomes. PP2A-STRN associates with germinal 
center III kinases (GCKIII) MST3, MST4 and Serine/Threonine Kinase 25 (STK25) through 
the adaptor protein CCM3, and PP2A is believed to function as a negative regulator of the 
associated kinases. MST3 promotes apoptosis in Jurkat cells via its effects on NF-κB 
signaling. PP2A inhibits the MST3 kinase via dephosphorylation [189] and, subsequently, 
counteracts MST3-mediated apoptosis pointing towards a tumor promoting function of PP2A-
STRN within certain STRIPAK complexes [188]. Of note, CCM3 is mutated in familial cerebral 
cavernous malformation, a condition of abnormal brain capillary architecture, associated with 
symptoms ranging from dizziness and headaches to severe stroke and death [190].  
 
(2) In addition, positive regulation of STRIPAK on ERK signaling was suggested in 
Drosophila and in mammalian cells, since a STRIPAK (dSTRIPAK) complex containing dGckIII 
and PP2A stimulates the ERK pathway and since mammalian GCKIII kinases, MST3 and 
MST4, are important for maintaining basal ERK phosphorylation [191-193]. Interestingly, 
mutant Aα HEC-1-A cells show reduced phosphorylation of ERK, consistent with a disturbed 
phosphorylation/dephosphorylation balance within STRIPAK due to the enhanced STRN3-
PP2A association (Figure 7). Moreover, this suggests a gain-of-function of STRN-PP2A, rather 
than a dominant-negative effect on STRIPAK substrates. Absence of TIPRL1 incorporation in 
these complexes might be explained by the different structure/composition of the 
multiprotein A-C-STRN signaling complex compared to A-C-B/B’/B” heterotrimers.  
 
(3) STRIPAK complexes are also involved in the regulation of Hippo signaling. SLMAP is 
responsible for recruiting MST1/2 kinases to the STRIPAK complex [51]. When MST1/2 
kinases are phosphoylated, they phosphorylate and activate large tumor suppressor kinase 1 
and 2 (LATS1/2), which in turn phosphorylate the transcriptional coactivators Yes-associated 
protein 1 (YAP1) and Tafazzin (TAZ) leading to their cytosolic retention or degradation. In 
contrast, absence of phosphorylation causes YAP1 and TAZ to translocate into the nucleus, 
ultimately inhibiting apoptosis and stimulating proliferation. Moreover, siRNA-mediated 
knockdown of PP2Ac results in an increased abundance of phoshorylated MST1/2 [51], 
leading to the suggestion that gain-of-binding of PP2A mutant Aα and C subunits to this 
STRIPAK complex might indeed block apoptosis and stimulate cell proliferation by activating 
Hippo signaling.  
 
(4) Finally, STRIPAK complexes play a major role in cancer cell migration and invasion, 
which may be highly relevant for tumor metastasis. Striatin depletion alters the localization 
of the tight junction protein ZO-1 and affects the organization of F-actin, suggesting a 
contribution of Striatin in cell-cell adhesion [194]. Another STRIPAK complex, containing 
STRN3, PP2A, CMM3, STRIP1 (FAM40A) and STRIP2 (FAM40B), regulates the mode of 
cancer cell migration by facilitating the interaction of the actomyosin network with either the 
plasma membrane or with the extra-cellular matrix, and this through control of MST3/4- 
kinase activity, with high and low activity respectively. Interaction with the plasma 
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membrane facilitates 3D migration, while interaction with the extra-cellular matrix favours 2D 
migration [56]. Dedicated functional assays in HEC-1-A cells expressing the cancer-
associated Aα mutants should provide further insights into whether cell adhesion, migration 
of invasion into the extracellular matrix are affected, and potentially, increased, as opposed 
to WT Aα expressing cells. This could possibly lead to the conclusion that Aα mutation might 
also contribute to the metastatic potential of the endometrial cancer cells. 
 
 
Potential contribution of other Aα interactome constituents to the cancer growth 
phenotype 
 
Of course, additional PP2A interaction partners, including those amongst the putatively novel 
interactors, might also contribute to the observed cancer phenotype. Some of the 
established Aα partners, CCDC6, ANKLE2, TMPO, PP4, liprin α and the Integrator complex, 
have already been reported to have links with cancer pathology. 
 
CCDC6 was originally identified as a translocation partner with RET in human thyroid 
papillary carcinomas generating the RET/PTC1 oncogene [195]. This rearrangement was also 
detected in lung adenocarcinomas and CCDC6 gene rearrangements with other genes have 
been reported in solid tumors and leukemia.  Mechanistically, CCDC6 is a substrate of ATM 
and aids to protect genome integrity by negatively modulating PP4c activity directed towards 
H2AX after DNA damage. Furthermore, CCDC6 interacts with CREB1 to repress its 
transcriptional activity [195]. Interaction between CCDC6 and Aα mutants was variable; 
some displayed increased binding compared to WT Aα (P179R, S256F), others showed 
decreased binding (R182W and R183G/Q). 
 
PP2A regulates barrier-to-autointegration factor (BAF) chromatin recruitment during mitotic 
exit and is required for BAF’s function in nuclear envelope assembly [196]. Both C. elegans 
and human PP2A complexes are required to dephosphorylate BAF during mitotic exit and 
thus allow its efficient recruitment to chromatin. ANKLE2 serves a dual role in this process by 
(1) supporting PP2A-mediated BAF dephosphorylation and (2) by inhibiting the mitotic BAF 
kinase, VRK-1 [196]. ANKLE2 is a member of the LAP2-Emerin-MAN1 (LEM) domain protein 
family, as well as TMPO (or LAP2α). TMPO, present in the nucleoplasm, has been reported to 
control cell proliferation by affecting the activity of retinoblastoma protein in tissue 
progenitor cells and numerous studies showed upregulation of LAP2α in cancer. Both LEM 
proteins show variable binding to mutant Aα in comparison with WT Aα [197].  
 
PP4 is believed to be tumor-promoting, since overexpression of PP4C-PP4R2-PP4R3α was 
discovered in human primary breast and lung tumors, and subsequent inhibition of PP4C 
expression sensitized these cells to cisplatin treatment [198]. Also in pancreatic ductal 
adenocarcinoma PP4C is overexpressed, and this is associated with poor prognosis in 
patients with stage II disease [199]. More recently, increased PME-1 expression and 
increased PME-1 binding to PP4 was also found in endometrial cancers, although the 
contribution of potential PP4 dysregulation in PME-1 overexpressing tumors remains unclear 
[140]. Noteworthy, TIPRL1 is also a reported interactor of PP4 [114] and previously reported 
Aα-containing PP4 complexes have been shown to specifically harbor B’δ and B55α/δ 
 146 
 
subunits [200, 201]. Thus, it is definitely worthwhile to further investigate the potential role 
of mutant Aα -PP4 complexes in the cell biology of endometrial cancer. 
 
The B’γ3 and B’δ binding partner PPFIA1 (Liprin α1) was found to be required for metastasis 
and invasion of the highly invasive breast cancer cell line MDA-MB-231 [202, 203] and is 
overexpressed with high frequency in several tumor types (cBioportal), suggesting it is an 
oncogen. Our MS data show decreased binding of liprin α1 to all Aα mutants tested. 
However, since the we do not know how PP2A affects Liprin α1 within the complex, it is hard 
to speculate about the contribution of Liprin α1 loss-of-binding to the cancer phenotype.  
Finally, the Integrator complex functions in gene expression regulation [204]. It is a U-rich 
small nuclear RNAs (UsnRNAs) 3’-end processing factor via its association with RNA 
polymerase II. UsnRNAs represent a family of small non-coding RNAs, essential for the 
biosynthesis of ribosomal RNA, removal of introns and proper expression of histone mRNA, 
and are highly expressed throughout development and the cell cycle of all cells. Again, the 
role of PP2A within the Integrator complex is completely unknown, as well as a potential link 
to cancer.  
 
 
Contribution of STRN3 gain-of-function to the ID phenotype? 
 
Despite the common defect in B’δ-dependent dephoshorylation in the 16 reported ID cases 
here, the Aα cases were more severely affected than the B’δ cases and show some 
differential symptoms; all had severe ID, absent speech, small head size and partial or 
complete corpus callosum agenesis. This difference is in line with the expected greater 
difficulty to compensate for a general scaffolding (A) subunit dysfunction than a specific 
regulatory (B) subunit dysfunction. However, the data obtained from the endometrial cancer-
associated Aα mutations might suggest the contribution of additional factors to the 
phenotype, possibly the gain-of-function of STRIPAK complexes. The striatin family 
members are highly expressed in brain, especially in the striatum, hence their name. They 
concentrate in dendritic spines, the sites of most of the excitatory synapses, and are involved 
in the control of motor function, since downregulation of striatins is associated with reduced 
motor activity [205]. Downregulation also results in reduced growth of dendrites [205]. So, 
the striatin family is essential for dendritic spine formation, possibly in a Ca2+-regulated 
manner, since Ca2+ is required for proper neuronal maturation [206]. Dendritic spine 
localization is dependent on CTTNBP2, a CTTNBP2NL-holomogue, of which the knock down 
also causes a reduction in the number of dendritic spines [57]. Interestingly, CTTNBP2 is 
being investigated as a possible autism susceptibility gene, because a de novo 2-base-pair 
frame shift deletion in CTTNBP2, likely disturbing protein function, was found in a male 
autism patient [207]. Furthermore, striatin’s interaction with phocein (Mob4) might be 
involved in synaptic plasticity via spine remodeling by endocytosis [208]. Striatins associate 
with estrogen receptor α (ERα) and are involved in the non-genomic actions of estrogen 
[209]. In brain, loss of estrogen is associated with vulnerability to epilepsy, memory 
problems, defects in fine motor coordination and reaction time, and depression and anxiety 
[209]. Non-genomic functions of estrogen include rapid action on excitability of neuronal and 
pituitary cells, activation of MAPK and Akt pathways, protection of neurons from excitotoxin- 
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and free radical-mediated damage, and regulation of calcium channels and calcium ion entry. 
Estrogen is also involved in formation of excitatory synapses in the hippocampus [209]. 
Furthermore, striatin co-localizes with APC in PC12 cells during neurite outgrown following 
NGF treatment [194].  
 
Therefore, the literature highlights the indisputably important function of striatins in brain 
biology and may predict a pathological role for gain-of-function STRN-(mutant Aα)-C 
complexes in ID. 
 
 
All ID-associated PPP2R1A mutations are common to uterine cancer 
With advances in genome sequencing, several hundreds of new candidate genes for 
neurodevelopmental disorders have been identified and need to be prioritized. Among the 
factors that determine whether a gene is a “disease gene” worthwhile to pursue, are (1) 
recurrence of the de novo mutation, (2) the position of the mutation in the protein 
(clustering), (3) presence of the mutant protein within a disease-implicated protein network 
and (4) presence of a link with cancer biology [165]. Indeed, many recurring genes and 
pathways have been implicated in both neurodevelopmental diseases and cancer, e.g. 
mutation of the tumor suppressor gene PTEN found in Cowden syndrome. Strikingly, in some 
cases identical point mutations are causative for cancer when mutated somatically and for 
neurodevelopmental disorder when mutated in the germline. This is indeed the case for all 
the ID-associated Aα mutations P179L, R182W and R258H (but not for the B’δ 
mutations). Also for MCAP/MPPH, identical mutations within the PI3K/Akt pathway have 
been found in cancer. For these patients, a mild increase of 3% in cancer incidence was 
reported with detection of Wilms tumor, leukemia, medulloblastoma and meningioma in 
patients aging from 10 months to 18 years [210]. However, none of our patients (ages 1 to 
11 years old) have been diagnosed with or treated for cancer yet. In addition, the single ID-
associated mutation tested in our cancer model (R182W) seems to have a very mild 
tumorigenic potential in endometrial cancer, with no hyperactivation of oncogenic Akt and 
mTOR signaling pathways compared to R183G/Q and S256F, and no significant difference in 
AIG and in vivo tumor formation in mice compared to WT Aα. Only further patients and 
patient follow-ups will provide a clear answer, but a major cancer risk seems unlikely. Finally, 
it could be hypothesized that the timing of the mutational event determines the different 
outcomes (germline/constitutively vs somatic), as well as the specific genetic background 
and the cellular context [165]. In case of PP2A, the latter might be very important since B’δ 
and STRN3 are highly enriched in the brain, potentially explaining why the germline 
mutations found in the ID patients seem to majorly affect this specific organ only.  
 
 
Therapeutic implications for the treatment of PPP2R1A mutant endometrial 
cancers 
 
Compared to Type I endometrioid carcinoma, serous uterine carcinoma (type II) is less 
common but is characterized by high mortality due to a tendency for early metastasis and 
resistance to conventional chemotherapy. Besides TP53 mutations, occurring in up to 80-
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95% of cases, relatively few additional molecular genetic aberrations were reported in this 
cancer type, among which PPP2R1A appears the most frequently altered in 18.4 up to 43.2% 
of cases, depending on the study [100-103, 105, 133-135]. Also, PPP2R1A mutations occur 
in high-grade endometrioid cancer and is therefore associated with poor outcome and 
aggressive behavior of both the endometrioid and serous types of endometrial 
adencarcinoma. This opens interesting perspectives for the use of PPP2R1A as a therapeutic 
biomarker. 
 
Our functional data would indeed suggest that PPP2R1A mutant tumor cells could be 
targeted by kinase inhibitors directed against the Akt and mTOR signaling 
pathways, like Akt, mTORC1, isoform-specific PI3K, Pan-PI3K, dual PI3K/mTOR and 
mTORC1/2 inhibitors, or a combination of these drugs [130]. Moreover, since we do not 
observe oncogenic activation of the Ras/Raf/MEK pathway (probably due to STRN-PP2A 
gain-of-function), cross-talk between this pathway and the Akt/mTOR signaling pathways, 
often the basis for resistance, might not be a big issue in mutant Aα endometrial cancer.  
 
Combined, our observations predict a good therapeutic efficiency for Akt/mTOR inhibitors 
and might suggest a substantial benefit of stratification of patients based on mutant or WT 
Aα status of the tumor. In addition, the PAD PPZ might have therapeutic potential to 
reactivate mutant Aα. PPZ is believed to bind to the A subunit [162]. One plausible 
explanation for its reactivating ability is that PPZ might enhance the local aspecific activity of 
PP2A holoenzymes by dissociating the B subunit, therefore enhancing the activity of the 
“uncontrolled” A-C dimer. If this is true, then PPZ might just as well dissociate remaining 
mutant Aα-B’ subunit interactions, and alleviate the dominant-negative effects of these 
complexes. 
Finally, our data highlight the therapeutic potential of inhibiting TIPRL1. Therefore, it is of 
great importance to gain more insight into the PP2A inhibitory function of TIPRL1 and the 
TIPRL1-PP2A(Aα) interaction to ultimately be able to design or screen for small molecules 
targeting this PP2A-inhibitor interaction. Alternatively, since PPZ and TIPRL1 both seem to 
bind the A subunit, there is a possibility that PPZ might dissociate TIPRL1 from PP2A as 
another mechanism-of-action. 
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FUTURE PERSPECTIVES 
 
Regarding the role of PP2A dysfunction in ID: 
 
Future experiments should focus on: 
 
(1) the identification of neuronal substrates of B’δ, whose hyperphosphorylation contributes 
to the disease. To this end, we could exploit potential differential binding of relevant 
substrates to WT B’δ, to the E198K mutant (substrate trapping) and to P53S (mutant with 
potential loss of substrate binding) 
(2) the generation and characterization of appropriate cellular and in vivo models of 
B56deltopathy. Essentially, these should be knock-in (KI) models, technically achievable for 
instance by using CRISPR-Cas9 technology. This technology allows to introduce the relevant 
point mutation into the PPP2R5D or PPP2R1A locus. Such B56deltopathy models should be 
instrumental to further investigate or validate the consequences of PP2A dysfunction on 
neuronal signaling and brain function. Moreover, they could be utilized to test therapeutics 
(e.g. kinase inhibitors or PADs) pre-clinically, and to monitor for potential increased 
susceptibility to cancer development. 
(3) In the meantime, the lab became aware of additional genetic alterations in PP2A genes in 
brain diseased patients. Therefore, we should continue to collaborate with clinical geneticists 
to provide biochemical and functional evaluation of newly discovered ID-associated 
mutations in PP2A subunit genes. In this respect, I recently already obtained preliminary 
biochemical data on the reported B’γ T157del mutation in an overgrowth patient [152], 
finding significant binding defects with A and C subunits, and hyperphosphorylation of Akt 
Thr308 upon its ectopic expression in HEK293 cells. 
 
Regarding the biomarker role of PPP2R1A mutation in endometrial cancer: 
 
Our data provide a molecular basis for improved design of targeted therapies, which should 
be further experimentally tested. Future experiments should focus on: 
 
(1) targeting the affected Akt/mTOR signaling pathways, testing multiple drugs and their 
combinations, like Akt, mTORC1, isoform-specific PI3K, Pan-PI3K, dual PI3K/mTOR and 
mTORC1/2 inhibitors. To this end, their therapeutic effects in Aα mutant HEC-1-A cells, e.g. 
on cell survival, oncogenic signaling, AIG and tumor formation in mice, should be tested.  
(2) evaluating PPZ as a potential PP2A (re)activator of mutant Aα in the same experimental 
set-up as described above. 
(3) gaining more insight into the relationship between TIPRL1 and PP2A(Aα) to ultimately be 
able to disrupt their interaction, perhaps via PPZ. 
(4) studying more elaborately the contribution of the PP2A-STRN gain-of-function to the 
observed cancer phenotype by evaluating the phosphorylation states of STRIPAK-associated 
kinases (e.g. MST3) and substrates, and also by determining potential changes in cell 
adhesion, migration and invasion of the mutant Aα expressing cells. 
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SUMMARY 
 
Here, we report inherited dysregulation of protein phosphatase activity as a novel cause of 
intellectual disability (ID). De novo missense mutations in 2 PP2A subunit genes (PPP2R1A 
and PPP2R5D) were identified in 16 individuals with ID of unknown etiology. Mutant B’δ was 
A and C binding–deficient, while mutant Aα subunits bound B’δ well but were unable to bind 
C or bound a catalytically impaired C, suggesting a dominant-negative effect where mutant 
subunits hinder dephosphorylation of B’δ-anchored substrates. The same dominant-negative 
mechanism caused increased cancer cell growth in high grade uterine cancers bearing 
somatic PPP2R1A missense mutations, some of which were identical to all the Aα mutations 
found in ID. PPP2R1A mutation represents one of only a few genomic alterations occurring 
with high frequency in serous endometrial carcinoma and carcinosarcoma, typically 
aggressive uterine cancers. This thesis reports on the biochemical and functional 
consequences of eleven recurrent mutations clustering into Aα HEAT-repeats 5 and 7. 
Besides the predicted loss-of-function effects on formation of some PP2A holoenzymes, we 
confirm the dominant-negative effects of these mutations in the cancer context and this on 
specific, tumor suppressive PP2A complexes. Dominant-negative Aα mutants retain binding 
to specific B-type subunits, but form substrate-trapping complexes with impaired 
phosphatase activity due to increased incorporation of a cellular PP2A inhibitor, TIPRL1. In 
addition, we reveal gain-of-binding of the Aα mutants to the B”’/striatin subunits of PP2A, 
which we suspect also contributes to the dominant behavior of the mutants. Accordingly, 
ectopic expression of these mutants in endometrial carcinoma cells increases anchorage-
independent growth and tumor formation in vivo, and causes hyperphosphorylation of 
several oncogenic PP2A substrates in the Akt and mTOR signaling pathways. Although 
identical Aα mutations are found in both pathologies, a major cancer risk for the ID patients 
seems unlikely. Together, our data not only reveal how mutations affect PP2A assembly and 
function, oncogenic signaling and ID disease pathogenesis, they also provide a basis for 
improved design of targeted therapies. 
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SAMENVATTING 
Wij rapporteren hier een aangeboren afwijking van proteïne fosfatase activiteit als een 
nieuwe oorzaak van mentale retardatie (MR). De novo missense mutaties in 2 PP2A 
subeenheid genen (PPP2R1A en PPP2R5D) werden geïdentificeerd in 16 personen met MR 
met een ongekende oorzaak. Mutante B'δ regulatorische subeenheden waren deficiënt in A 
en C subeenheid binding, terwijl mutante Aα subeenheden B'δ nog goed bonden maar 
verstoorde katalytische activiteit vertoonden. Deze data wijzen op een dominant-negatief 
effect waarbij de mutante subeenheden niet meer in staat zijn om B'δ substraten te 
defosforyleren. Hetzelfde dominant-negatieve mechanisme veroorzaakt verhoogde 
agressiviteit/groei in baarmoederkankercellen met somatische PPP2R1A missense mutaties, 
waarvan sommigen identiek zijn aan alle Aα mutaties gevonden bij MR patiënten. PPP2R1A 
mutatie vertegenwoordigt één van de weinige genomische veranderingen die zich voordoen 
met hoge frequentie in sereuze baarmoederkanker en in carcinosarcoom, beide agressieve 
vormen van uteriene kanker. Deze thesis toont de biochemische en functionele gevolgen van 
elf baarmoederkanker-geassocieerde en recurrente mutaties in PPP2R1A die samenklusteren 
in HEAT-repeats 5 en 7. Naast het voorspelde verlies van interactie met sommige PP2A 
subeenheden, bevestigen wij de dominant-negatieve effecten van deze mutaties in de 
kanker context en dit op specifieke gekende tumor onderdrukkende PP2A complexen. 
Dominant-negatieve Aα mutanten behouden binding aan specifieke B regulatorische 
subeenheden, maar vormen substraat-“trapping” complexen met verminderde fosfatase 
activiteit te wijten aan verhoogde incorporatie van een cellulaire PP2A inhibitor, TIPRL1. Zo 
toonden we aan dat ectopische expressie van deze mutanten in baarmoederkankercellen 
resulteerde in een sterker tumor fenotype in vitro, en in vivo in muizen. Verder kon 
verhoogde fosforylatie van verschillende oncogene eiwitten binnen de Akt en mTOR 
signaaltransductiewegen hiermee gecorreleerd worden. Tot slot, toonden we voor het eerst 
ook een verhoogde binding van de Aα mutanten aan de B”’/striatine subeenheden van PP2A 
aan, waarvan we vermoeden dat deze eigenschap eveneens bijdraagt aan het dominante 
karakter van deze mutanten. Alhoewel identieke Aα mutaties zijn teruggevonden in beide 
ziektebeelden, lijkt een groot kankerrisico voor de MR patiënten onwaarschijnlijk. 
Samengevat, tonen onze data niet enkel hoe specifieke, ziekte-geassocieerde mutaties 
invloed hebben op PP2A vorming en functie, oncogene signalering en MR pathogenese, zij 
vormen ook een rationele basis voor de ontwikkeling van verbeterde doelgerichte 
therapieën. 
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